# Table of Contents

**Introduction**

<table>
<thead>
<tr>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>i</td>
</tr>
</tbody>
</table>

**Contributors**

<table>
<thead>
<tr>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>ii</td>
</tr>
</tbody>
</table>

**Record of Revisions**

<table>
<thead>
<tr>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>iii</td>
</tr>
</tbody>
</table>

**Section 1: Influenza 101**

- What is Influenza? I.2
- Types of Influenza I.3
- Influenza Naming Convention I.5
- Testing I.6
  - Role of laboratory diagnosis of influenza I.6
  - Rapid diagnostic testing for influenza: Information for healthcare professionals I.7
  - Rapid diagnostic testing for influenza: Information for clinical laboratory directors I.7
  - Descriptions of common influenza testing types I.10
- Prevention I.12
- Vaccinations I.13
- Antivirals I.15
- References I.17

**Section II: Influenza Surveillance Overview**

- Goals of Influenza Surveillance II.2
  - Texas goals of influenza surveillance II.2
- Components of Influenza Surveillance II.3
  - Mortality surveillance II.4
  - Morbidity surveillance II.4
  - Viral surveillance II.8
Section III: Influenza Surveillance Reporting

- Background
- Seasonal Influenza Surveillance
  - DSHS reporting process MMWR week 40 – MMWR week 20
  - DSHS reporting process MMWR week 21 – MMWR week 39
  - Timeline for voluntary surveillance reporting
  - Other reporting time frames and requirements
  - Surveillance roles: local/regional/state
- National Influenza Surveillance Report
- Texas Influenza Surveillance Report
- Regional / Local Influenza Surveillance Report
- References

Section IV: Influenza Surveillance Activities

- Key Texas Surveillance Activities

Subsection a) ILINet

- ILINet Overview
- Summarizing ILINet Data Using Pivot Tables in Microsoft Excel
  - What is a pivot table?
  - Instructions
  - Definitions for ILINet data fields
  - Quick reference and helpful hints for pivot tables
• Data Quality Checks in ILINet  IV.15
• ILINet Application Form  IV.16

Subsection b) IISP  IV.17
• IISP Overview  IV.17
• Example Report Form  IV.18

Subsection c) ILI Activity  IV.19
• ILI Activity Overview  IV.19
• Data Collection  IV.20
• Example Influenza Surveillance Report Forms  IV.22

Subsection d) Laboratory Surveillance  IV.25
• Laboratory Surveillance Overview  IV.25
• Coordinating Laboratory Surveillance  IV.26
• How to Obtain Laboratory Data  IV.28

Subsection e) NREVSS  IV.29
• NREVSS Overview  IV.29
• How to Use NREVSS Data  IV.31
• NREVSS Data Dictionary  IV.35

Subsection f) Influenza-Associated Pediatric Mortality  IV.37
• Influenza-Associated Pediatric Mortality Overview  IV.37
  o Influenza-associated pediatric mortality surveillance  IV.37
  o Influenza-associated pediatric mortality investigations  IV.37
  o Influenza-associated pediatric mortality reporting  IV.38

Subsection g) Novel/Variant Influenza  IV.40
• Novel/Variant Influenza Overview  IV.40
Subsection h) Influenza-Associated Pregnant/Postpartum Mortality

- Influenza-Associated Pregnant/Postpartum Mortality Overview

Subsection i) Other Surveillance Activities

- Other Surveillance Activities Overview
  - Outbreak Investigations
    - Enhanced influenza surveillance
    - Active influenza surveillance
  - Absenteeism surveillance
  - Syndromic surveillance
    - Hospital/emergency room visit based syndromic surveillance systems
    - Medication based syndromic surveillance
    - Internet search based surveillance
    - Self-report surveillance
  - Border Influenza Surveillance Network

Section V: Recruitment and Retention of Influenza Surveillance Reporters

- Recruitment and Retention of Influenza Surveillance Reporters Overview
- Reporters to Consider for Recruitment
  - Healthcare providers
  - Hospitals
  - Laboratories
  - Schools
- Steps for Recruiting
- ILINet Recruitment
  - ILINet recruitment process
• Retention of Influenza Surveillance Reporters V.11
• Sample Tools V.12
  o Example healthcare provider/hospital letter V.12
  o Example of ILINet recruitment handout V.13
  o Example NREVSS recruitment handout V.14
  o Example influenza reports V.15

Section VI: Laboratory Support
• Viral Transport Medium VI.2
  o Receiving and storing DSHS VTM VI.3
• Ordering Supplies VI.4
• Testing Performed by DSHS Austin VI.6
  o Summary of DSHS influenza testing methods VI.8
• Specimen Collection VI.9
• How to Submit Specimens VI.11
  o Specimen storage VI.11
  o Specimen shipping VI.11
  o Specimen rejection VI.13
• LRN Overview VI.14
• Frequently Asked Questions VI.15
• G-2V Submission Form Example VI.16
• Packaging Diagrams VI.17
• Sample VTM Order Form VI.19

Section VII: Influenza Outbreaks
• Outbreaks Overview VII.2
• Why Conduct an Outbreak Investigation? VII.2
• Which Outbreaks Should Be Investigated? VII.3
• What is an Outbreak? VII.4
• Outline of an Outbreak Response VII.6
• Basic Information to Collect VII.8
• Case Definitions VII.10
• Line Lists VII.12
• Epi Curves VII.16
  o Instructions for creating a basic epi curve using Microsoft Excel 2003 VII.17
  o Other outbreak graphs VII.19
• Case Confirmation VII.20
• Basic Control Measures for Influenza VII.21
  o General recommendations for the public VII.21
  o General recommendations for long term care facilities VII.21
  o General recommendations for schools VII.22
  o Use of antivirals for prophylaxis VII.23
  o Environmental cleaning information VII.23
  o Notes on using these recommendations for non-influenza outbreaks VII.24
• Resources and Training VII.25
• References VII.27

Section VIII: Glossary and Acronyms
• Glossary VIII.1
• Acronyms VIII.3
Appendix

- DSHS Contact Information A.2
  - DSHS Central Office Influenza Surveillance Team A.2
  - DSHS Laboratory A.2
  - DSHS Regional Influenza Surveillance Coordinators A.3
- LRN Contact Information A.4
- Where to Find Influenza Data A.5
- Recommended Influenza Resources A.6
- Nasopharyngeal Swab Collection for Influenza A.7
- Investigation and Report Forms A.8
Introduction

Influenza surveillance is a multi-component surveillance network with local, regional, state and national contributions. The majority of influenza surveillance activities are dependant upon healthcare professionals and laboratorians volunteering their time to collect and report data to public health. Influenza surveillance coordinators at local and regional health departments devote energy and time to maintaining these volunteer reporters and improving influenza surveillance activities. Influenza surveillance is often one of many competing responsibilities of the epidemiologist, surveillance investigator or nurse acting as the influenza surveillance coordinator in local and regional health departments.

The purpose of this handbook is to provide a centralized resource for influenza surveillance coordinators at the local and regional levels in Texas. This handbook is intended as a tool to help local and regional influenza surveillance coordinators with their surveillance activities. It is also intended as a starting point for public health staff new to influenza surveillance activities and as a reference for experienced influenza surveillance coordinators. Our hope is that this handbook will continue to grow over the years and highlight some of the best influenza surveillance practices in the state.

This handbook will be updated annually by the Texas Department of State Health Services (DSHS) Influenza Surveillance Team. If you have suggestions for improving this handbook, please let us know by sending an email to flutexas@dshs.state.tx.us.

The DSHS Influenza Surveillance Team
Carol, Lesley and Bob
Contributors

Principal contributors:

Lesley Brannan    DSHS Influenza Surveillance Coordinator and Epidemiologist
Carol M Davis    Lead Respiratory and Invasive Disease Epidemiologist

The following people also contributed to the first edition of this handbook:

Suparna Bandyopadhyay    DSHS Influenza Surveillance Intern, Summer 2010
Irene Brown    DSHS ILINet Coordinator and Public Health Technician
Grace Kubin    Branch Manager – Emergency Preparedness, DSHS Laboratory
Martha Thompson    Medical Virology Group Manager – DSHS Laboratory

We would like to acknowledge the following people who provided information, data, editorial or other support to this handbook:

Connie Alaniz    Public Health Technician – Health Service Region 8
Dawni Allen    Group Manager – Container Preparation, DSHS Laboratory
Larry Beard    Program Specialist – Emerging and Acute Infectious Diseases Branch
Dan Bost    Program Specialist – Emergency Preparedness, DSHS Laboratory
Heather Cooks-Sinclair    Epidemiologist – Austin/Travis County Health & Human Services
Thi Dang    Epidemiologist – Health Service Region 2/3
Elizabeth ‘Liz’ Delamater    Branch Manager – Microbiological Sciences, DSHS Laboratory
Walter Douglass    Group Manager – Microbiological Check-In, DSHS Laboratory
Rita Espinoza    Group Manager – Emerging and Acute Infectious Diseases Branch
Marilyn Felkner    Group Manager – Emerging and Acute Infectious Diseases Branch
Vivienne Heines    Epidemiologist – Health Service Region 11
Sandi Henley    Nurse Epidemiologist – Health Service Region 7
Kelly Johnson    Harris County Public Health and Environmental Services
Johnathan Ledbetter    Epidemiologist – Health Service Region 2/3
Huai Lin    Epidemiologist – Health Service Region 6/5S
Kevin McClaran    Epidemiologist – Health Service Region 1
Horace McCorvey    Epidemiologist – Health Service Region 4/5N
Susan Penfield    Unit Manager – Infectious Disease Control Unit
Robert ‘Bob’ Russin    ILINet Coordinator – Emerging and Acute Infectious Disease Branch
Jeff Taylor    Branch Manager – Emerging and Acute Infectious Diseases Branch
Vanessa Telles    Program Specialist – Emergency Preparedness, DSHS Laboratory
Kristen Tolbert    Epidemiologist – Health Service Region 2/3
Crystal Van Cleave    Viral Isolation Team Leader – DSHS Laboratory
Bobbie Warr    Staff Services Officer – Emerging and Acute Infectious Diseases Branch
Kathleen Wehmeyer    Public Health Technician – Health Service Region 9/10
Rachel Wiseman    Epidemiologist – Emerging and Acute Infectious Diseases Branch

All attendees of the 2010 DSHS Influenza Surveillance Coordinators Conference
# Record of Revisions

<table>
<thead>
<tr>
<th>Month / Year</th>
<th>Sections Revised</th>
</tr>
</thead>
<tbody>
<tr>
<td>October 2010</td>
<td>First edition of handbook released</td>
</tr>
<tr>
<td>September 2011</td>
<td>Several minor editorial changes made primarily for clarity throughout the handbook. Combined reporting and surveillance information for each activity (section III and IV). Added information on IISIP (section II, III, IVb), BISN (section II, IVg), reporting timeframes (section III), specimen collection instructions (section VI, appendix), Epi curves (section VII), line lists (section VII), case definitions (section VII), case confirmation (section VII), outbreak definitions (section VII) and references/links to investigation forms (appendix). Updated diagrams and tables throughout the handbook to reflect current year and processes.</td>
</tr>
<tr>
<td>May 2012</td>
<td>Several minor editorial changes made primarily for clarity throughout the handbook. Added information on antiviral treatment (section I and VII), the Texas Medical Board website (section V), recruiting process for ILINet (section V), commercial VTM (section VI), new CDC flu outbreak definition (section VII), and fever in the elderly (section VII). Updated diagrams, tables, phone numbers, web links and names throughout the handbook to reflect current year and processes. Changed references from nosocomial to healthcare-associated.</td>
</tr>
<tr>
<td>September 2013</td>
<td>Several minor editorial changes made primarily for clarity throughout the handbook. Added information on flu vaccine abbreviations and quadrivalent vaccine (Section I); novel flu as a reportable condition (Section II); reporting details for IISIP in 2013-2014 (Section III); the ILINet recruiting plan, Microsoft Excel 2010 PivotTable instructions for ILINet and NREVSS, Right Size project, surveillance methods (Section IV); ILINet recruiting plans (Section V); testing information for outbreak specimens, instructions for the new G-2V form (Section VI); interaction with regulatory agencies, when to submit an outbreak summary</td>
</tr>
</tbody>
</table>
form, outbreak specimens, school closures (Section VII); and acronyms (Section VIII). Updated diagrams, graphs, tables, phone numbers, web links and names throughout the handbook to reflect the current year and processes.
Section I: Influenza 101

Table of Contents

- What is Influenza  I.2
- Types of Influenza  I.3
- Influenza Naming Convention  I.5
- Testing  I.6
  - Role of laboratory diagnosis of influenza  I.6
  - Rapid diagnostic testing for influenza: Information for healthcare professionals  I.7
  - Rapid diagnostic testing for influenza: Information for clinical laboratory directors  I.7
  - Descriptions of common influenza testing types  I.10
- Prevention  I.12
- Vaccinations  I.13
- Antivirals  I.15
- References  I.17
What is Influenza?

Influenza, more commonly referred to as the flu, is a respiratory disease caused by influenza viruses. Influenza can range from mild to severe illness and even death (1). Symptoms of influenza include fever, cough, sore throat, rhinorrhea (runny nose), myalgia (muscle aches), headaches and fatigue. Among children, otitis media, nausea, vomiting and diarrhea are also commonly reported. Influenza is usually a self-limiting infection, but in people with chronic medical conditions such as heart or lung disease, it can lead to pneumonia and other life-threatening complications. Adults over 65 years of age account for more than 90% of deaths attributed to pneumonia and influenza. An estimated 23,607 (range 3,349-48,614) deaths associated with influenza occur every year in the United States (2).

Influenza is an infectious disease that is easily transmitted from person to person (1). Transmission occurs via “droplet spread.” After a person infected with influenza coughs or sneezes, influenza viruses contained in the respiratory droplets travel through the air; other persons nearby can become infected if these droplets land in their noses or mouths. These droplets can also contaminate surfaces, and people can become infected when they touch an object or a surface on which these droplets have landed and then touch their noses or mouths. Transmission may also occur by direct contact, such as kissing (3). Symptoms of influenza usually come on suddenly, one to four days after the virus enters the body (1). Infected persons can start shedding virus up to 24 hours before the onset of symptoms. Additionally, some persons who become infected with influenza remain asymptomatic.

Some people are at higher risk of severe illness or complications from influenza, including people who (1, 4):

- are less than 5 years of age
- are 50 years of age or older
- have chronic pulmonary (including asthma), cardiovascular (excluding hypertension), endocrine, renal, hepatic, neurologic, hematologic or metabolic disorders
- are immunosuppressed
- are or will become pregnant during the influenza season
- are 6 months to 18 years of age and on long term aspirin therapy
- are residents of nursing homes and other chronic care facilities
- are morbidly obese (body mass index ≥40)
Types of Influenza

Influenza viruses are single-stranded RNA viruses that belong to the family Orthomyxoviridae \( (5) \). There are three types of influenza viruses: Influenza A, B and C \( (6) \). Influenza A and B are the viruses seen during the regular influenza season in the United States. Influenza C is also present, but not very common. Influenza C causes a mild or subclinical illness and is not associated with epidemics.

Influenza A viruses are further divided into subtypes based on differences in surface proteins. Influenza A has two surface proteins on the virus capsule called neuraminidase (10 variations) and hemagglutinin (17 variations), as seen in the diagram below. Different combinations of these surface proteins result in many subtypes of influenza A including H3N2 and H1N1, the subtypes currently circulating in humans. Influenza A viruses are unique in that they are able to cause infection in animal species as well as in humans \( (7) \). All subtypes of influenza A have been isolated from avian species. Influenza A subtypes have also been found in pigs, horses, seals, and whales, as well as many other animal species. Influenza B and C infections are primarily associated with illness in humans and are not often found in animals. Influenza B viruses are not subtyped; instead influenza B viruses are divided into lineages (i.e., Yamagata and Victoria) \( (8) \).

Influenza viruses undergo two different methods of antigenic change: antigenic drift and antigenic shift \( (3,9) \). Antigenic drift is the result of point mutations that occur during viral replication resulting in new virus strains. Antigenic drift is the reason that the influenza vaccine must be updated each year. Antigenic shift is a more dramatic change resulting in a novel subtype of influenza. Antigenic shift can lead to a pandemic because the majority of the population would have little or no immunity to novel subtypes created through reassortment. A pandemic could also occur through antigenic drift that allows an animal influenza virus to infect humans, followed by an “adaptive mutation” that allows the virus to spread readily within the human population \( (10) \).
The chart below demonstrates the changes in circulating subtypes of influenza A. New subtypes of influenza A may dramatically emerge as part of a pandemic such as in 1918. Sometimes the new subtypes will continue to circulate though the specific strains may vary, such as with H1N1. Other times the new subtypes eventually quit circulating, such as with H2N2.

**Emergence of Novel Influenza A Subtypes in Humans**

1918—H1N1 appears, “Spanish Influenza”, 500,000 excess deaths
1957—H2N2 appears, “Asian Influenza”, 69,800 excess deaths
1968—H3N2 appears, “Hong Kong Influenza”, 33,800 excess deaths

Adapted from Cox NJ, Kawaoka Y. In: Microbiology and Microbial Infections. 9th ed. 1998; 413
Influenza Naming Convention

Influenza viruses are often called by common names such as Spanish influenza, Hong Kong Flu or Russian Flu (3). These names are easily recognizable by the general public and usually refer to a specific strain of influenza associated with a large epidemic or pandemic. Referring to influenza viruses by their subtypes (e.g., H1N1, H3N2, etc.) is also becoming fairly mainstream. One challenge with referring to influenza viruses by subtype is that the general public does not understand that there are different strains of influenza associated with each subtype. One strain of H1N1 may be very different from another strain of H1N1, as seen with the 2009 pandemic strain of H1N1 compared with the “seasonal” strain of H1N1 that was circulating prior to 2009.

Terms like “swine flu” and “avian flu” are also used to describe influenza but are frequently misused. Both of those terms refer to influenza subtypes that normally circulate among pig and bird populations, respectively (7). While a person may become infected with an avian or swine strain of influenza, it is no longer considered to be avian or swine influenza once it has adapted to spread easily among humans.

It is important for public health professionals to be familiar with the technical names of influenza viruses to help distinguish between current and novel strains as well as between strains that are included in the vaccine and those that are not. Naming influenza viruses is a fairly simple procedure. First, the virus type is classified. Influenza A is indicated with an “A” and influenza B is indicated with “B” (11). Second, the host origin is identified. This is omitted if the virus has a human origin. Third, the geographic location in which the strain was first isolated is indicated. Fourth, the strain number is indicated; this is followed by the year the strain was isolated. The year is marked with two digits if isolated during the 1900s and four digits if isolated in or after the year 2000. Last, influenza A viruses will be followed with the virus subtype (H#N#). The number symbol indicates which of the 17 subtypes of hemagglutinin and the 10 subtypes of neuraminidase is present.

Human origin examples:
A/New Caledonia/20/99 (H1N1)
A/Perth/16/2009 (H3N2)
A/California/07/2009 (H1N1)
B/Brisbane/60/2008

Non-human origin example:
A/mallard/Memphis/123/95 (H5N1)
Testing

Note: Role of Laboratory Diagnosis of Influenza, Rapid Diagnostic Testing for Influenza: Information for Health Care Professionals and Rapid Diagnostic Testing for Influenza: Information for Clinical Laboratory Directors are from the Resource Manual for Seasonal and Pandemic Influenza Testing in Texas, Texas Department of State Health Services. Unless otherwise indicated, the material was taken from the Centers for Disease Control and Prevention (CDC) website: http://www.cdc.gov/flu/professionals/diagnosis/labrole.htm (12)
http://www.cdc.gov/flu/professionals/diagnosis/rapidclin.htm (13)
http://www.cdc.gov/flu/professionals/diagnosis/rapidlab.htm (14)

Role of Laboratory Diagnosis of Influenza
Appropriate treatment of patients with respiratory illness depends on accurate and timely diagnosis. Early diagnosis of influenza can reduce the inappropriate use of antibiotics and provide the option of using antiviral therapy. However, because certain bacterial infections can produce symptoms similar to influenza, bacterial infections should be considered and appropriately treated, if suspected. In addition, bacterial infections can occur as a complication of influenza.

Influenza surveillance information and diagnostic testing can aid clinical judgment and help guide treatment decisions. The accuracy of clinical diagnosis of influenza on the basis of symptoms alone is limited because symptoms from illness caused by other pathogens can overlap considerably with influenza. Influenza surveillance by state and local health departments and CDC can provide information regarding the presence of influenza viruses in the community. Surveillance can also identify the predominant circulating types, influenza A subtypes, and strains of influenza.

Diagnostic tests available for influenza include viral culture, serology, rapid antigen testing, polymerase chain reaction (PCR), and immunofluorescence assays. Sensitivity and specificity of any test for influenza might vary by the laboratory that performs the test, the type of test used, and the type of specimen tested. Among respiratory specimens for viral isolation or rapid detection, nasopharyngeal specimens are typically more effective than throat swab specimens. As with any diagnostic test, results should be evaluated in the context of other clinical and epidemiologic information available to healthcare providers. Please see Table 1 on pages I.10-I.11 for basic descriptions of common influenza testing types.

Commercial rapid diagnostic tests are available that can detect influenza viruses within 15 minutes. Some tests are approved for use in any outpatient setting, whereas others must be used in a moderately complex clinical laboratory. These rapid tests differ in the types of influenza viruses they can detect and whether they can distinguish between influenza types. Different tests can detect 1) only influenza A viruses; 2) both influenza A and B viruses, but not distinguish between the two types; or 3) both influenza A and B and distinguish between the two types.

None of the rapid diagnostic tests provides any information about influenza A subtypes. The types of specimens acceptable for use (i.e., throat, nasopharyngeal, or nasal aspirates, swabs, or
washes) also vary by test. The specificity and, in particular, the sensitivity of rapid tests are lower than for viral culture and vary by test. Due to the lower sensitivity of the rapid tests, physicians should consider confirming negative tests with viral culture or other means because of possible false-negative rapid test results, especially during periods of peak community influenza activity. In contrast, false-positive rapid test results are less likely, but can occur during periods of low influenza activity. Therefore, when interpreting rapid influenza test results, physicians should consider the positive and negative predictive values of the test in the context of the level of influenza activity in their community. Package inserts and the laboratory performing the test should be consulted for more details regarding use of rapid diagnostic tests.

Despite the availability of rapid diagnostic tests, collecting clinical specimens for viral culture is critical, because only culture isolates can provide specific information regarding circulating strains and subtypes of influenza viruses. This information is needed to compare current circulating influenza strains with vaccine strains, to guide decisions regarding influenza treatment and chemoprophylaxis, and to formulate vaccine for the coming year. Virus isolates also are needed to monitor the emergence of antiviral resistance and of novel influenza A subtypes that might pose a pandemic threat.

Rapid Diagnostic Testing for Influenza: Information for Healthcare Professionals
Rapid diagnostic tests for influenza can provide timely results that may be helpful with patient management. It is important to understand how the conditions under which these tests are used affect their reliability. To minimize false results:

- Use rapid diagnostic tests with high sensitivity and specificity.
- Collect specimens as early in the illness as possible (within 4-5 days).
- Follow manufacturer’s instructions, including handling of specimens.
- Consider sending specimens for viral culture or PCR to confirm results of rapid tests especially when community prevalence of influenza is low and the rapid diagnostic test result is positive and when the rapid diagnostic test result is negative but disease prevalence is high.

Rapid Diagnostic Testing for Influenza: Information for Clinical Laboratory Directors
The availability and use of commercial influenza rapid diagnostic tests by laboratories and clinics have substantially increased in recent years.

- Influenza rapid diagnostic tests are screening tests for influenza virus infection that can provide results within 15 minutes.
- More than 10 rapid influenza tests have been approved by the U.S. Food and Drug Administration (FDA).
- Rapid tests differ in some important respects:
  - Some tests identify influenza A and B viruses and distinguish between the two types.
  - Some tests identify influenza A and B viruses but cannot distinguish between the two types.
  - Some tests are waived from requirements under the Clinical Laboratory Improvement Amendments of 1988 (CLIA).
  - Most tests can be used with a variety of specimen types, but the accuracy of the tests
can vary based on the type of specimen collected (for example, throat swab versus nasal swab).

- FDA approval is based upon specific specimen types.
- The rapid tests vary in terms of sensitivity and specificity when compared with viral culture or RT-PCR. Product insert information and research publications indicate that:
  - Sensitivities are approximately 50-70%
  - Specificities are approximately 90-95%
- When using rapid tests, the optimal specimen collection time in adults is as close as possible to the start of symptoms but usually no more than 4-5 days later. In very young children, influenza viruses can be shed for longer periods; therefore, in some instances, testing for a few days after this period may still be useful.

Accuracy Depends Upon Prevalence
The positive and negative predictive values vary considerably depending upon the prevalence of influenza in the community.

- False-positive (and true-negative) influenza test results are more likely to occur when disease prevalence is low, which is generally at the beginning and end of the influenza season.
- False-negative (and true-positive) influenza test results are more likely to occur when disease prevalence is high, which is typically at the height of the influenza season.

Clinical Considerations of Testing When Influenza Prevalence is Low
When disease prevalence is relatively low, the positive predictive value (PPV) is low and false-positive test results are more likely. By contrast, when disease prevalence is low, the negative predictive value (NPV) is high, and negative results are more likely to be true.

<table>
<thead>
<tr>
<th>If Flu Prevalence is...</th>
<th>And Specificity is...</th>
<th>Then PPV is...</th>
<th>False Pos. rate is...</th>
</tr>
</thead>
<tbody>
<tr>
<td>VERY LOW (2.5%)</td>
<td>POOR (80%)</td>
<td>V. POOR (6-12%)</td>
<td>V. HIGH (88-94%)</td>
</tr>
<tr>
<td>VERY LOW (2.5%)</td>
<td>GOOD (98%)</td>
<td>POOR (39-56%)</td>
<td>HIGH (44-61%)</td>
</tr>
<tr>
<td>MODERATE (20%)</td>
<td>POOR (80%)</td>
<td>POOR (38-56%)</td>
<td>HIGH (44-62%)</td>
</tr>
<tr>
<td>MODERATE (20%)</td>
<td>GOOD (98%)</td>
<td>GOOD (86-93%)</td>
<td>LOW (7-14%)</td>
</tr>
</tbody>
</table>

The interpretation of positive results should take into account the clinical characteristics of the case. If an important clinical decision is affected by the test result, the rapid test result should be confirmed by another test, such as viral culture or polymerase chain reaction (PCR).

Clinical Considerations of Testing When Influenza Prevalence is High
When disease prevalence is relatively high, the NPV is low and false-negative test results are more likely. When disease prevalence is high, the PPV is high and positive results are more likely to be true.
If Flu Prevalence is...

<table>
<thead>
<tr>
<th>And Sensitivity is...</th>
<th>Then NPV is...</th>
<th>False Neg. rate is...</th>
</tr>
</thead>
<tbody>
<tr>
<td>MODERATE (20%)</td>
<td>POOR (50%)</td>
<td>MODERATE (86-89%)</td>
</tr>
<tr>
<td>MODERATE (20%)</td>
<td>HIGH (90%)</td>
<td>V. GOOD (97-99%)</td>
</tr>
<tr>
<td>HIGH (40%)</td>
<td>POOR (50%)</td>
<td>MODERATE (70-75%)</td>
</tr>
<tr>
<td>HIGH (40%)</td>
<td>HIGH (90%)</td>
<td>V. GOOD (93-94%)</td>
</tr>
</tbody>
</table>

The interpretation of negative results should take into account the clinical characteristics of the patient. If an important clinical decision is affected by the test result, then the rapid test result should be confirmed by another test, such as viral culture or PCR.

Selecting Tests

Many factors should be considered when selecting a test, including the following:

- Sensitivity and specificity. Tests with higher sensitivity and specificity will provide better positive and negative predictive values.
- Types of specimens that provide the most accurate results

Information about these characteristics can be found in product inserts and scientific articles, and by contacting the manufacturer.

Changes in Recommended Procedures Can Affect Test Results

Modification by the user can affect test performances and increase false-positive and/or false-negative rates. Such modifications include:

- Using specimens for which the test is not optimized
- Using swabs that did not come with the rapid test kits [unless recommended].

When Is Use of Rapid Diagnostic Tests Beneficial?

- Testing during an outbreak of acute respiratory disease can determine if influenza is the cause.
- During influenza season, testing of selected patients presenting with respiratory illnesses compatible with influenza can help establish whether influenza is present in a specific patient population and help health-care providers determine how to use their clinical judgment for diagnosing and treating respiratory illness. (Testing need not be done for all patients.)
- Otherwise, rapid tests do not address the public health need for influenza virus isolated that can only be obtained through the collection of specimens for viral culture. Influenza virus isolates are essential for determining the match between circulating influenza viruses and those viruses contained in the vaccine and for aiding in the selection of new vaccine strains.

“Commercial rapid influenza antigen testing in the evaluation of suspected influenza H5N1 cases should be interpreted with caution. Clinicians should be aware that these tests have relatively low sensitivities, and a negative result would not exclude a diagnosis of influenza H5N1. In addition, a positive result does not distinguish between seasonal and avian or other novel influenza A viruses (15).”
<table>
<thead>
<tr>
<th>Test Name</th>
<th>Test Description</th>
<th>Identifies*</th>
<th>Minimum Testing Time†</th>
<th>Notes</th>
</tr>
</thead>
</table>
| Viral culture ‡§ (aka viral isolation) | The patient specimen is inoculated into cell culture in a laboratory in order to grow the influenza virus, if present in the patient sample. Following virus isolation, confirmation and identification tests--such as immunofluorescence and hemagglutination inhibition--are performed to further classify the virus. | Type Subtype Lineage | 3-10 days** | • Traditionally considered the “gold standard” for influenza testing  
• Test requires that the virus be able to infect a host cell and multiply  
• Allows identification of viruses other than influenza if host cell line is sensitive to the specific virus |
| Real-time reverse transcription polymerase chain reaction (rRT-PCR) ‡§ | Portions of the influenza virus’s genetic code, if present in the patient sample, are amplified and detected using sophisticated laboratory equipment. | Type Subtype | 4-6 hours | • “The most sensitive and specific influenza diagnostic test” (17)  
• Can detect viruses no longer capable of causing infection as long as the target genetic sequences are present and intact  
• Can detect viruses present in a sample at low numbers |
| Serology | The patient’s serum is tested for influenza-specific antibodies in a laboratory. | Type | ≥ 2 weeks | • Requires paired acute and convalescent sera  
• Not recommended for routine influenza testing; special studies only (14) |
| Hemagglutination inhibition ‡§ | Antisera specific for either subtypes or strains and guinea pig blood are added to virus isolated in cell culture. The absence of agglutination (inhibition) indicates a positive result. | Subtype | 3-6 hours | • Requires a cell culture isolate |
| Immunofluorescence ‡§ [Direct Fluorescent Antibody (DFA) or Indirect Fluorescent Antibody (IFA) Staining] | An antibody with a fluorescent tag (direct method) recognizes and binds to influenza antigen in the patient sample, if present; the fluorescent antibody-antigen complex can be visualized under a laboratory microscope (16). IFA testing can be used to detect influenza antigen or specific antibody isotypes in the patient sample. | Type Subtype | 2-4 hours | • “Sensitivity is usually higher than rapid tests but lower than culture or rRT-PCR” (17)  
• Specificity is high (17) |
<table>
<thead>
<tr>
<th>Test Name</th>
<th>Test Description</th>
<th>Identifies*</th>
<th>Minimum Testing Time†</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Enzyme Immunoassay (EIA or ELISA)</td>
<td>There are two categories of EIA tests--the antigen detection method (direct or indirect) and the antibody detection method (competitive or noncompetitive) (^{(16)}). The antigen detection testing method detects influenza antigens present in the patient sample when they bind to antibodies fixed to the test kit plate. The antibody detection testing method detects antibodies present in the patient sample when they bind to antigens fixed to the test kit plate. In both methods, another molecule that recognizes or competes with the target influenza antigen or antibody from the patient sample is added, along with an enzyme label. A chemical is added, it interacts with the enzyme label, and produces a signal (e.g., color, fluorescence, etc.) which can be measured using laboratory equipment; the intensity of the signal is compared to a standard cutoff value for the specific test to determine whether the sample is positive or negative.</td>
<td>Type</td>
<td>2 hours</td>
<td>• Indirect EIA antigen detection tests are more sensitive than direct versions of the test (^{(16)}).</td>
</tr>
</tbody>
</table>
| Rapid Diagnostic Tests | Monoclonal antibodies in the test kit are used to detect influenza antigens in the patient specimen, if present. | Type only; some tests cannot distinguish between influenza A and B | ≤ 15 minutes | • Point-of-care (CLIA-waived) tests can be performed in a doctor’s office; moderately complex tests (not CLIA-waived) must be performed in a laboratory \(^{(14)}\).  
• Specificity is 90-95% \(^{(17)}\)  
• Sensitivity is 50-70%; however, reported sensitivities for 2009 pandemic influenza A H1N1 ranged from 10%-70% \(^{(17)}\) |

*Type = influenza A or B; Subtype = H1N1, H3N2, H5N1, or other subtype that can be detected by current diagnostic testing methods (for influenza A viruses only); Lineage = Victoria or Yamagata (for influenza B viruses only). Testing for other uncommon or novel influenza A subtypes is available at the CDC Influenza Laboratory.
†Minimum testing time does not include time to rerun a specimen, if necessary, or time to report the results to the submitter, and is a best case scenario where no other competing laboratory duties are present. Actual testing turnaround times vary by laboratory.
‡Testing performed in the DSHS Austin Laboratory; please see Section VI: Laboratory Support for more information on DSHS testing capabilities and testing turnaround times.
§Not all laboratories that can perform these tests have the capability to subtype and/or determine influenza B lineage.
**Time required for traditional viral culture; shell vial culture, if available, may produce a more rapid result \(^{(14)}\)

Note: The CDC Influenza Laboratory can perform additional tests to further identify influenza strains and antiviral resistance markers.
Prevention

It is especially important for people who are at higher risk of severe illness or complications from influenza and for close contacts of higher risk individuals to take steps to prevent the spread of influenza. There are several actions that can be taken to protect oneself and to prevent the spread of influenza (18):

- Get vaccinated for influenza every year
- Wash hands frequently with soap and water, especially after coughing or sneezing
- Use alcohol-based hand sanitizers when facilities are not available for hand washing
- Cover coughs and sneezes with disposable tissues or your arm/sleeve
- Avoid touching your eyes, nose or mouth
- Avoid close contact with people who are sick
- When you are sick, limit contact with others and stay home until fever free for 24 hours without the use of fever-reducing medications
- Take antiviral medications if prescribed by your doctor

Educational materials for preventing the spread of influenza can be found at:

- [http://texasflu.org/materials.htm](http://texasflu.org/materials.htm)
- [http://www.preventinfluenza.org/patients_who.asp](http://www.preventinfluenza.org/patients_who.asp)
Vaccinations

Vaccination is the primary method of preventing influenza infection. There are two ways a vaccine can be administered: injection or nasal spray (4). The “flu shot” contains a dead virus [known as inactivated influenza vaccine (IIV)] while the nasal spray contains a weakened virus [known as live, attenuated influenza vaccine (LAIV)]. Although there are a few mild side effects, neither method of vaccination causes influenza illness in the vaccine recipient.

There are several categories of influenza vaccine available including inactivated influenza vaccine (IIV); recombinant hemagglutinin influenza vaccine (RIV); and live, attenuated influenza vaccine (LAIV) (19). Within the IIV category, there are the traditional egg-based trivalent inactivated influenza vaccines (IIV3), cell culture-based trivalent inactivated influenza vaccines (ccIIV3), and the egg-based quadrivalent inactivated influenza vaccines (IIV4). There are also several other vaccine options within the IIV3 category, including standard dose and high-dose formulations (the latter for adults 65 years and older), as well as an intradermal vaccine with a smaller needle. The RIV category currently contains a recombinant trivalent hemagglutinin influenza vaccine (RIV3) that is not produced using eggs and therefore can be given to individuals with egg allergies (20). The LAIV category contains the trivalent live, attenuated influenza vaccine (LAIV3) and the quadrivalent live, attenuated influenza vaccine (LAIV4); however, beginning in the 2013-2014 season, only the LAIV4 formulation will be manufactured. Vaccines are licensed for specific age groups and health statuses.

Every year a new influenza vaccine is developed for each hemisphere; strain recommendations for each vaccine are made using virologic data collected by World Health Organization (WHO) Collaborating Laboratories located throughout the world (21). Recommended strains for the Northern Hemisphere’s influenza vaccine are chosen by the WHO each February; strains for the Southern Hemisphere’s influenza vaccine are chosen each September. Until recently, the seasonal influenza vaccine has been available solely as a trivalent vaccine, containing three strains of the influenza virus—two influenza A components, usually an H1N1 and an H3N2, and one influenza B virus component. Beginning in the 2013-2014 influenza season, some influenza vaccines will be available in quadrivalent formulations, containing four strains of the influenza virus—two influenza A components, usually an H1N1 and an H3N2, and two influenza B components representing each influenza B lineage (19).

It is recommended that all persons over 6 months of age be vaccinated annually for influenza (22). There are certain groups of people who have a higher risk of contracting influenza or developing severe, life-threatening illness from influenza. It is important for high risk individuals and their close contacts to protect themselves and others by getting vaccinated. The Advisory Committee on Immunizations Practices (ACIP) considers the following categories of people as high risk or close contacts of people at high risk:

- all children aged 6 months to 4 years (59 months);
- all persons aged ≥50 years;
- adults and children who have chronic pulmonary (including asthma), cardiovascular (except isolated hypertension), renal, hepatic, neurological, hematologic or metabolic disorders (including diabetes mellitus);
- persons who have weakened immune systems (including immunosuppression caused by medications or by HIV);
- women who are or will be pregnant during the influenza season;
- children and adolescents (aged 6 months to 18 years) who are receiving long-term aspirin therapy and who might be at risk for experiencing Reye syndrome after influenza virus infection;
- residents of nursing homes and other long term care facilities;
- American Indians/Alaska Natives;
- persons who are morbidly obese (BMI ≥40);
- healthcare professionals (HCPs);
- household contacts and caregivers of children aged <5 years and adults aged ≥50 years, with particular emphasis on contacts of children aged <6 months; and
- household contacts and caregivers of persons with medical conditions that put them at higher risk for severe complications from influenza.

Some people should not be vaccinated for influenza (1). These include people who:
- are less than 6 months of age
- are severely allergic to any vaccine component, including chicken eggs
- are ill at the time of vaccination (these people should seek vaccination once they are well)
- have had a severe adverse reaction after receiving influenza vaccine
- have developed Guillain-Barré Syndrome shortly after receiving influenza vaccine

Influenza vaccines are not equally effective in all persons. Vaccine effectiveness varies depending on each person’s age and general health; it also depends on how well circulating influenza strains match the current season’s vaccine strains (22-23). Influenza vaccine efficacy may be reduced for some immunocompromised persons and persons over 65 years of age (22). However, even when influenza vaccine effectiveness is reduced, influenza vaccination provides protection against severe influenza-related complications, hospitalizations and deaths, especially in the elderly (23).
Antivirals

Antiviral medications are prescription medications given to persons in order to treat an influenza illness or to prevent influenza illness from occurring; however, antiviral medications are not a replacement for the annual influenza vaccine.

Two classes of antiviral medications are currently available for clinical use—the adamantanes and the neuraminidase inhibitors. The adamantanes, amantadine and rimantadine, inhibit viral replication by interacting with the viral M2 protein (3). Influenza B viruses lack an M2 protein; therefore, the adamantanes are not effective against them.

The neuraminidase inhibitors, oseltamivir and zanamivir, interact with neuraminidase and eventually reduce the amount of virus released by host cells (3,24). During the 2009 influenza A (H1N1) pandemic, another neuraminidase inhibitor, intravenous peramivir, temporarily was made available by the FDA for emergency use in certain hospitalized patients (25). Antiviral medications are typically available either in pill or liquid form for oral administration, or as an inhaled powder (26).

An antiviral medication given within the first 48 hours of illness may shorten the duration and severity of illness (27). Antiviral medications also may be given for illness prevention to persons who were exposed to someone with an influenza illness and can be 70% to 90% effective in preventing illness. Antiviral medications are usually recommended only for those persons who have a severe illness or those who are at higher risk for developing serious illness or complications due to influenza (26). Antivirals also may be considered for chemoprophylaxis in settings where persons live in close proximity. First responders and public health workers involved in response to an investigation of very severe illnesses due to novel influenza A subtypes and strains may be given antivirals for illness prevention.

The CDC recommends influenza antiviral medications should be given to the following groups of people (28):

- Hospitalized patients with suspected or confirmed influenza;
- Persons with severe or progressive illness;
- Outpatients who are at high risk for influenza complications (for example, young children, people 65 and older, pregnant women, and persons with certain underlying chronic medical conditions) (For a full list of people at high risk of influenza complications, see: http://www.cdc.gov/flu/about/disease/high_risk.htm); and
- Persons with uncomplicated influenza who are not in a high risk group and who present within 48 hours of illness onset. These persons can be treated with antiviral medications based upon clinical judgment, because reviews of RCTs and observational studies have found consistent clinical benefit of early oseltamivir treatment in reducing the risk of lower respiratory tract complications such as those requiring antibiotics.
An important reason for limiting the use of antiviral medications is the increasing development of antiviral resistance to currently available medications. A large percentage of circulating influenza A (H3N2) viruses and some influenza A (H1N1) viruses have been shown to be resistant to adamantanes; therefore, the CDC continues to recommend the use of neuraminidase inhibitors over adamantanes (8). In the 2007-2008 season, 10.9% of influenza A (H1N1) viruses from across the nation tested by the CDC demonstrated resistance to oseltamivir, compared to only 0.7% in the 2006-2007 influenza season. In the 2008-2009 season, oseltamivir resistance was observed in almost all (99.6%) of the seasonal influenza A (H1N1) viruses tested by CDC; additionally, a small percentage (0.5%) of 2009 pandemic influenza A (H1N1) viruses tested positive for resistance to oseltamivir (29). Throughout the 2009-2010 influenza season, the number of oseltamivir-resistant 2009 pandemic influenza A (H1N1) viruses detected by CDC remained low (1.3%); almost all of the 2009 pandemic influenza A (H1N1) viruses have shown resistance to the adamantanes (30). In the 2011-2012 season, a cluster of 2009 pandemic influenza A (H1N1) viruses with resistance to oseltamivir was detected through routine surveillance in Texas Health Service Region 11. Resistance trends will continue to be monitored.
References


Section II: Influenza Surveillance Overview

Table of Contents

- Goals of Influenza Surveillance II.2
  - Texas goals of influenza surveillance II.2
- Components of Influenza Surveillance II.3
  - Mortality surveillance II.4
  - Morbidity surveillance II.4
  - Viral surveillance II.8
  - Ad hoc surveillance II.9
- A Brief History of Influenza Reporting in Texas II.10
- References II.11
Goals of Influenza Surveillance

Influenza has a tremendous impact on the health of the public. Every year an influenza epidemic occurs in the United States. This epidemic occurs regularly between October and May, and therefore this time period is referred to as influenza season. An estimated 23,607 (range 3,349-48,614) deaths associated with influenza occur every year in the United States (1).

In addition to yearly epidemics, influenza pandemics may also occur. An influenza pandemic occurs when a new influenza virus strain begins circulating among people. The number of people impacted by influenza increases substantially during pandemics because there is little to no immunity against the new strain among the population. The severity of the pandemic depends on the actual strain. Some pandemics have high case fatality rates while others have low case fatality rates.

Influenza surveillance is performed in order to monitor yearly epidemics and detect possible introductions of new strains of influenza. The information collected from influenza surveillance is used to guide public health recommendations for prevention and control at local, state, national and international levels.

Texas goals of influenza surveillance

- Determine when and where influenza viruses are circulating
- Determine if circulating influenza viruses match the vaccine strains
- Detect changes in the influenza viruses
- Track influenza-like illness
- Determine the severity of influenza activity

The Texas goals align closely with the national goals:

- Determine when and where influenza activity is occurring
- Track influenza-related illness
- Determine what influenza viruses are circulating
- Detect changes in influenza viruses
- Measure the impact influenza is having on deaths in the United States
Components of Influenza Surveillance

Influenza surveillance in the United States has three major components: mortality, morbidity and viral surveillance. For each of these components, activities may be conducted at the national, state or local level. Texas has regional health departments that perform both state and local level surveillance activities.

Influenza Surveillance Components

The following pages provide a brief description of the most common influenza surveillance activities. For a more detailed description of the activities conducted in Texas, please refer to Section IV of this handbook.
Mortality Surveillance
Mortality surveillance focuses on tracking deaths associated with influenza. Mortality surveillance is used as one indicator of severity of influenza epidemics and pandemics.

The following table describes the main activities included in mortality surveillance:

<table>
<thead>
<tr>
<th>Activity</th>
<th>Conducted at</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Influenza-Associated Pediatric Mortality</td>
<td>Local, state and national levels</td>
<td>Local and regional health departments investigate reports of influenza-associated pediatric deaths, a reportable condition. State health departments and the CDC track these deaths and monitor the data for trends. The data are used to support public health recommendations for influenza prevention. This surveillance occurs year-round.</td>
</tr>
<tr>
<td>See Section IVf</td>
<td></td>
<td></td>
</tr>
<tr>
<td>122 Cities Mortality Reporting System (2)</td>
<td>National level</td>
<td>Vital Statistics offices in 122 major cities in the United States report directly to the CDC the total number of death certificates received and the number of those for which pneumonia or influenza was listed as the underlying or contributing cause of death by age group. The percentage of all deaths due to pneumonia and influenza is compared with a seasonal baseline and an epidemic threshold value is calculated for each week. Seven cities in Texas participate by submitting data weekly. This surveillance occurs year-round.</td>
</tr>
</tbody>
</table>

Some health jurisdictions may conduct other surveillance activities to track influenza-related mortality. For example, health departments may receive reports from their local vital statistics office on the number of deaths attributable to pneumonia and influenza each week. Other health departments may work closely with local hospitals, medical examiners and justices of the peace to obtain aggregate data on the number of deaths due to influenza each week.

Morbidity Surveillance
Morbidity surveillance focuses on tracking illness associated with influenza. The breadth of activities classified under morbidity surveillance reflects the wide spectrum of disease associated with influenza. Morbidity surveillance can be subdivided into surveillance activities related to laboratory confirmed influenza, influenza-like illness or a combination of the two. Morbidity surveillance can also focus on different spectrums of illness. For example, influenza data collected from hospitals reflect more severe cases of illness while influenza data collected from over-the-counter sales of cough and cold medicine reflect milder cases of illness.
The following table describes the main activities included in morbidity surveillance:

<table>
<thead>
<tr>
<th>Activity</th>
<th>Conducted at</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Novel Influenza</td>
<td>Local, state and national levels</td>
<td>Local, regional and state health departments investigate reports of novel influenza to identify possible spread in the community. Novel influenza is a reportable disease in Texas. The first indication of novel influenza is often a specimen that is not able to be subtyped by a laboratory with subtyping capability. Initial confirmation of novel influenza can only be done by the CDC Laboratory. This surveillance occurs year-round.</td>
</tr>
<tr>
<td>FluSurv-NET (2)</td>
<td>National level</td>
<td>Laboratory confirmed cases of influenza in hospitalized persons from selected hospitals in 15 states are reported to the CDC. Cases are identified by reviewing hospital laboratory and admission databases and infection control logs for children and adults with a documented positive influenza test [viral culture, direct/indirect fluorescent antibody assay (DFA/IFA), reverse transcription-polymerase chain reaction (RT-PCR), or a commercial rapid antigen test] conducted as a part of routine patient care. Estimated hospitalization rates are reported each week during the influenza season by the CDC. This surveillance is not conducted in Texas. This is an expansion of the flu surveillance activities performed through the Emerging Infections Program (EIP).</td>
</tr>
<tr>
<td>New Vaccine Surveillance Network</td>
<td>National level</td>
<td>Hospitals in three counties (Hamilton County, OH; Davidson County, TN; and Monroe County, NY) reported laboratory confirmed influenza hospitalization rates for children &lt;5 years of age. Children admitted to NVSN hospitals with fever or respiratory symptoms were prospectively enrolled and respiratory samples were collected and tested by viral culture and RT-PCR. NVSN estimated rates were reported every two weeks through 2011 during the influenza season by the CDC. This surveillance was not conducted in Texas.</td>
</tr>
<tr>
<td>Activity</td>
<td>Conducted at</td>
<td>Description</td>
</tr>
<tr>
<td>----------</td>
<td>-------------</td>
<td>-------------</td>
</tr>
<tr>
<td>U.S. Outpatient Influenza-like Illness Surveillance Network (ILINet)</td>
<td>Primarily supported at the state and national levels; local level participation varies</td>
<td>Healthcare providers report the total number of patients seen and the number of those patients with influenza-like illness (ILI) by age group to a CDC database that is accessible to state health departments. This surveillance occurs year-round but not all participants enter data outside of the official influenza season.</td>
</tr>
<tr>
<td>Influenza Incidence Surveillance Project (IISP)</td>
<td>Primarily supported at the state and national levels; local level participation varies</td>
<td>Healthcare providers report the total number of patients seen by age group and the number of those patients with ILI by age group to the state health department. Healthcare providers also submit specimens with demographic and clinical information on the first ten patients seen each week with ILI. Participation is limited to six to eight healthcare providers in Texas. This surveillance occurs year-round. The 2012-2013 season was the last surveillance year for the full project. An IISP-like project will continue in 2013-2014.</td>
</tr>
<tr>
<td>ILI Activity</td>
<td>Primarily conducted at the local level; collected data contribute to state and national influenza reports</td>
<td>ILI activity surveillance is highly variable from one health department to another. In addition to or in lieu of having providers report through ILINet, health departments (HDs) have providers report directly to the HD. This enables the HD to tailor the information collected to their needs. HDs may collect more information than ILINet captures, such as rapid influenza test data. This activity also allows providers to report less information than ILINet (e.g., no age group information). ILI activity data can also be reported from non-traditional influenza reporters such as schools. ILI data from schools can include the number of students seen by the school nurse with ILI or the number of students who are absent with the parents reporting ILI as the reason. Some HDs have established electronic systems to collect reports from school nurses and administration. This surveillance can occur either year-round or seasonally.</td>
</tr>
<tr>
<td>Activity</td>
<td>Conducted at</td>
<td>Description</td>
</tr>
<tr>
<td>----------------------------------------------</td>
<td>--------------</td>
<td>-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>Behavioral Risk Factor Surveillance System (BRFSS) (3)</td>
<td>National level</td>
<td>BRFSS is an on-going telephone health survey system, tracking health conditions and risk behaviors in the United States. The CDC added questions to assess ILI in BRFSS calls in 2009. It was thought that these questions would capture milder illnesses that may not have resulted in provider visits. The usefulness of this type of surveillance is still being explored by the CDC. This surveillance occurs year-round.</td>
</tr>
<tr>
<td>Outbreak Investigations</td>
<td>Primarily conducted at the local and state levels; collected data contribute to state and national influenza reports</td>
<td>Local, regional and state health departments investigate reports of outbreaks and implement immediate control measures to stop the outbreaks. This surveillance occurs year-round.</td>
</tr>
<tr>
<td>Absenteeism Surveillance</td>
<td>Primarily conducted at the local level; collected data contribute to state and national influenza reports</td>
<td>Absenteeism surveillance activities vary widely. Absenteeism data specific to ILI are better for influenza surveillance than general absentee counts; however, broader absenteeism data can be beneficial for monitoring overall community health and detecting potential outbreaks. This surveillance can occur either year-round or seasonally.</td>
</tr>
</tbody>
</table>
| Syndromic Surveillance                        | Primarily conducted at the local level; collected data contribute to state and national influenza reports | Automated data mining of healthcare facility databases allows flexible and timely analysis of trends in accessing care. The two most common uses of syndromic surveillance data for influenza surveillance include examining:  
- Percentage of total visits due to ILI and comparison of visits with historical trends  
- Percentage of cough medications sold by zip code and comparison of sales with historical trends  
This surveillance occurs year-round. |
| Border Influenza Surveillance Network (BISN)   | Primarily conducted at the local level; collected data contribute to a multi-state report | The Border Influenza Surveillance Network is a multi-state collaboration to share influenza data from the border regions of California, New Mexico, Texas and Mexico. The network uses data from existing influenza surveillance activities. This reporting is seasonal. |
Viral Surveillance

Viral surveillance focuses on laboratory identification of circulating influenza strains and their characteristics. Viral surveillance is critical for detecting novel strains of influenza and helping public health monitor for antiviral resistance among all circulating strains of influenza.

The following table describes the main activities included in viral surveillance:

<table>
<thead>
<tr>
<th>Activity</th>
<th>Conducted at</th>
<th>Description</th>
</tr>
</thead>
</table>
| National Respiratory and Enteric Virus Surveillance System (NREVSS)  
  *See Section IVe* | Primarily supported at the state and national levels; local level participation varies | Laboratories report the total number of respiratory specimens tested and the number positive for influenza types A (categorized by subtype, if known) and B. Laboratory data for additional respiratory and enteric viruses are also collected through NREVSS. This surveillance occurs year-round. |
| World Health Organization (WHO) Collaborating Laboratories | National level | Many laboratories that participate in NREVSS surveillance also support WHO surveillance. The DSHS Virology Laboratory is a WHO Collaborating Laboratory. This surveillance occurs year-round. |
| Laboratory Surveillance  
  *See Sections IVd and VI* | Primarily conducted at the local and state levels; collected data contribute to national influenza reports | Specimens from patients with symptoms compatible with influenza are submitted to the DSHS Laboratory for influenza testing. Testing at the DSHS Laboratory may include culture, PCR and antiviral resistance testing. Several specimens are submitted to CDC for further testing and identification throughout the season. This surveillance occurs year-round with increased participation during the influenza season. |
**Ad Hoc Surveillance**

Ad hoc surveillance includes any surveillance activities that are designed and implemented to respond to a specific situation and usually only occur for a specific time period. Ad hoc surveillance may be done to capture the same elements as mortality, morbidity or viral surveillance.

The following table describes the examples of ad hoc surveillance:

<table>
<thead>
<tr>
<th>Activity</th>
<th>Conducted at</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Confirmed pH1N1 Hospitalization Surveillance</td>
<td>Conducted from June 2009 to May 2010</td>
<td>Hospitals were asked by the CDC and DSHS to voluntarily report the number of people that were hospitalized (admitted) who were confirmed as having pH1N1. Aggregate hospitalization counts were reported beginning in September 2009. This surveillance was created specifically as a response to the 2009 pandemic to help track severity.</td>
</tr>
<tr>
<td>Influenza-Associated Pregnant/Postpartum Mortality Surveillance</td>
<td>Conducted from August 2009 through 2010-2011 influenza season</td>
<td>Health departments were asked by the CDC to investigate reports of influenza-associated deaths in women who were pregnant or up to six weeks postpartum. This surveillance was created after reports were received of increased impact of pH1N1 on women who were pregnant during the 2009 pandemic. This surveillance was extended through the 2010-2011 influenza surveillance season.</td>
</tr>
<tr>
<td>Enhanced Surveillance for an Outbreak</td>
<td>Performed during an outbreak investigation and may extend for a week or more after the outbreak</td>
<td>A health department investigating an outbreak may conduct enhanced surveillance for influenza in the community to help determine if the outbreak is contained or has spread to the community. The extent of the surveillance, what data are collected and how frequently data are reported is determined by the lead epidemiologist/investigator of the outbreak.</td>
</tr>
</tbody>
</table>

*See Section IVh*

*See Sections VII and IVi*
A Brief History of Influenza Reporting in Texas

Influenza morbidity has been reported in Texas since at least 1920, although not continuously and not using the same case definition. Starting in 1920 and continuing through 1945, annual public health reports and summary tables included “influenza” case counts (4). The reports from 1946 to 1951 changed to “influenza/flu-like” cases. Influenza and influenza-like illnesses (ILI) reporting ceased from 1952 through 1967 and then resumed again from 1968 until 1993. We do not have a record of how influenza, influenza-like illness and ILI were defined during these time periods so the data may not reflect actual disease trends. It is clear that by the end of the 1970s, influenza and ILI were only reportable to the state health department as aggregate counts rather than individual reports. By 1994, influenza and ILI were again removed from the Texas Notifiable Conditions list since influenza data collected through surveillance were thought to vastly underestimate true morbidity (5).

After 1993, voluntary surveillance from “sentinel” sites became the main source of influenza surveillance data in Texas and continues to this day for influenza and ILI. In this type of surveillance, reports of influenza and ILI are received from a subset of healthcare providers rather than from all healthcare providers. In 2007, Texas expanded influenza surveillance by adding influenza-associated pediatric mortality to the list of notifiable conditions. From April 2009 through May 2010, human cases, hospitalizations, ICU admissions and deaths related to the pandemic influenza A (H1N1) virus were reportable under the “exotic disease” or “unusual group expression” portion of the Notifiable Conditions list (6). The case definitions for reporting changed frequently as the pandemic evolved; in particular, reporting of cases of 2009 influenza A (H1N1) in persons without more severe disease manifestations (i.e., hospitalizations or deaths) was discontinued early in the pandemic. In 2013, Novel Influenza was added to the Texas Notifiable Conditions list.

**Influenza & ILI as Reportable Conditions in Texas, 1920–2011**

![Graph showing influenza and ILI cases reported in Texas from 1920 to 2011.](image)
References


# Section III: Influenza Surveillance Reporting

## Table of Contents

- Background III.2
- Seasonal Influenza Surveillance III.3
  - DSHS reporting process MMWR week 40 – MMWR week 20 III.3
  - DSHS reporting process MMWR week 21 – MMWR week 39 III.3
  - Timeline for voluntary surveillance reporting III.4
  - Other reporting time frames and requirements III.5
  - Surveillance roles: local/regional/state III.6
- National Influenza Surveillance Report III.7
- Texas Influenza Surveillance Report III.8
- Regional / Local Influenza Surveillance Report III.9
- References III.10
Background

Influenza surveillance occurs year-round. Seasonal influenza surveillance activities occur during the traditional influenza reporting period from Morbidity and Mortality Weekly Report (MMWR) week 40 of one year through week 20 of the next year (i.e., approximately the beginning of October through the third week of May). Week 40 to week 20 corresponds with the annual influenza reporting season in the United States.

Influenza surveillance data are collected and reported on a weekly basis. The reporting week starts on Sunday and ends on the following Saturday. This reporting week is equivalent to the CDC designated MMWR week. Reporting weeks are referred to by their week number or week ending date (e.g., 2010 MMWR week 32 or the week ending August 14, 2010).

Influenza surveillance reporting is a complex process. Healthcare providers and others who interact professionally with potentially ill people report data to their local or regional health departments. Healthcare professionals may also report data to the U.S. Outpatient Influenza-like Illness Surveillance Network (ILINet); these data are accessible to local, regional, state and national health departments. Laboratories report results to healthcare professionals and may also report data to health departments. Local, regional, state and national health departments also exchange data. The data collected from these multiple sources are compiled, analyzed and shared in weekly influenza surveillance reports. This section of the handbook presents more detail on the reporting process.

Simplified reporting diagram
Seasonal Influenza Surveillance

DSHS Reporting Process: MMWR Week 40 to MMWR Week 20
The DSHS Emerging and Infectious Disease Branch (EAIDB) requests that two reports—a preliminary report and a final report—be submitted each week by the DSHS Regional Health Departments (RHDs) for MMWR week 40 through MMWR week 20. Each week’s report contains information on influenza activity from the previous week; therefore, influenza reports have an approximate 1 week delay.

The preliminary report deadline for the RHDs is by the close of business (COB) on Monday. All preliminary reports are needed by this deadline to determine the Texas Influenza Activity Code (submitted by DSHS EAIDB to CDC each Tuesday by 10am). The report should contain answers to the following questions and can be sent via email to flutexas@dshs.state.tx.us:

1. Is ILI occurring in your region(s)?
2. Are there rapid influenza test confirmed cases of influenza in your region(s)?
3. Are there culture or PCR confirmed cases of influenza in your region(s)?
4. Are there any school or institutional outbreaks of influenza or ILI in your region(s)?
5. Has influenza activity in your region(s) increased, decreased or remained the same compared to the previous week?

The final report deadline for the RHDs is by noon on Thursday. This ensures that the DSHS EAIDB Influenza Surveillance Coordinator at Central Office can process and compile all reports to generate the Texas Weekly Flu Report, which is posted on the web on Friday by the close of business. Final report updates sent by the close of business on Thursday will be incorporated into the Texas Weekly Flu Report if time allows. The DSHS EAIDB Influenza Surveillance Coordinator will evaluate the feasibility of incorporating changes for reports or updates sent after the close of business on Thursday. Final and amended reports should be sent to flutexas@dshs.state.tx.us.

DSHS Reporting Process: MMWR Week 21 to MMWR Week 39
During the off season for influenza (MMWR week 21 to MMWR week 39), surveillance efforts continue but may be scaled back. All local and regional health departments are encouraged to continue influenza surveillance activities but may reduce the number of healthcare providers who submit data weekly. RHDs do not have to submit a preliminary report but should continue to submit the final report by noon on Thursday. With the exception of the preliminary report, the reporting time frames are the same.
## Timeline for Voluntary Surveillance Reporting

<table>
<thead>
<tr>
<th>Day</th>
<th>ILINet Reporters</th>
<th>IISP Reporters</th>
<th>Non-ILINet/IISP Reporters</th>
<th>LHD</th>
<th>RHD</th>
<th>CO</th>
</tr>
</thead>
<tbody>
<tr>
<td>Monday</td>
<td></td>
<td></td>
<td></td>
<td>By 1pm*: Submit influenza or ILI activity reports for previous week to L/RHD</td>
<td>By 3pm*: Submit initial influenza activity report to RHD</td>
<td>By COB*: Submit preliminary influenza activity report to DSHS EAIDB</td>
</tr>
<tr>
<td>Tuesday</td>
<td>By noon: Enter ILI report for the previous week into ILINet or fax report form to CDC</td>
<td>By noon: Enter ILI report for the previous week into ILINet or fax report form to CDC</td>
<td></td>
<td>By COB*: Submit final influenza activity report to RHD</td>
<td>By 10am: Texas Influenza Activity Code due to CDC</td>
<td></td>
</tr>
<tr>
<td>Wednesday</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>By 11am: IISP data due to CDC</td>
<td></td>
</tr>
<tr>
<td>Thursday</td>
<td></td>
<td></td>
<td></td>
<td>By noon: Submit final influenza activity report to DSHS EAIDB</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Friday</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>By COB: Post state report on the DSHS website</td>
<td></td>
</tr>
</tbody>
</table>

* These are recommended submission deadlines. The actual deadline is set by each local health department or DSHS region.
### Other Reporting Time Frames and Requirements

<table>
<thead>
<tr>
<th>What</th>
<th>Required by law</th>
<th>Time frame</th>
<th>Mechanism for health departments to share reports with DSHS CO</th>
</tr>
</thead>
</table>
| Influenza-associated pediatric mortality  | Yes             | Providers should report cases to the health department within 1 working day by phone or fax. | 1) Call RHD or DSHS EAIDB to give a preliminary summary when the case is first reported.  
2) Fax completed influenza-associated pediatric mortality investigation form to RHD. RHD will forward to EAIDB.  
3) Complete investigation in NBS. |
| *See Section IVf*                         |                 |                                                |                                                                                                                                                                                          |
| Novel influenza                           | Yes             | Providers should report suspected cases to the health department immediately. Laboratories with subtyping capabilities should forward unsubtypable influenza isolates to the DSHS laboratory as soon as possible. | 1) Fax completed general influenza investigation form along with supplemental sections on travel history, animal exposures and contacts to RHD. RHD will forward to EAIDB. |
| *See Section IVg*                         |                 |                                                |                                                                                                                                                                                          |
| Influenza or ILI outbreaks                | Yes             | Providers should report suspected outbreaks to the health department immediately. | 1) Call RHD or DSHS EAIDB to give a preliminary summary when the outbreak is first reported.  
2) Fax or email the respiratory outbreak summary report or a written summary of the outbreak investigation to RHD. RHD will forward to EAIDB. |
| *See Sections IVi and VII*                |                 |                                                |                                                                                                                                                                                          |
| Influenza-associated pregnant/postpartum mortality | No, voluntary | Discontinued in May 2011                      | 1) Fax completed CDC influenza-associated pregnant/postpartum investigation form to RHD. RHD will forward to EAIDB.                                                                 |
| *See Section IVh*                         |                 |                                                |                                                                                                                                                                                          |
# Surveillance Roles: Local/Regional/State

<table>
<thead>
<tr>
<th>Level</th>
<th>Person</th>
<th>Responsibility</th>
</tr>
</thead>
<tbody>
<tr>
<td>Local Health Department</td>
<td>Local influenza surveillance coordinator</td>
<td>• Recruit and maintain influenza surveillance reporters&lt;br&gt;• Collect influenza activity information from local surveillance partners&lt;br&gt;• Summarize information&lt;br&gt;• Share influenza reporting information with the Regional Influenza Surveillance Coordinator and local surveillance partners</td>
</tr>
<tr>
<td>Regional Health Department</td>
<td>Regional influenza surveillance coordinator</td>
<td>• Recruit and maintain influenza surveillance reporters&lt;br&gt;• Collect influenza activity information from local health departments and regional surveillance partners&lt;br&gt;• Consolidate and summarize local influenza activity reports&lt;br&gt;• Review ILINet and NREVSS data for the Region&lt;br&gt;• Share influenza reporting information with the State Influenza Surveillance Coordinator and regional surveillance partners&lt;br&gt;• Provide guidance on influenza surveillance to local health departments</td>
</tr>
<tr>
<td>DSHS EAIDB Central Office</td>
<td>EAIDB influenza surveillance coordinator</td>
<td>• Consolidate and summarize regional influenza activity reports, CDC influenza testing results and other laboratory and agency specific data&lt;br&gt;• Share influenza reporting information on the DSHS website&lt;br&gt;• Facilitate shipping of influenza testing supplies (VTM, swabs and shipping materials)&lt;br&gt;• Provide guidance to regional and local health departments on influenza surveillance and reporting</td>
</tr>
<tr>
<td>ILINet Coordinator</td>
<td></td>
<td>• Coordinate ILINet surveillance and review ILINet data for the state&lt;br&gt;• Lead recruitment efforts for ILINet</td>
</tr>
<tr>
<td>Respiratory and invasive diseases epidemiology team lead</td>
<td></td>
<td>• Provide guidance to regional and local health departments on respiratory and invasive disease outbreak investigations&lt;br&gt;• Coordinate IISP surveillance and review IISP data for the state&lt;br&gt;• Provide guidance to regional and local health departments on influenza surveillance and reporting</td>
</tr>
</tbody>
</table>
National Influenza Surveillance Report

The Influenza Branch at CDC collects and reports information on influenza activity in the United States each week during the national reporting season. The weekly national influenza surveillance report, FluView, is posted each Friday at http://www.cdc.gov/flu/weekly/.

The FluView report is based upon data collected from five complementary surveillance sources:

1. Viral surveillance
   a. World Health Organization (WHO) Collaborating Laboratories and
   b. the National Respiratory and Enteric Virus Surveillance System (NREVSS)

2. Outpatient illness surveillance
   a. U.S. Outpatient Influenza-like Illness Surveillance Network (ILINet)

3. Mortality surveillance
   a. 122 Cities Mortality Reporting System and
   b. Influenza-Associated Pediatric Mortality Surveillance System

4. Hospitalization surveillance
   a. FluSurv-NET

5. Geographic spread surveillance
   a. State and Territorial Epidemiologists Reports

A brief description of these surveillance activities can be found in Section II of this handbook.

The reported information answers the questions of where, when and what influenza viruses are circulating. This information may also be used to determine if influenza activity is increasing or decreasing, but it cannot be used to ascertain how many people have become ill with influenza during the season.
Texas Influenza Surveillance Report

The DSHS Influenza Surveillance Team at Central Office collects and collates reports from the local and regional health departments, participating laboratories and ILINet to produce the Texas Weekly Flu Report. This report is posted each Friday at http://www.dshs.state.tx.us/idcu/disease/influenza/ under the link for “Current Flu Report”.

The Texas Influenza report is based upon data collected from the following sources:
1. The National Respiratory and Enteric Virus Surveillance System (NREVSS), the DSHS Austin Laboratory, and the Laboratory Response Network Laboratories (LRNs)
2. U.S. Outpatient Influenza-like Illness Surveillance Network (ILINet)
3. Influenza Incidence Surveillance Project (IISP)
4. ILI activity reported directly to local and regional health departments
5. Influenza-Associated Pediatric Mortality reports
6. Outbreak and school closure investigations and notifications
7. Novel influenza A case investigations

Descriptions of these surveillance activities can be found in Sections II and IV of this handbook.

As with the national influenza report, the surveillance information answers the questions of where, when and what influenza viruses are circulating. It may also be used to determine if influenza activity is increasing or decreasing, but it cannot be used to ascertain how many people have become ill with influenza during the season.

During the influenza off-season (MMWR week 21 to week 39), the Texas Influenza Surveillance Report continues to be posted weekly. However, the report is abbreviated and does not include sections for outbreaks, deaths or comprehensive testing results unless needed.
Regional/Local Influenza Surveillance Report

Influenza surveillance reports that are specific to a regional or local health jurisdiction are beneficial for multiple reasons. The reports can be used to encourage providers to continue reporting since they demonstrate that the information they provide is being utilized. The reports are also good mechanisms to share what is happening with influenza with local leadership, the medical community and the general public. Furthermore, archived reports are helpful for documenting historical influenza trends.

Regional/local influenza surveillance reports should reflect the data that are captured by influenza surveillance in the regional/local jurisdiction. These reports should also include information that is of interest to the local community. Regional/local influenza surveillance reports can range from simple, one-page reports and graphs to extensive reports mirroring information found in the CDC or DSHS influenza reports.

Here are examples of data sources that can be included in a report:
- ILI activity reported directly to health departments
- U.S. Outpatient Influenza-like Illness Surveillance Network (ILINet) data
- National Respiratory and Enteric Virus Surveillance System (NREVSS) data
- Other laboratory data
- Influenza-associated hospitalizations data
- Syndromic surveillance data
- School absenteeism data or influenza-like illness data
- Influenza-Associated Pediatric Mortality reports
- Outbreak and school closure investigations and notifications
- Novel influenza A case investigations

Some health departments post influenza reports on their websites. Other health departments email or fax the reports to healthcare providers and other public health partners. See Section V of this handbook for an example of an influenza surveillance report that is emailed to stakeholders. Here are some examples of influenza reports that are posted on health department websites:

- [http://www.abilenetx.com/health/epidemiology.htm](http://www.abilenetx.com/health/epidemiology.htm)
- [http://www.dshs.state.tx.us/region7/Epidemiology.shtm](http://www.dshs.state.tx.us/region7/Epidemiology.shtm)
- [http://www.dallascounty.org/department/hhs/h1n1.html](http://www.dallascounty.org/department/hhs/h1n1.html)
References


2. Texas Administrative Code, Title 25, Part 1, Chapter 97, Subchapter A, Rule 97.3 (June 5, 2007).
Section IV: Influenza Surveillance Activities

Table of Contents

Key Texas Surveillance Activities

Subsection a) ILINet

- ILINet Overview
- Summarizing ILINet Data Using Pivot Tables in Microsoft Excel
  - What is a pivot table?
  - Instructions
  - Definitions for ILINet data fields
  - Quick reference and helpful hints for pivot tables
- Data Quality Checks in ILINet
- ILINet Application Form

Subsection b) IISP

- IISP Overview
- Example Report Form

Subsection c) ILI Activity

- ILI Activity Overview
- Data Collection
- Example Influenza Surveillance Report Forms

Subsection d) Laboratory Surveillance

- Laboratory Surveillance Overview
- Coordinating Laboratory Surveillance
- How to Obtain Laboratory Data

Subsection e) NREVSS
### Subsection f) Influenza-Associated Pediatric Mortality

- Influenza-Associated Pediatric Mortality Overview
  - Influenza-associated pediatric mortality surveillance
  - Influenza-associated pediatric mortality investigations
  - Influenza-associated pediatric mortality reporting

### Subsection g) Novel/Variant Influenza

- Novel/Variant Influenza Overview

### Subsection h) Influenza-Associated Pregnant/Postpartum Mortality

- Influenza-Associated Pregnant/Postpartum Mortality Overview

### Subsection i) Other Surveillance Activities

- Other Surveillance Activities Overview
  - Outbreak Investigations
    - Enhanced influenza surveillance
    - Active influenza surveillance
  - Absenteeism surveillance
  - Syndromic surveillance
    - Hospital/emergency room visit based syndromic surveillance systems
    - Medication based syndromic surveillance
    - Internet search based surveillance
    - Self-report surveillance
  - Border Influenza Surveillance Network
Key Texas Surveillance Activities

Section II of this handbook provided an overview of influenza surveillance at the national, state and local levels. This section provides technical information on the main influenza surveillance activities that are conducted in Texas. This section is meant to serve as a tool for influenza surveillance coordinators to build and maintain influenza surveillance.

Texas Surveillance Components

Influenza Surveillance

Mortality

Morbidity

Viral

- Flu
- ILI
- Other

- Mortality
- Morbidity
- Viral

N  S  L
Influenza-Associated Pediatric
Novel Influenza
ILI Activity
ILI
Syndromic
NREVSS / WHO
Laboratory
Ad Hoc

Level
N National
S State
L Local

N  S  L

Ad Hoc
Varies by situation

Surveillance Activities Last updated 09/13/2013

IV.3
Influenza Surveillance Activities - ILINet

ILINet Overview

The U.S. Outpatient Influenza-like Illness Surveillance Network (ILINet) is an online reporting system maintained by the CDC that is designed to collect information on influenza-like illness (ILI). For the purposes of ILINet, ILI is defined as fever of at least 100°F plus cough or sore throat in the absence of a known cause of illness other than influenza. Volunteers report the total number of patients seen with ILI by age group and the total number of patients seen for any reason during each reporting week. Participants have the option of reporting during the official influenza season only (i.e., October through May); however, year-round participation is preferred.

Participation in ILINet is open to the following healthcare providers and settings: Family practice, pediatricians, internal medicine, student health, infectious disease, hospital emergency departments, community clinics, OB/GYNs, and urgent care. Though not required for participation in ILINet, influenza surveillance laboratory testing of a sample of patient specimens is also offered to participants free of charge at the state laboratory.

Providers report data weekly by noon each Tuesday through the CDC’s ILINet website or by fax. Upon approval from the DSHS ILINet Coordinator, data for multiple sites may be emailed as a spreadsheet to flutexas@dshs.state.tx.us. An example of the CDC online reporting form is included below.

![Influenza Surveillance Program](image-url)
Data entered into ILINet are available for download to local, regional and state public health staff in Texas by requesting access through flutexas@dshs.state.tx.us. The default download file is a Microsoft Excel file. An example of the downloaded data is included below.

<table>
<thead>
<tr>
<th>A</th>
<th>B</th>
<th>C</th>
<th>D</th>
<th>E</th>
<th>F</th>
<th>G</th>
<th>H</th>
<th>I</th>
<th>J</th>
<th>K</th>
<th>L</th>
<th>M</th>
<th>N</th>
<th>O</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Phys ID Code</td>
<td>County</td>
<td>Practice Type</td>
<td>Date Code</td>
<td>Date Called</td>
<td>Time Called</td>
<td>Source</td>
<td>Age 0-4</td>
<td>Age 5-14</td>
<td>Age 15-49</td>
<td>Age 50-64</td>
<td>Age 65 and older</td>
<td>Total Patients Seen</td>
<td>Total ILI</td>
</tr>
<tr>
<td>2</td>
<td>48033</td>
<td>Hutchinson</td>
<td>Family Practice</td>
<td>201032</td>
<td>08/17/2010</td>
<td>10:13:42 AM</td>
<td>Internet Physician</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>165</td>
<td>0</td>
</tr>
<tr>
<td>3</td>
<td>48166</td>
<td>Harris</td>
<td>Family Practice</td>
<td>201032</td>
<td>08/20/2010</td>
<td>11:42:49 AM</td>
<td>Fax - 08/20/10</td>
<td>9</td>
<td>7</td>
<td>6</td>
<td>0</td>
<td>0</td>
<td>174</td>
<td>22</td>
</tr>
<tr>
<td>4</td>
<td>48006</td>
<td>Gregg</td>
<td>Family Practice</td>
<td>201032</td>
<td>08/24/2010</td>
<td>1:59:12 PM</td>
<td>Internet Physician</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>138</td>
<td>0</td>
</tr>
<tr>
<td>5</td>
<td>48129</td>
<td>Denton</td>
<td>Student Health</td>
<td>201032</td>
<td>08/16/2010</td>
<td>11:34:24 AM</td>
<td>Internet Physician</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>77</td>
<td>0</td>
</tr>
<tr>
<td>6</td>
<td>48077</td>
<td>El Paso</td>
<td>Pediatrician</td>
<td>201032</td>
<td>08/30/2010</td>
<td>11:03:18 AM</td>
<td>Internet Physician</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>1165</td>
<td>0</td>
</tr>
<tr>
<td>7</td>
<td>48246</td>
<td>El Paso</td>
<td>Student Health</td>
<td>201032</td>
<td>08/30/2010</td>
<td>7:27:44 PM</td>
<td>Internet Physician</td>
<td>0</td>
<td>1</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>159</td>
<td>1</td>
</tr>
<tr>
<td>8</td>
<td>48074</td>
<td>Collin</td>
<td>Family Practice</td>
<td>201032</td>
<td>08/13/2010</td>
<td>4:25:00 PM</td>
<td>Internet Physician</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>25</td>
<td>0</td>
</tr>
<tr>
<td>9</td>
<td>48126</td>
<td>Brazoria</td>
<td>Family Practice</td>
<td>201032</td>
<td>08/14/2010</td>
<td>1:29:57 PM</td>
<td>Internet Physician</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>90</td>
<td>0</td>
</tr>
<tr>
<td>10</td>
<td>48295</td>
<td>San Saba</td>
<td>Family Practice</td>
<td>201032</td>
<td>08/17/2010</td>
<td>4:58:00 PM</td>
<td>Internet Physician</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>147</td>
<td>0</td>
</tr>
</tbody>
</table>

Data from ILINet are used to demonstrate where and when ILI activity is occurring. An unpublished study conducted by the University of Texas on behalf of DSHS in 2010 demonstrated that Texas ILINet data correlate with hospitalizations and deaths from influenza and pneumonia.

The data from ILINet are included in the Texas Weekly Flu Report, incorporated in the determination of Texas’s weekly influenza activity code report to CDC and used to monitor changes in ILI activity over time. An example ILINet data graph comparing multiple influenza seasons is shown below.

![Percentage of Visits Due to Influenza-like Illness Reported by Texas Participants in ILINet, 2009–2013 Seasons](image-url)
DSHS EAIDB has an ILINet Coordinator who recruits and enrolls providers, tracks reporting progress and sends reporting reminders to participants. The ILINet Coordinator also works with providers to correct data entry errors. Local and regional health departments in Texas assist the ILINet Coordinator with recruitment. The CDC goal for participation in ILINet is 1 provider for every 250,000 population; however, because not all enrolled providers report to the system every week, it may be beneficial to recruit more than the minimum required. Additionally, DSHS recommends that each county with a population of 100,000 or more should have at least 1 regularly reporting ILINet provider. With those goals in mind, the target numbers for providers in counties with a population of at least 100,000 are listed below. ILINet providers can be recruited from any county in Texas regardless of population. The DSHS ILINet Coordinator has created a plan for systematic ILINet recruiting in each DSHS Region based on recent population estimates and study data from the University of Texas. These recruitment plans are available upon request from flutexas@dshs.state.tx.us.

<table>
<thead>
<tr>
<th>County</th>
<th>2010 Census</th>
<th>ILINet Provider Target Recruiting Number</th>
</tr>
</thead>
<tbody>
<tr>
<td>Harris</td>
<td>4,092,459</td>
<td>16</td>
</tr>
<tr>
<td>Dallas</td>
<td>2,368,139</td>
<td>9</td>
</tr>
<tr>
<td>Tarrant</td>
<td>1,809,034</td>
<td>7</td>
</tr>
<tr>
<td>Bexar</td>
<td>1,714,773</td>
<td>7</td>
</tr>
<tr>
<td>Travis</td>
<td>1,024,266</td>
<td>4</td>
</tr>
<tr>
<td>El Paso</td>
<td>800,647</td>
<td>3</td>
</tr>
<tr>
<td>Collin</td>
<td>782,341</td>
<td>3</td>
</tr>
<tr>
<td>Hidalgo</td>
<td>774,769</td>
<td>3</td>
</tr>
<tr>
<td>Denton</td>
<td>662,614</td>
<td>3</td>
</tr>
<tr>
<td>Fort Bend</td>
<td>585,375</td>
<td>2</td>
</tr>
<tr>
<td>Montgomery</td>
<td>455,746</td>
<td>2</td>
</tr>
<tr>
<td>Williamson</td>
<td>422,679</td>
<td>2</td>
</tr>
<tr>
<td>Cameron</td>
<td>406,220</td>
<td>2</td>
</tr>
<tr>
<td>Nueces</td>
<td>340,223</td>
<td>1</td>
</tr>
<tr>
<td>Brazoria</td>
<td>313,166</td>
<td>1</td>
</tr>
<tr>
<td>Bell</td>
<td>310,235</td>
<td>1</td>
</tr>
<tr>
<td>Galveston</td>
<td>291,309</td>
<td>1</td>
</tr>
<tr>
<td>Lubbock</td>
<td>278,831</td>
<td>1</td>
</tr>
<tr>
<td>Jefferson</td>
<td>252,273</td>
<td>1</td>
</tr>
<tr>
<td>Webb</td>
<td>250,304</td>
<td>1</td>
</tr>
<tr>
<td>McLennan</td>
<td>234,906</td>
<td>1</td>
</tr>
<tr>
<td>Smith</td>
<td>209,714</td>
<td>1</td>
</tr>
<tr>
<td>Brazos</td>
<td>194,851</td>
<td>1</td>
</tr>
<tr>
<td>Hays</td>
<td>157,107</td>
<td>1</td>
</tr>
<tr>
<td>Johnson</td>
<td>150,934</td>
<td>1</td>
</tr>
<tr>
<td>Ellis</td>
<td>149,610</td>
<td>1</td>
</tr>
<tr>
<td>Ector</td>
<td>137,130</td>
<td>1</td>
</tr>
<tr>
<td>Midland</td>
<td>136,872</td>
<td>1</td>
</tr>
<tr>
<td>Guadalupe</td>
<td>131,533</td>
<td>1</td>
</tr>
<tr>
<td>County</td>
<td>2010 Census</td>
<td>ILINet Provider Target Recruiting Number</td>
</tr>
<tr>
<td>------------</td>
<td>-------------</td>
<td>----------------------------------------</td>
</tr>
<tr>
<td>Taylor</td>
<td>131,506</td>
<td>1</td>
</tr>
<tr>
<td>Wichita</td>
<td>131,500</td>
<td>1</td>
</tr>
<tr>
<td>Gregg</td>
<td>121,730</td>
<td>1</td>
</tr>
<tr>
<td>Potter</td>
<td>121,073</td>
<td>1</td>
</tr>
<tr>
<td>Grayson</td>
<td>120,877</td>
<td>1</td>
</tr>
<tr>
<td>Randall</td>
<td>120,725</td>
<td>1</td>
</tr>
<tr>
<td>Parker</td>
<td>116,927</td>
<td>1</td>
</tr>
<tr>
<td>Tom Green</td>
<td>110,224</td>
<td>1</td>
</tr>
<tr>
<td>Comal</td>
<td>108,472</td>
<td>1</td>
</tr>
<tr>
<td>Kaufman</td>
<td>103,350</td>
<td>1</td>
</tr>
<tr>
<td>Texas</td>
<td>25,145,561</td>
<td>101</td>
</tr>
</tbody>
</table>

*Population data available from DSHS Center for Health Statistics, [http://www.dshs.state.tx.us/chs/popdat/](http://www.dshs.state.tx.us/chs/popdat/)
Summarizing ILINet Data Using Pivot Tables in Microsoft Excel

Note: These instructions were created using Microsoft Office Excel 2010. Other versions of Excel may vary slightly in the placement of the icons, menus and layouts, as well as in the wizard or PivotTable instructions.

What is a pivot table?
A pivot table is an easy and dynamic way to summarize and organize data. A pivot table allows the user to quickly filter, sort, group and perform mathematical calculations (e.g., count, sum, product, average, standard deviation, variance, etc.) on data. The data can be moved easily from one field to another, allowing the user to quickly change how and where the data are displayed. Also, data in a pivot table can be transformed easily into a dynamic graph called a PivotChart.

Instructions
Example question: Which providers reported patients with ILI for Region 6/5S for week 45 in 2009?
1. Log into the ILINet system.
   Website: http://www2a.cdc.gov/iline/
   ID and password: Health departments can request the ID and password by emailing flutexas@dshs.state.tx.us

2. Choose your data set.
   a. Select “2009-2010 season (from 10/04/2009 to 10/2/2010)” from the dropdown menu.
   b. When you have made your selection, press the “Download ILI Data” button.
3. When a “File Download” window appears, click on “Save”. The default file is a Microsoft Excel file. Make sure to open the file when you are finished saving it. (Note: If you choose the “Open” option instead of the “Save” option, you will encounter an error when you try to create a pivot table.)

4. Now you are ready to create a pivot table.
   a. To create a pivot table, click anywhere in the body of the data (not in the column headers line).
   b. Then go to the ribbon, select Insert and then select PivotTable.
   c. Make sure the radio button next to “Select a table or range” is selected. Look at the blank next to “Table/Range” and make sure that the range includes all of the data and data headers for the data that you wish to pivot (in this case, it is all of the data and headers in the spreadsheet that you downloaded).
   d. For “Choose where you want the PivotTable to be placed”, select the radio button next to “New Worksheet”, if it is not already selected.
   e. Press “OK”.
   f. Now you will have the shell of a PivotTable, and you should see a PivotTable field list on some part of your screen. If you do not see the field list, right click with your mouse on the PivotTable and select “Show Field List”.
      i. The next step is to create the layout of your PivotTable.
         1. Drag “County” into the Row Labels field that is available below the field list.
         2. Drag “Phys ID Code” into the Column Labels field.
         4. Finally, since we want to know which providers reported patients with ILI, drag “Total ILI” into the Values field. (Because we chose a field containing numerical data for the Values field, the pivot table automatically defaulted to sum the values in the Total ILI column.)
5. Now you should see your completed pivot table, but you still need to do a few things to answer your original question.
   a. In the dropdown menu next to “Date Code,” select “200945” which stands for MMWR week 45 of 2009.
   b. In the dropdown menu next to “Row Labels” (these are the counties), select only the counties in HSR 6/5S (look for Austin, Brazoria, Chambers, Colorado, Fort Bend, Galveston, Hardin, Harris, Jefferson, Liberty, Matagorda, Montgomery, Orange, Walker, Waller and/or Wharton counties). Click the “Show All” button in the dropdown to uncheck or check all counties. Once you have selected the proper counties, click “OK” to close the dropdown.

c. The end result should be a pivot table that answers your original question.

   ![Pivot Table Example]

   During week 45 in HSR 6/5s:
   - One provider with ID code 48126 in Brazoria County reported 1 patient with ILI.
   - Nine providers in Harris County reported a total of 195 patients with ILI (one reported zero patients with ILI).
   - One provider in Wharton County reported 6 patients with ILI.
   - Also, note that one provider in Liberty County reported zero patients with ILI.

d. If you don’t like the layout, you can change it. One example is to swap the Row and Column fields of the pivot table by dragging “County” over and dropping it in the
Column Labels field, and then dragging “Phys ID Code” over and dropping it in the Row Labels field. Try this and see below for the result.

<table>
<thead>
<tr>
<th>Date Code</th>
<th>Sum of Total Ills</th>
</tr>
</thead>
<tbody>
<tr>
<td>482165</td>
<td>48</td>
</tr>
<tr>
<td>48260</td>
<td>19</td>
</tr>
<tr>
<td>48271</td>
<td>3</td>
</tr>
<tr>
<td>48272</td>
<td>41</td>
</tr>
<tr>
<td>48273</td>
<td>6</td>
</tr>
<tr>
<td>48274</td>
<td>0</td>
</tr>
<tr>
<td>48282</td>
<td>62</td>
</tr>
<tr>
<td>48288</td>
<td>15</td>
</tr>
<tr>
<td>48298</td>
<td>0</td>
</tr>
<tr>
<td>48304</td>
<td>6</td>
</tr>
</tbody>
</table>

### Definitions for ILINet Data Fields

**Phys ID Code:** The unique number assigned to each provider enrolled in ILINet

**County:** The county where the provider’s practice is located

**Practice Type:** Type of provider practice (options include Emergency Medicine, Family Practice, Infectious Disease, Internal Medicine, Pediatrician, Student Health, Urgent Care or Other)

**Date Code:** MMWR year and week that the data represent (format: YYYYWW)

**Date Called:** The date that the data were reported to the system

**Time Called:** The time that the data were reported to the system

**Source:** How the provider reported the data (options include Fax or Internet Physician)

**Age 0-4:** Number of patients aged 0-4 years that meet the definition of ILI

**Age 5-24:** Number of patients aged 5-24 years that meet the definition of ILI

**Age 25-49:** Number of patients aged 25-49 years that meet the definition of ILI

**Age 50-64:** Number of patients aged 50-64 years that meet the definition of ILI

**Age 65 and older:** Number of patients 65 years and older that meet the definition of ILI
Total Patients Seen: Total number of patients seen for any reason, including those seen with ILI
Total ILI: Sum of the number of patients with ILI reported in all age groups
ILI Percent: (Total ILI / Total Patients Seen) x 100

Quick Reference and Helpful Hints for Pivot Tables

1. Anatomy of a Pivot Table

2. Caveats of Pivot Tables
   a. The column that you select to drop in the Values field (previously known as the Data Area) of a pivot table must contain an entry for each line of data. If any lines in this selected column are blank, the pivot table will not summarize all rows in the original data set. In the ILINet data set, all columns are populated with data in all cells, so any of these columns would be a good choice for the Values field.
   b. If your pivot table returns “unusual” results (e.g., very large numbers or very small numbers), check in the upper left corner (called the Data Field) between the Row Labels and Column Labels fields of the pivot table to determine what mathematical function (e.g., sum, count, etc.) the pivot table is using to summarize the data. (Note: If you do not have anything in the Column Labels field, the Data Field will appear in the usual place of the Column Labels field.)
c. If the choice is not appropriate, right click on the Data Field, choose “Value Field Settings” and change the “Summarize Values By” selection. See the example below.

i. For example, if you wanted to find out how many providers reported data from each of the HSR 6/5S counties, you would need a **Count** of the “Phys ID Code” field; however, the pivot table defaults to a Sum because the Phys ID Code contains numerical values (see below).

![Pivot Table Example](image1.png)

ii. To change this, right-click with your mouse on the Data Field and choose “Value Field Settings” from the list. On the “Summarize Values By” tab, change the selection to “Count” and click “OK”.

iii. Now you see a count of the number of HSR 6/5S providers who reported to ILINet during this particular week.
d. Always double check to make sure that your pivot table data seem reasonable. Before attempting any filtering in a pivot table, check that the grand total in the original spreadsheet matches the grand total in the pivot table.

3. Miscellaneous
   a. If you close the Pivot Table Field List, you can reopen it by right-clicking with your mouse inside of the pivot table and then selecting “Show Field List”.
   b. If you change the original data set after you have created the pivot table, you must refresh the pivot table if you want to incorporate the changes. To do this, right click with your mouse on the PivotTable and select “Refresh”.
   c. To create a chart directly from your pivot table, go to the Insert tab on the ribbon and select one of the chart types (e.g., 2D column). The PivotChart is modifiable in the same way as the PivotTable to change the layout and the specific data that are displayed.
Data Quality Checks in ILINet

It is a good idea to perform a few quality checks on ILINet data each week. In the past, some data quality issues have been detected, particularly while examining data from newly recruited participants.

**ILI Percent Column**

**Very High Values**
The ILI Percent column should be examined each week for values of 100 percent ILI. In the past, followup with participants reporting 100 percent ILI (i.e., the number of total patients seen for any reason equal to the number of patients seen for ILI) has always revealed reporting errors and confusion about the definitions of the different data elements. If a participant is reporting 100 percent ILI, that participant should be contacted, questioned about the entry, and retrained on proper data entry if necessary.

**Very Low Values**
The ILI Percent column should also be examined each week for values that are consistently and unusually low. In particular, values of ILI under 1 percent consistently reported by a participant during peak influenza season are unusual and should be questioned. In the past, participants with this data characteristic were found to be including in their denominator patient visit totals from all physicians in their clinic system, regardless of whether or not certain specialty physician types were likely to ever see patients with ILI. Only provider types that actually see patients with ILI should be included in data reported to ILINet; other specialty provider types like orthopedists, urologists and others who would be very unlikely to see patients with ILI should not be included in the data reported to ILINet.

**Total Patients Seen and Total ILI Columns**
The Total Patients Seen and Total ILI columns should be examined for any unusual data, including rounding of the number of patient visits. Previously, data quality issues have been discovered in the form of patient visits rounded to the nearest 10 or 100; retraining is needed for participants whose data consistently appear rounded for convenience.
US Outpatient Influenza-like Illness Surveillance Network (ILINet) Application Form

E-mail to: flutexas@dshs.state.tx.us or fax to: 512-776-7616

Provider Information

<table>
<thead>
<tr>
<th>Last Name</th>
<th>Degree (MD, PA, DO)</th>
</tr>
</thead>
<tbody>
<tr>
<td>First Name</td>
<td></td>
</tr>
<tr>
<td>Practice Name</td>
<td>Type of Practice</td>
</tr>
<tr>
<td>(Name of facility)</td>
<td>(Pediatrics, Family Practice)</td>
</tr>
<tr>
<td>Street Address</td>
<td></td>
</tr>
<tr>
<td>City</td>
<td>Texas</td>
</tr>
<tr>
<td>Area Code/ Telephone Number</td>
<td></td>
</tr>
<tr>
<td>Fax Number</td>
<td></td>
</tr>
<tr>
<td>Contact Person</td>
<td></td>
</tr>
<tr>
<td>Contact Person Telephone Number</td>
<td>Extension</td>
</tr>
<tr>
<td>E-Mail Address</td>
<td></td>
</tr>
</tbody>
</table>

Agreement

I understand that by voluntarily reporting outpatient influenza-like illness by age group to the CDC on a weekly basis the CDC and the Texas Department of State Health Services develops a national picture of influenza virus activity, the geographic distribution of influenza viruses, and the clinical impact of the circulating viruses. I understand that Surveillance providers receive feedback on the data submitted, summaries of regional and national influenza data, and free subscriptions to CDC’s Morbidity and Mortality Weekly Report and Emerging Infectious Diseases journal. In addition, as a surveillance provider I can submit specimens from a subset of patients for virus isolation free of charge.

A certificate is sent annually to regular participants submitting 50% or more of ILI data.

For additional information about the ILINet
www.dshs.state.tx.us/idcu/disease/influenza/surveillance/ILINet

Robert Russin or Lesley Brannan
Emerging and Acute Infectious Disease Branch
Phone: (512) 776-6242 or 776-6354
Fax: (512) 776-7616
E-mail: flutexas@dshs.state.tx.us

Thank you for completing this application form and for your support of public health.
Influenza Surveillance Activities - IISP

IISP Overview

From 2009–2013, the Centers for Disease Control and Prevention (CDC) and the Council of State and Territorial Epidemiologists (CSTE) provided funding for twelve state or large local health departments to participate in the Influenza Incidence Surveillance Project (IISP). In 2011, the Texas Department of State Health Services was selected to participate in the project after a competitive application process. The project monitors the age-specific incidence of medically-attended ILI throughout the influenza season through voluntary reporting of influenza-like illness and specimen submission from selected healthcare providers.

Provider participation in IISP in Texas is available for up to six healthcare providers in any of the following settings: family practice, pediatricians, internal medicine, student health, infectious disease, community clinics or urgent care. The providers should also have a moderate patient volume of 100-150 patient visits per week. The combined patient population of all participating providers should represent all age groups. Providers must also commit to participation for a full year.

Providers participating in IISP send weekly reports directly to the Influenza Surveillance Team at DSHS Central Office in Austin. Reports are due by noon on Tuesday. The reports include aggregate counts of total patients seen and the number of patients seen with ILI. Aggregate counts are reported in eight age group categories that are collapsible to ILINet age groups. ILI is defined differently for IISP compared to ILINet. For patients ≥ 2 years of age, ILI is defined as illness onset in the past four days of fever with a cough and/or sore throat. In patients < 2 years of age, ILI is defined as illness onset in the past four days of fever AND at least 2 of the following: rhinorrhea, nasal congestion, sore throat or cough.

In addition to aggregate reporting, IISP providers collect nasopharyngeal specimens on the first ten patients they see each week with ILI. The specimens, along with patient demographic and clinical data, are submitted to DSHS. The specimens are tested for influenza, respiratory syncytial virus, adenovirus, parainfluenza viruses 1-3, human metapneumovirus and rhinovirus.

Data collected from this surveillance project are used to describe the incidence and presentation of influenza and other viruses associated with acute respiratory infections in Texas. Providers participating in IISP receive regular reports summarizing the data from the provider’s clinic and comparing those data to the combined data from all the Texas IISP providers.

For 2013-2014, Texas will continue to participate in IISP with an “enhanced ILINet” program. The program will be similar to the IISP program from 2011-2013, except that providers will report ILI data directly to ILINet instead of reporting those data to DSHS. To align with the data collection method for ILINet, the total patients seen each week will no longer be reported by age group.
An example of the IISP aggregate count reporting tool from 2011-2013 is included below:

To:  Influenza Surveillance – Texas Department of State Health Services

Fax Number:  512-776-7616

Date:  ________ / _______ / _______  Pages, including Cover Sheet:  ________

Re:  Influenza-like Illness Weekly Report

Weekly ILI Report

Clinic Name:  _________________________________

Report for the 7-day period ending on Saturday:  _____/_____/_____  

<table>
<thead>
<tr>
<th>Total Patient Visits for Any Reason</th>
<th>(Sunday through Saturday)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (yrs)</td>
<td>&lt;1</td>
</tr>
<tr>
<td># of patients seen</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Number of Patients Seen with ILI</th>
<th>(Sunday through Saturday)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (yrs)</td>
<td>&lt;1</td>
</tr>
<tr>
<td># of patients with ILI</td>
<td></td>
</tr>
</tbody>
</table>

Influenza-like illness (ILI) definition:
Patients ≥ 2 years old: Onset in the past 4 days of fever with a cough and/or with a sore throat
Children < 2 years: Onset in the past 4 days of fever AND at least 2 of the following:
rhinorrhea, nasal congestion, sore throat, or cough.

Please email report to flutexas@dshs.state.tx.us or fax it to  512-776-7616  (no cover sheet needed) by noon each Tuesday. Thank you!
Influenza Surveillance Activities – ILI Activity

ILI Activity Overview

The primary surveillance program for estimating influenza-like illness (ILI) at the state level in Texas is ILINet. However, regional and local health departments may want to supplement ILINet surveillance with additional ILI activity surveillance to better understand and track ILI in their own jurisdictions. Most health departments and regions collect data on test results, emergency room admissions and ILI activity reported by hospitals, clinics, provider offices or even schools as a way to monitor influenza activity. This provides a much more detailed picture of influenza activity in a community, county or region.

One advantage of ILINet is the statewide consistency in data collection. All providers who use ILINet report the total number of patients seen by the provider and the total number of patients seen with ILI by age group. Additionally, an unpublished study conducted by the University of Texas on behalf of DSHS in 2010 demonstrated that Texas ILINet data correlate with hospitalizations and deaths from influenza and pneumonia. One disadvantage of ILINet is that the state, regional and local health departments cannot modify what variables are collected in the system. It also reduces local and regional health department interactions with providers, hospitals, infection control professionals and clinics within their own communities.

Many regional and local health departments in Texas have built their own ILI activity surveillance systems using volunteer providers and hospital staff who report data directly to local public health officials. Having reports sent directly to the local or regional health department has the advantage of flexibility, immediacy and the ability to respond quickly to events occurring within a local or regional jurisdiction; these events may include outbreaks or identification of unusual strains or perceived risk factors that may contribute to hospitalizations or deaths. Health departments can use their own criteria for recruiting reporters and can select what information they are interested in receiving. However, since regional offices and local health departments differ in their approaches to influenza surveillance, it can be difficult to compare an influenza report from one community to that from another community.

This section provides recommendations for the types of data that should be collected from influenza reporters that report directly to a health department.
Data Collection

There is a wealth of health and medical information that could potentially be used to assess influenza and ILI activity in a community. Influenza illness can range from mild to severe depending on an individual’s health status and the strain of influenza. Increases in hospitalizations and deaths from pneumonia and influenza often correlate with increases in ILI activity among patients seen at private provider offices, clinics and hospitals. Public health professionals and organizations have been exploring other potential data sources to enhance the ability of public health to describe influenza and ILI activity and estimate the impact on the community.

Data may be collected from healthcare providers and from non-healthcare providers. Some health departments only collect the number of people seen with ILI each week or the number of tests that were positive for influenza each week. These data help provide a rough idea of the amount of ILI activity occurring during a reporting week; however, the data will be heavily influenced by the number of people who happen to see a healthcare provider and the number of reporters who actually report each week. Counts cannot be compared with data from another health jurisdiction because they lack information about the underlying population. A perceived peak in activity could be an artifact of adding a new reporter, having a reporter expand his practice or having more reporters participating in one week compared to other weeks. It is also difficult to make comparisons among weeks and influenza seasons since the numbers and types of reporters are so variable.

DSHS recommends that in addition to collecting reports on the number of people seen with ILI each week, the total number of people seen for any reason should also be collected from the healthcare provider. This additional variable allows the calculation of the proportion of people seen with ILI. Using the proportion of people seen with ILI instead of just the total number of people with ILI helps control for variation in the number and types of reporters. It also allows comparisons among other weeks, seasons and jurisdictions since both denominator and numerator data are captured.

If a provider is able to report the number of patients seen with ILI by age group categories and the total number of patients seen, this information could be used in ILINet in addition to local and regional surveillance systems. The provider can report through ILINet and to the health department or the provider can just report to the health department. In the latter case, the health department can then fax the information to DSHS or CDC for data entry into ILINet.

Providers, clinics and hospitals can also enhance the data collected by reporting influenza test results. Physicians may use rapid tests in their offices or submit specimens for influenza testing to commercial or public health laboratories. Obtaining the number of tests that were positive for influenza A, influenza B, undifferentiated influenza A/B or specific subtypes of influenza assists public health in determining which types of influenza are circulating around the state.

Some health departments use non-medical or quasi-medical entities to report ILI activity such as schools, large businesses and nursing homes. The data that can be collected from these entities...
will vary slightly depending on the type of reporting facility. Examples of data that may be collected from these entities are included in the table below:

<table>
<thead>
<tr>
<th>Entity</th>
<th>Data</th>
</tr>
</thead>
<tbody>
<tr>
<td>Grade schools</td>
<td>• School closures from ILI-related absenteeism among students/staff</td>
</tr>
<tr>
<td></td>
<td>• Total number of students and the number of students absent each week</td>
</tr>
<tr>
<td></td>
<td>• Number of students absent that parents report as ILI</td>
</tr>
<tr>
<td></td>
<td>• Total number of students seen by the school nurse and the number of those students with ILI</td>
</tr>
<tr>
<td>Large businesses</td>
<td>• Total number of employees and the number of employees who call in sick each week</td>
</tr>
<tr>
<td></td>
<td>• Number of employees who self-report ILI</td>
</tr>
<tr>
<td>Nursing homes</td>
<td>• Total number of residents and the number with ILI each week</td>
</tr>
<tr>
<td></td>
<td>• Total number of residents transferred to a hospital with ILI or pneumonia each week</td>
</tr>
<tr>
<td></td>
<td>• Total number of staff and the number of staff that call in sick each week</td>
</tr>
<tr>
<td>First responders [may include Emergency Medical Services (EMS) or Fire]</td>
<td>• Total number of calls/incidents and the number of those calls/incidents that were ILI related</td>
</tr>
<tr>
<td></td>
<td>• Total number of employees and the number of employees who call in sick each week</td>
</tr>
</tbody>
</table>

Deciding how many influenza/ILI reporters to recruit is important. The determination of the number of reporters to recruit for participation varies by jurisdiction and depends upon the types of influenza surveillance questions that the jurisdiction wants to be able to answer. Section IVa includes a table showing the recommended number of ILINet reporters per county. These recommendations are based upon CDC guidance and DSHS goals for representativeness in Texas. Health jurisdictions may want to have more reporters than recommended to increase awareness of ILI activity within their area. This may include having at least one medical care provider reporting from every major population area in the jurisdiction. If a medical care provider is not available, non-medical reporters such as schools or large businesses can provide information as well.
Example Influenza Surveillance Report Forms

FACSIMILE TRANSMITTAL SHEET

To: Sandi Henley RN, CIC  
FAX NUMBER: 254-899-0405

COMPANY: Texas Department of State Health Services  
TOTAL NO. OF PAGES INCLUDING COVER: 1

PHONE NUMBER: 254-778-6744  
INFLUENZA REPORTING

2010-11

CLINIC WEEKLY ILI/FLU REPORT
Submit by 3:00 each Monday for the week prior (Sunday – Saturday)

Name (Clinic):

Name of Reporter: ________________

Phone Number: __________ Email of Reporter: ________________

Week Ending: ____________________

Definitions:
- Flu case confirmed by rapid test, culture, antigen detection, or PCR (Flu A, Flu B, Not Differentiated Flu), and/or.
- Influenza-like illness activity (ILI): ILI is defined as fever over 100°F and cough and/or sore throat in the absence of another diagnosis.

Please complete the table listing the number of flu and ILI cases seen in your facility

<table>
<thead>
<tr>
<th>County (Residence of patient)</th>
<th>ILI</th>
<th>Rapid Flu A</th>
<th>Rapid Flu B</th>
<th>Rapid Flu ND*</th>
<th>Culture/PCR+ flu A</th>
<th>Culture/PCR+ flu B</th>
<th>'09 H1N1 Culture/PCR+</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*ND = Not Differentiated Flu

Please email report to: hsr7.epi@dshs.state.tx.us by 3 p.m. on Mondays. If Monday is a holiday, send ASAP. The report may also be faxed to 254-899-0405 (no cover sheet needed). You may call 254-778-6744 with questions or comments. If sending additional information for a previously submitted report, please highlight the changes being made. Thank you!
Tarrant County Public Health  
Division of Epidemiology and Health Information  
INFLUENZA SURVEILLANCE WEEKLY REPORT FORM

I. HOSPITALS / CLINICS / SENTINEL PHYSICIANS

<table>
<thead>
<tr>
<th>Name of Organization</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Total Patients Seen</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Number of Patients with ILI* (by age group)</th>
</tr>
</thead>
<tbody>
<tr>
<td>&lt; 1</td>
</tr>
<tr>
<td>------</td>
</tr>
</tbody>
</table>

* Influenza-like illness (ILI). ILI is defined as fever ≥ 100°F PLUS a cough or sore throat, in the absence of another known cause other than influenza.

<table>
<thead>
<tr>
<th>Number of Flu Tests Performed</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of Positive Flu Results</td>
</tr>
<tr>
<td>Type A</td>
</tr>
<tr>
<td></td>
</tr>
</tbody>
</table>

INSTRUCTIONS - INFLUENZA SURVEILLANCE

1. All information requested is weekly, beginning Sunday and ending Saturday.
   - Please report ALL the Influenza-Like Illness (ILI) seen in your ER and/or facility. ILI is defined as fever ≥ 100°F PLUS a cough or sore throat in the absence of another known cause other than influenza.
     i. If your facility performs any influenza testing, include all positive and negative patients in determining the number of ILI seen in your facility.
     ii. If applicable, report the number of influenza tests performed at your facility including influenza type (A or B) detected.

2. Complete Influenza Surveillance Questionnaire for patient presenting with ILI AND recent travel history to avian influenza endemic areas (Asia, Africa or Eastern Europe).

3. Clinical specimens MUST be submitted to TCPH for any patient presenting with ILI AND recent travel history to avian influenza endemic areas (Asia, Africa or Eastern Europe). Testing is for surveillance purposes only.
   - Notify TCPH public health personnel for clinical specimen pick-up and delivery to the North Texas Regional Laboratory.

4. Fax (817) 321-5333 or email (flu@tarrantcounty.com) the completed form by 1:00 PM, Monday of the following week. Information collected will be used to update your facility, other participating facilities, Tarrant County, The Texas Department of State Health Services (DSSH), Centers for Disease Control (CDC), and the World Health Organization (WHO).

   If you have any questions regarding this form, please contact the Tarrant County Public Health, Epidemiology and Health Information Division (817) 321-5386.
HEALTH SERVICE REGION 2/3
Influenza Reporting Form – Healthcare Facilities

Date of Report: __/__/____  Reporting Facility: ___________________________ Phone: ______________
Reporter: __________________ Email: ________________________________

Please include on this form each patient who presents to the emergency department/hospital/health care facility with symptoms consistent with influenza, which include fever ≥100.4°F, malaise, muscle aches, cough, runny nose, sore throat, chills, and headache. If you have any questions, please call 817-264-4657.

SUMMARY: Influenza Activity level has: ☐ Increased ☐ Decreased ☐ Stayed the Same ☐ Unsure

Patients have presented to this facility who have (check all that apply): ☐ No influenza-like illness
☐ Flu A (rapid test) ☐ Flu B (rapid test) ☐ Undifferentiated (positive A/B) ☐ Influenza-like illness

Fax/email forms each Monday to 817-264-4557 or HSR2-3.EpiReporting@dshs.state.tx.us

<table>
<thead>
<tr>
<th>Patient Initals</th>
<th>Date Seen</th>
<th>City of Residence</th>
<th>Sex (M/F)</th>
<th>&lt;24 mos</th>
<th>2-4 yrs</th>
<th>5-14 yrs</th>
<th>15-24 yrs</th>
<th>25-39 yrs</th>
<th>40-64 yrs</th>
<th>≥65 yrs</th>
<th>Vacc'd (Y/N)</th>
<th>Test Result Type A/B/U/NT</th>
<th>ILI (Y/N)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<sup>1</sup> A=Type A; B=Type B; U=Undifferentiated; NT=Not Tested  <sup>2</sup> ILI=Influenza-Like Illness

Fax/email forms each Monday to 817-264-4557 or HSR2-3.EpiReporting@dshs.state.tx.us
F31-12361
August 2010
Influenza Surveillance Activities – Laboratory Surveillance

Laboratory Surveillance Overview

Laboratory surveillance for influenza is conducted year-round at the DSHS Austin and Laboratory Response Network (LRN) laboratories. The objectives of laboratory surveillance for influenza include detecting where viruses are circulating, which viruses are circulating, if circulating influenza viruses match the vaccine strains and if the influenza viruses are changing in any important ways (e.g., new strains or strains demonstrating antiviral resistance). Laboratory surveillance is an essential component of influenza surveillance. Volunteer healthcare providers at clinics and hospitals collect specimens from patients who have symptoms of influenza and ship those specimens to DSHS Austin and the LRN laboratories for testing. RT-PCR testing at Texas public health laboratories is the primary screening method for these specimens; a sample of these specimens is tested further by DSHS and CDC to determine strain characterization and antiviral resistance properties. Patient specimens are tested at DSHS Austin and the LRNs to determine if they are positive for influenza types and subtypes; RT-PCR results are reported to submitters and are available to epidemiologists through the DSHS laboratory information system, PHLIMS/LabWare. A graph displaying influenza data from the DSHS Virology Laboratory is included below.
Coordinating Laboratory Surveillance

The EAIDB Influenza Surveillance Coordinator at DSHS Austin coordinates the state’s laboratory surveillance program, receives and processes viral transport medium (VTM) and supply orders and forwards these to the DSHS Container Preparation Group for completion, and monitors specimen submissions to the DSHS Austin Virology Laboratory throughout the season. Local and regional health departments recruit providers prior to and throughout the season to participate in laboratory surveillance by forwarding specimens to Texas public health laboratories. See the recruitment section of this handbook (Section V) for tips on encouraging providers to participate in laboratory surveillance. See the laboratory support section (Section VI) for details on surveillance conducted at the DSHS Austin and LRN laboratories.

Beginning in the 2013-2014 influenza season, each Health Service Region is asked to ensure submission of a minimum number of specimens per week to Texas public health laboratories (PHLs). The number of specimens required is determined by regional population and the number of specimens needed to maintain situational awareness for influenza at the state level as specified by the Influenza Virologic Surveillance Right Size guidelines. For the 2013-2014 season, the minimum weekly number of specimens required from all submitters in each region is shown below:

<table>
<thead>
<tr>
<th>Jurisdiction</th>
<th>Weekly specimen submission to a Texas PHL required to meet Right Size goals for influenza</th>
</tr>
</thead>
<tbody>
<tr>
<td>Region 1</td>
<td>4</td>
</tr>
<tr>
<td>Region 2/3</td>
<td>41</td>
</tr>
<tr>
<td>Region 4/5N</td>
<td>8</td>
</tr>
<tr>
<td>Region 6/5S</td>
<td>36</td>
</tr>
<tr>
<td>Region 7</td>
<td>16</td>
</tr>
<tr>
<td>Region 8</td>
<td>14</td>
</tr>
<tr>
<td>Region 9/10</td>
<td>7</td>
</tr>
<tr>
<td>Region 11</td>
<td>12</td>
</tr>
<tr>
<td>Texas</td>
<td>138†</td>
</tr>
</tbody>
</table>

†Overall weekly Texas specimen submission required to maintain situational awareness for influenza at the state level with a 95% confidence level and 5% margin of error. Regional populations for specimen submission calculations are an average of the projected populations for each year in the influenza season.
A surveillance protocol is sent to healthcare providers who agree to support DSHS influenza laboratory surveillance along with their first VTM order. The following items are included in this protocol:

- Storage of viral transport medium
- Specimen collection
- Specimen storage
- Specimen labeling and DSHS G-2V laboratory submission form completion
- Packaging specimens for shipment
- Shipping specimens to DSHS

It is important to encourage participating providers to submit specimens throughout the entire influenza season.

- Pre-season specimens and early season specimens: These specimens can provide important information regarding circulation of strains as compared to the previous season, information on the match between vaccine and circulating strains and information necessary for the vaccine formulation for the next year.
- Representative number of specimens collected during peak activity: These specimens provide information on which strains are likely driving the peaks.
- Late season specimens collected after the majority of peak activity is finished: Occasionally secondary, smaller waves of influenza illness can occur. Late season specimens help identify if different strains of influenza are circulating.
- Specimens obtained during outbreaks: Outbreaks may occur in immunized populations or in non-immunized populations.

In addition to specimen submission for the aforementioned reasons, all healthcare providers should be encouraged to submit specimens from:

- Persons in which antiviral resistance is suspected such as anyone who did not recover from their influenza illness after receiving antiviral therapy and their close contacts who also become ill
- Persons with suspected animal-to-human transmission of influenza viruses
- Persons with extremely severe or unusual presentations of influenza-like illness
How to Obtain Laboratory Data

Laboratory data from the DSHS Austin Laboratory and most LRN laboratories are available through PHLIMS/LabWare. LabWare access is available to DSHS Austin and DSHS Health Service Region staff. Local health department staff can also access results for their jurisdiction in LabWare.

To gain access to LabWare or the Public Health Web Portal, please send an email requesting access to flutexas@dshs.state.tx.us.

Users will have to fill out the following forms to access PHLIMS:
- Facility Security Agreement
- User Security Rights and Confidentiality Form for each user account

These forms are located at http://www.dshs.state.tx.us/lab/remotedata.shtm under the heading “Applying for Remote Data Systems Forms.” It also may be helpful to visit the frequently asked questions page at http://www.dshs.state.tx.us/lab/rdsFAQ.shtm.

Please see http://www.dshs.state.tx.us/lab/remotedata.shtm for more information on accessing PHLIMS.
Influenza Surveillance Activities - NREVSS

NREVSS Overview

NREVSS is a CDC-maintained online reporting system for select respiratory and enteric viruses including influenza, parainfluenza, respiratory syncytial virus (RSV), rhinovirus, enterovirus, adenovirus, human metapneumovirus and rotavirus. NREVSS reporters are hospital or public health laboratories that voluntarily enter aggregated weekly laboratory testing results into the online reporting system. Laboratories report the number of tests performed and the number of tests positive—by type or subtype, if applicable—as well as the type of testing performed (i.e., antigen detection testing, viral isolation or PCR). Laboratories may choose to report data on any or all viruses for which the system captures information. The deadline for reporting the previous week’s data is each Tuesday by noon. An example of the online reporting form is included below.

Every Tuesday afternoon, the DSHS EAIDB Influenza Surveillance Coordinator downloads the Texas data spreadsheet from the system and forwards it to a distribution list of regional influenza coordinators and other interested public health entities. Health departments that wish to be added
to this distribution list should send an email to flutexas@dshs.state.tx.us with the name and organization of a contact person and the email address to which the file should be sent.

NREVSS data are monitored to determine when and where respiratory and enteric viruses are circulating. The types and subtypes of influenza detected throughout the state can also be monitored when laboratories that have those testing capabilities enter their data in NREVSS. The data from the NREVSS system are included in the Texas Weekly Flu Report, incorporated in the determination of Texas’ weekly influenza activity code report to CDC and used to monitor the influenza viruses seen across Texas throughout the year. Data from other NREVSS viruses are monitored and reported as necessary. Additionally, an RSV report is compiled each week during RSV season using NREVSS data and posted to the DSHS website at http://www.dshs.state.tx.us/RSV/disease/rsv-Data.aspx. An example of a NREVSS data graph for influenza viruses for the 2008-2009 season is shown below.

NREVSS participants are recruited by the local, regional and state health departments and enrolled by the CDC NREVSS Program. There is always a need for more laboratories to participate in the NREVSS program. Currently, the greatest need is for the recruitment of reliable reporting laboratories in the northern “panhandle” area of Texas, far western Texas (especially El Paso) and eastern and northeastern areas of Texas. Interested laboratories may contact flutexas@dshs.state.tx.us for information. Information on recruiting laboratories can be found in section V.
How to Use NREVSS Data

The NREVSS file is a Microsoft Excel file that contains the most recent one to two years of data at a time. The data file is updated each week to include new data from laboratories reporting for the most recent MMWR week, as well as data from laboratories reporting “late” for previous MMWR weeks. The EAIDB Influenza Surveillance Coordinator emails NREVSS data to regional influenza surveillance coordinators every week.

One of the most useful ways to look at the data is to create a pivot table either in Microsoft Excel or Access. Pivot tables easily and dynamically organize and summarize data.

Note: These instructions were created using Microsoft Office Excel 2010.

Note: These instructions were created using the NREVSS data file sent on 07-30-2013 without any sorting performed on the data. Later data files may show updated data and therefore totals may be different.

Example questions:
1. How many influenza tests were performed and reported from NREVSS participating laboratories in San Antonio during 2013 MMWR week 10?
2. How many of these influenza tests were positive?

Question 1
1. Open the NREVSS data file that was forwarded to you from flutexas@dshs.state.tx.us.
2. Click on the upper left corner square of the worksheet to highlight the entire worksheet.
3. With the worksheet highlighted, double-click with your mouse on the vertical line that separates columns A and B to expand all of the columns and rows so that the data can be viewed fully.
4. Spend some time familiarizing yourself with the data contained in the NREVSS columns and rows so that you will be prepared to pivot the data appropriately. Please refer to the NREVSS data dictionary at the end of this subsection for more information.
a. The columns of interest are: CITY, WEEK, FLU_TEST, FluPanAH1N1pos, AH1N1POS, AH3N2POS, AUNK_POS, FLUB_POS

5. In order to make it a little easier to answer to Question 2 later, we need to add a new column to the NREVSS dataset that is the sum of all of the influenza positive columns.
   a. On the NREVSS data worksheet, insert a column between the columns “FLUB_POS” and “ROT_TEST”. [to add a column: click on the column Y heading to highlight column Y (ROT_TEST); right click with your mouse and select Insert]
   b. Name the column “TOTALFLU_POS”
   c. In cell Y2, type the following formula: =sum(T2:X2)
   d. Press Enter to finish the formula. You should now have a zero in cell Y2.
   e. In order to populate the formula all the way down the worksheet to the end of the data lines, click on cell Y2 to make sure it is selected. Then, double-click on the fill handle (little black box at the lower right corner of the highlighted cell Y2).

6. Now you are ready to create a pivot table.
   a. To create a pivot table, click anywhere in the body of the data (not in the column headers line).
   b. Then go to the ribbon, select the Insert tab and then select PivotTable to start the PivotTable Wizard.
   c. A box with the title “Create PivotTable” will pop up.
      i. The radio button next to “Select a table or range” should be selected, and the appropriate range of your data set should be populated in the “Table/Range:” blank. Check to see that all of your NREVSS data are selected, and correct the data selection if it is incorrect.
      ii. The radio button next to “Use an external data source” should not be selected.
      iii. Under the wording “Choose where you want the PivotTable to be placed”, select the radio button for New Worksheet, and click OK.
   d. Now you should see a blank pivot table on a new worksheet.
      i. Drag “CITY” into the Row Labels field.
      ii. Drag “WEEK” into the Report Filter.
      iii. Finally, since we want to know how many influenza tests were performed, drag “FLU_TEST” into the Values field. (Because we chose a field containing numbers for the Values field, the pivot table automatically defaulted to sum the values in the FLU_TEST column.)
   e. Now that you have data in your pivot table, you need to perform two additional steps to answer question #1.
      i. In the dropdown menu next to “WEEK”, select “1310” which stands for MMWR week 10 of 2013.
      ii. Click on the dropdown menu next to “CITY”.
         1. Click on “(Select All)” to uncheck all selections.
2. Then scroll down the list and click on the box next to San Antonio to check the box.
3. Click OK.
4. Only the results for San Antonio are displayed.

<p>| | | | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>A</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>WEEK</td>
<td>1310</td>
<td></td>
</tr>
<tr>
<td></td>
<td>CITY</td>
<td></td>
<td>Total</td>
</tr>
<tr>
<td>3</td>
<td>Sum of FLU_TEST</td>
<td></td>
<td></td>
</tr>
<tr>
<td>4</td>
<td>San Antonio</td>
<td>603</td>
<td></td>
</tr>
<tr>
<td>5</td>
<td>Grand Total</td>
<td>603</td>
<td></td>
</tr>
</tbody>
</table>

5. During MMWR week 10 in 2013, NREVSS participants in San Antonio reported performing 603 tests for influenza.

f. If you want a little more information about which institutions reported those tests and which types of tests they performed, you can also get that information in just a few more steps.

i. Click on your pivot table to reveal the Pivot Table Field List. If that doesn’t work, right click on the pivot table, go down to the bottom of the dropdown and select “Show Field List”.

ii. Drag “INST” (short for institution) into the Row field of the pivot table, to the left of CITY. Move CITY from the Row field up to the Report Filter by dragging and dropping it there.

1. The current view shows flu test subtotals by institution.

iii. Now you can add the test type data.

1. Click on your pivot table to reveal the Pivot Table Field List. If that doesn’t work, right click on the pivot table, go down to the bottom of the dropdown and select “Show Field List”.

2. Drag “TestType” into the Column Labels field of the pivot table.

3. Now you see the totals for influenza tests performed by institution and by test type reported by San Antonio NREVSS participants during 2013 MMWR week 10.

<table>
<thead>
<tr>
<th></th>
<th>A</th>
<th>B</th>
<th>C</th>
<th>D</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>WEEK</td>
<td>1310</td>
<td></td>
<td></td>
</tr>
<tr>
<td>2</td>
<td>CITY</td>
<td>San Antonio</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>4</td>
<td>Sum of FLU_TEST</td>
<td></td>
<td>TestType</td>
<td></td>
</tr>
<tr>
<td>5</td>
<td>INST</td>
<td></td>
<td>AG</td>
<td>PCR</td>
</tr>
<tr>
<td>6</td>
<td>Methodist Children's Hospital</td>
<td>183</td>
<td>107</td>
<td>290</td>
</tr>
<tr>
<td>7</td>
<td>Santa Rosa Health Care</td>
<td>200</td>
<td></td>
<td>200</td>
</tr>
<tr>
<td>8</td>
<td>University Hospital/South Texas Medical Center</td>
<td>55</td>
<td>53</td>
<td></td>
</tr>
<tr>
<td>9</td>
<td>Grand Total</td>
<td>443</td>
<td>160</td>
<td>603</td>
</tr>
</tbody>
</table>
Question 2
1. Continue to use the same pivot table to answer question 2.
2. Locate the gray box in the pivot table that says “Sum of FLU_TEST” (this box is called the Values field).
   i. Click on the Values field and drag “Sum of FLU_TEST” out of the bounds of the pivot table.
   ii. Your pivot table should now have a blank Values field.
3. Now you are ready to add another data item to your Data Area.
   i. Click on your pivot table to reveal the Pivot Table Field List. If that doesn’t work, right click on the pivot table, go down to the bottom of the dropdown and select “Show Field List”.
   ii. Drag “TOTALFLU_POS” into the Values field of the pivot table.
   iii. Your pivot table should now look like this:

<table>
<thead>
<tr>
<th>A</th>
<th>B</th>
<th>C</th>
<th>D</th>
</tr>
</thead>
<tbody>
<tr>
<td>WEEK</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CITY</td>
<td>San Antonio</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sum of TOTALFLU_POS</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>INST</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Methodist Children's Hospital</td>
<td>10</td>
<td>4</td>
<td>14</td>
</tr>
<tr>
<td>Santa Rosa Health Care</td>
<td>17</td>
<td>4</td>
<td>17</td>
</tr>
<tr>
<td>University Hospital/South Texas Medical Center</td>
<td>27</td>
<td>8</td>
<td>35</td>
</tr>
<tr>
<td>Grand Total</td>
<td></td>
<td></td>
<td>35</td>
</tr>
</tbody>
</table>

   - During 2013 MMWR week 10, San Antonio NREVSS participants reported 27 antigen tests and 8 PCR tests positive for influenza.
4. If you wanted to determine which types or subtypes were identified, you could do that by removing TestType from the PivotTable and pulling each type or subtype field into the Values field.
## NREVSS Data Dictionary

<table>
<thead>
<tr>
<th>Field Name</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>LabID</td>
<td>Six digit unique identification number for a lab</td>
</tr>
<tr>
<td>INST</td>
<td>Name of lab</td>
</tr>
<tr>
<td>CITY</td>
<td>Location of lab</td>
</tr>
<tr>
<td>STATE</td>
<td>Location of lab</td>
</tr>
<tr>
<td>Season</td>
<td>The 2 years included in a particular reporting season that runs from July to June</td>
</tr>
<tr>
<td>WEEK</td>
<td>First 2 digits represent the year; last 2 digits represent the week number of that year</td>
</tr>
<tr>
<td>WeekEnding</td>
<td>The Saturday marking the end of a particular reporting week (Sunday-Saturday)</td>
</tr>
<tr>
<td>TestType</td>
<td>AG= antigen detection; VI= virus isolation; PCR=Polymerase chain reaction test</td>
</tr>
<tr>
<td>RSV_TEST</td>
<td>Number of RSV tests performed by a lab during a given week for a given test type</td>
</tr>
<tr>
<td>RSV_POS</td>
<td>Number of positive RSV test results reported by a lab during a given week for a given test type</td>
</tr>
<tr>
<td>PARATEST</td>
<td>Number of human parainfluenza tests performed by a lab during a given week for a given test type</td>
</tr>
<tr>
<td>PAR1_POS</td>
<td>Number of positive human parainfluenza type 1 test results reported by a lab during a given week for a given test type</td>
</tr>
<tr>
<td>PAR2_POS</td>
<td>Number of positive human parainfluenza type 2 test results reported by a lab during a given week for a given test type</td>
</tr>
<tr>
<td>PAR3_POS</td>
<td>Number of positive human parainfluenza type 3 test results reported by a lab during a given week for a given test type</td>
</tr>
<tr>
<td>PAR4_POS</td>
<td>Number of positive human parainfluenza type 4 test results reported by a lab during a given week for a given test type</td>
</tr>
<tr>
<td>PARX_POS</td>
<td>Number of positive human parainfluenza untyped test results reported by a lab during a given week for a given test type</td>
</tr>
<tr>
<td>ADERTEST</td>
<td>Number of respiratory adenovirus tests performed by a lab during a given week for a given test type</td>
</tr>
<tr>
<td>ADER_POS</td>
<td>Number of positive respiratory adenovirus test results reported by a lab during a given week for a given test type</td>
</tr>
<tr>
<td>FLU_TEST</td>
<td>Number of influenza tests performed by a lab during a given week for a given test type</td>
</tr>
<tr>
<td>FluPanAH1N1Pos</td>
<td>Number of positive novel influenza A (H1N1) test results reported by a lab during the given week for a given test type</td>
</tr>
<tr>
<td>AH1N1POS</td>
<td>Number of positive SEASONAL influenza A (H1N1) test results reported by a lab during a given week for a given test type</td>
</tr>
<tr>
<td>AH3N2POS</td>
<td>Number of positive influenza A (H3N2) test results reported by a lab during a given week for a given test type</td>
</tr>
<tr>
<td>AUNK_POS</td>
<td>Number of positive influenza A (untyped) test results reported by a lab during a given week for a given test type (does NOT include Novel H1N1)</td>
</tr>
<tr>
<td>Field Name</td>
<td>Description</td>
</tr>
<tr>
<td>-------------</td>
<td>-----------------------------------------------------------------------------</td>
</tr>
<tr>
<td>FLUB_POS</td>
<td>Number of positive influenza B test results reported by a lab during a given week for a given test type</td>
</tr>
<tr>
<td>RotaTest</td>
<td>Number of rotavirus tests performed by a lab during a given week for a given test type</td>
</tr>
<tr>
<td>RotaPos</td>
<td>Number of positive rotavirus test results reported by a lab during a given week for a given test type</td>
</tr>
<tr>
<td>EAdenoTest</td>
<td>Number of enteric adenovirus tests performed by a lab during a given week for a given test type</td>
</tr>
<tr>
<td>EAdenoPos</td>
<td>Number of positive enteric adenovirus test results reported by a lab during a given week for a given test type</td>
</tr>
<tr>
<td>HMPVTEST</td>
<td>Number of human metapneumovirus tests performed by a lab during a given week for a given test type</td>
</tr>
<tr>
<td>HMPVPOS</td>
<td>Number of positive human metapneumovirus test results reported by a lab during a given week for a given test type</td>
</tr>
<tr>
<td>RhinoTest</td>
<td>Number of rhinovirus tests performed by a lab during a given week for a given test type</td>
</tr>
<tr>
<td>RhinoPos</td>
<td>Number of positive rhinovirus test results reported by a lab during a given week for a given test type</td>
</tr>
<tr>
<td>EnteroTest</td>
<td>Number of enterovirus tests performed by a lab during a given week for a given test type</td>
</tr>
<tr>
<td>EnteroPos</td>
<td>Number of positive enterovirus test results reported by a lab during a given week for a given test type</td>
</tr>
<tr>
<td>LabSubmitDate</td>
<td>Date the record was entered</td>
</tr>
</tbody>
</table>
Influenza Surveillance Activities – Pediatric Mortality

Influenza-Associated Pediatric Mortality Overview

Influenza-associated pediatric mortality surveillance
Influenza-associated pediatric deaths have been reportable in Texas since 2007. Surveillance for influenza-associated pediatric deaths is passive; however, providers who report influenza and ILI data should be reminded every year that pediatric deaths associated with influenza are reportable. If disease reporting training is conducted for healthcare providers in your jurisdiction, make sure that influenza-associated pediatric death reporting is covered.

Influenza-associated pediatric deaths can occur year-round even when influenza and ILI activity are at low levels. Healthcare providers should be encouraged to order influenza testing on any severe pediatric illness that is compatible with influenza regardless of the time of year. PCR and viral culture are the recommended testing types to confirm influenza-associated pediatric deaths. This testing is particularly important during the summer months when influenza typically circulates at low levels and rapid influenza tests are more likely to produce inaccurate results.

When summarizing influenza-associated pediatric deaths for influenza surveillance reports, vaccination status, age, underlying health conditions and type of influenza are important variables. All of this information is captured on the influenza-associated pediatric death report form.

Influenza-associated pediatric mortality investigations
The CDC investigation form for influenza-associated pediatric deaths is a valuable tool for investigating cases. The current investigation form is maintained on the DSHS website at http://www.dshs.state.tx.us/ideu/investigation/. The form specifies what information is required by the CDC for reporting and captures critical information to guide local responses. Deaths in children often result in intense public interest. The media and the general public will likely want to know why the child died and specifically if the death was preventable. It is important to keep the health department leadership and communications office apprised of the status of the investigation in order to effectively respond to concerns from the public and media inquiries.

When investigating a report of influenza-associated pediatric mortality, it is important to verify that the case meets the case definition. An influenza-associated pediatric death is defined for surveillance purposes as a death in a person less than 18 years of age resulting from a clinically compatible illness that was confirmed to be influenza by an appropriate laboratory or rapid diagnostic test (I). A death should not be reported if there is no laboratory confirmation of influenza virus infection; the influenza illness is followed by full recovery to baseline health status prior to death; the death occurs in a person 18 years or older; or after review and consultation there is an alternative agreed upon cause of death which is unrelated to an infectious process.

The following tests laboratory tests are acceptable:

- Influenza virus isolation in tissue cell culture from respiratory specimens
- Reverse-transcription polymerase chain reaction (RT-PCR) testing of respiratory specimens
- Immunofluorescent antibody staining (direct or indirect) of respiratory specimens
- Rapid influenza diagnostic testing of respiratory specimens
- Immunohistochemical (IHC) staining for influenza viral antigens in respiratory tract tissue from autopsy specimens
- Four-fold rise in influenza hemagglutination inhibition (HI) antibody

It is important to determine if the child died from a vaccine preventable strain of influenza. As soon as the case is reported, inquire about available respiratory specimens in order to maximize the possibility that healthcare facilities or clinical laboratories are still in possession of these specimens and can forward them to a public health laboratory. If influenza was confirmed by a hospital or commercial laboratory, request that the isolate be forwarded to the DSHS Laboratory in Austin or to your local LRN. If the only test done to confirm influenza was a rapid test, then request that any available respiratory specimens be sent to the DSHS Laboratory in Austin or to your local LRN. If specimens are not available, find out if and where an autopsy will be performed. On a case by case basis, the CDC may perform testing on tissue samples collected during an autopsy. Contact the DSHS EAIDB Influenza Surveillance Coordinator to obtain current information on CDC testing.

Another key aspect in the investigation is to determine if the case was vaccinated for influenza for the current season. A parent or guardian is the best source of information on the child’s vaccination history. However, it can be difficult to reach or interview a grieving parent. The healthcare provider who reported the death may or may not have information on vaccination history but will often be able to provide the name of the primary healthcare provider. The primary healthcare provider will have information on any vaccinations given to the child by his office. The Texas Immunization Registry, ImmTrac, can also be a good source of information.

**Influenza-associated pediatric mortality reporting**

Influenza-associated pediatric deaths should be reported to the health department within one working day of identification. Healthcare providers, infection preventionists, medical examiners, justices of the peace or any other persons who determine that the death was associated with influenza should contact their local or regional health department by phone or by fax. Contact information for local and regional health departments is available on the DSHS website at [http://www.dshs.state.tx.us/regions/default.shtm](http://www.dshs.state.tx.us/regions/default.shtm).

The health department with jurisdiction will conduct an investigation and complete the CDC investigation form for influenza-associated pediatric deaths. The current investigation form is maintained on the DSHS website at [http://www.dshs.state.tx.us/idcu/investigation/](http://www.dshs.state.tx.us/idcu/investigation/). This form should be faxed to DSHS EAIDB at 512-776-7616 as soon as possible. The case should also be entered into the National Electronic Disease Surveillance System (NEDSS) base system (NBS). Instructions for entering influenza-associated pediatric deaths are found in the NBS Data Entry Guide. The NBS Data Entry Guide is found under the documentation link on the log-in page for NBS. Upon first hearing of a death, a courtesy phone call from local and regional health departments to DSHS EAIDB with preliminary information would be greatly appreciated. If there is a long delay (>30 days) between the date of death and the date that the case is reported to
the health department, please document the reason for this delay (e.g., case not reported by hospital and found upon death certificate review, influenza test and death occurred in different locations, etc.).

DSHS EAIDB uses both NBS and a secure influenza-associated pediatric death reporting system to share reports with the CDC.
Influenza Surveillance Activities – Novel/Variant Influenza

Novel/Variant Influenza Overview

Novel/variant influenza is a reportable condition in Texas under the Texas Administrative Code (2). Novel/variant influenza is defined as a human case of infection with an influenza A virus subtype or strain that is different from circulating human influenza H1 and H3 viruses. A variant strain is designated with a ‘v’ following the subtype such as H3N2v. A healthcare provider may report a case of influenza that he suspects may be novel based on disease presentation, travel or exposure history. In this situation, please contact the DSHS EAIDB Influenza Surveillance Coordinator for specimen submission instructions.

Laboratory surveillance is essential for detecting novel influenza strains, especially because novel influenza may be clinically indistinguishable from seasonal influenza. Historically in Texas, cases of novel influenza were identified through routine influenza laboratory surveillance. Initial confirmation of novel influenza cases can only be performed by CDC laboratories; this confirmation occurs when influenza isolates that are unable to be subtyped are forwarded to CDC for identification. See Section IVd of this handbook for information on laboratory surveillance. In addition to laboratory surveillance, health departments can encourage healthcare providers to submit specimens for influenza testing when a patient with influenza-like illness has any of the following:

- An unexpected or unusually severe illness
- A history of international travel during the week before onset
- A recent history of close contact with poultry, water fowl (ducks, geese, etc.) or swine
- A current vaccination for seasonal influenza

Cases meeting the above criteria may or may not be identified as novel influenza but are of public health interest. The time period between submission of a specimen and determination of a novel strain may be extended. Initial identification of novel strains can only be done by the CDC. Specimens will be tested at the DSHS Laboratory in Austin to rule out seasonal influenza. If an unsubsubtypeable strain of influenza A is identified, it will be forwarded to the CDC for further characterization. Other laboratories in Texas that are capable of subtyping influenza A should notify the health department as soon as possible if an isolate cannot be subtyped.

The CDC will notify the state health department if a novel strain of influenza is confirmed. DSHS EAIDB will work with the local and regional health departments to investigate the report. Because of the number of state, federal and local agencies involved, these investigations can quickly become high profile. The goal of the investigation is to identify the source of exposure, determine the extent of person to person spread and prevent future spread if possible. The identification of the 2009 influenza A (H1N1) pandemic started with an investigation into a novel strain of influenza identified in both California and Texas. Guidance on investigating novel or variant influenza cases is available in the Guidelines for Investigation and Control of Invasive, Respiratory and Vaccine-Preventable Diseases. The guidelines are found at www.dshs.state.tx.us/idcu/health/vaccine_preventable_diseases/resources/.
Influenza Surveillance Activities –
Pregnant/Postpartum Mortality

Influenza-Associated Pregnant/Postpartum Mortality Overview

No longer an operative surveillance system – retained for historical perspective only

Reporting of influenza-associated deaths in women who were pregnant or up to six weeks postpartum was an ad hoc surveillance activity requested by the CDC during the 2009 pandemic and extended through the 2010-2011 influenza season.

This surveillance was discontinued at the end of May 2011. While the surveillance was ongoing, influenza-associated pregnant/postpartum deaths were to be reported to the health department within one working day of identification. Healthcare providers, infection preventionists, medical examiners, justices of the peace or any other persons who determined that the death was associated with influenza should have contacted their local or regional health department by phone or by fax.

An influenza-associated pregnant/postpartum death was defined for surveillance purposes as a death in a person who was pregnant or up to six weeks postpartum resulting from a clinically compatible illness that was confirmed to be influenza by an appropriate laboratory or rapid diagnostic test. No period of complete recovery (return to baseline health) was allowed between the illness and death. The following tests were acceptable:

- Influenza virus isolation in tissue cell culture from respiratory specimens
- Reverse-transcription polymerase chain reaction (RT-PCR) testing of respiratory specimens
- Immunofluorescent antibody staining (direct or indirect) of respiratory specimens
- Rapid influenza diagnostic testing of respiratory specimens
- Immunohistochemical (IHC) staining for influenza viral antigens in respiratory tract tissue from autopsy specimens
- Four-fold rise in influenza hemagglutination inhibition (HI) antibody

During the pandemic and throughout the 2010-2011 influenza season, the health department used the CDC investigation form for influenza-associated pregnant/postpartum deaths to investigate and report cases. If a health department chooses to continue investigating these cases, the health department can use the DSHS general influenza investigation form and the section on pregnant/postpartum in the DSHS supplemental influenza investigation form.
Influenza Surveillance Activities – Other Surveillance Activities

Other Surveillance Activities Overview

Outbreak Investigations
Influenza can cause outbreaks in long term care facilities, correctional facilities, schools, summer camps and other settings where people congregate. The number of reported outbreaks is an indicator of the impact of disease on a community. Furthermore, if control measures are not successfully implemented facilities may be unable to operate because of lack of well staff which may have further community impacts. For example, if too many teachers are absent then schools may be forced to close for a few days. When schools close, parents have to find alternative care for their children or may have to stay home from work. Refer to Section VII of this handbook for additional information on outbreak investigations.

Enhanced influenza surveillance
Standard influenza surveillance may be enhanced during outbreak investigations or during pandemic influenza responses. The nature of the enhancements will vary depending on the situation. Enhancements may include:

- Collecting data on individuals with ILI or influenza
- Conducting individual case investigations of influenza illnesses
- Collecting additional aggregate influenza-related data from reporters
- Increasing the frequency of reporting
- Actively calling reporters to obtain data
- Requesting submission of additional influenza specimens

During the 2009 influenza A (H1N1) pandemic, standard influenza surveillance was enhanced through a variety of surveillance activities conducted during different stages of the pandemic. Individual case investigations of ILI and influenza were conducted at the beginning of the pandemic. As the number of cases increased, individual case reporting for all pH1N1 influenza cases was replaced with aggregate reporting of confirmed pH1N1 hospitalizations, ICU admissions and deaths. In addition, the requirements for individual case investigations were limited to cases in which confirmed pH1N1-related ICU admissions or deaths had occurred. Voluntary reporting of confirmed pH1N1 influenza-related deaths among pregnant or postpartum (up to 6 weeks) women continued throughout the pandemic.

Active influenza surveillance
Most influenza surveillance is passive. Public health relies on healthcare partners to report on their own initiative. Active surveillance occurs when public health directly contacts healthcare partners asking for their reports to be submitted. Active surveillance may consist of contacting healthcare providers on a monthly, weekly or even daily basis over a specified period of time. It is very labor intensive.
Absenteeism surveillance
Absenteeism data may provide insight into mild ILI and other illnesses among people who do not necessarily seek medical care. General absenteeism data on its own is not a useful tool because the factors affecting absenteeism are diverse and often are not associated with infectious diseases. However, absenteeism data can provide increased situational awareness when viewed in context with other surveillance systems. For example, if ILINet is showing a peak of ILI activity, absenteeism data can be used to help define geographical areas of increased activity and to estimate the impact on schools and businesses.

Absenteeism data can potentially be collected from schools, large businesses and first responder agencies. Substantial increases in absenteeism require followup to assess the likely cause(s) and rule out possible outbreaks. It is helpful but not always feasible to collect the specific reason for absence (e.g., ill with ILI, ill with non-ILI, vacation, other).

Syndromic surveillance
The CDC defines syndromic surveillance as surveillance using health-related data that precede diagnosis and signal a sufficient probability of a case or an outbreak to warrant further public health response. For the purpose of this handbook, the definition of syndromic surveillance systems is further limited to those that use automated data feeds to collect health-related data to look for trends in syndrome categories. Most syndromic surveillance systems extract data from hospital emergency departments; however, syndromic surveillance systems can tap into any electronic system that stores health related information including medical clinics, pharmacies and EMS databases. DSHS does not endorse any one commercial syndromic surveillance system. The syndromic surveillance systems named here are ones that are commonly used in Texas and should not be viewed as recommendations or endorsements.

Hospital/emergency room visit-based syndromic surveillance systems
RODS and ESSENCE are two of the most common syndromic surveillance systems used by health departments in Texas. Both systems use automatic data feeds to mine data on hospital emergency room visits. The Texas Association of Local Health Officials (TALHO) and the Southwest Center for Advanced Public Health Practice (APC) in Tarrant County have both been involved with developing and expanding this type of syndromic surveillance in Texas.

BioSense 2.0 is a CDC supported syndromic surveillance system using cloud-based computing technology. Biosense essentially provides a data repository of emergency room visits and hospitalizations from participating healthcare facilities and from health departments using other healthcare data mining systems such as RODS or ESSENCE.

Medication-based syndromic surveillance
Over-the-counter (OTC) sales of medications are used to estimate illness among people who do not routinely seek or who have not yet sought medical care. The University of Pittsburg runs the National Retail Data Monitor (NRDM) system which collects data on over-the-counter medication sales from pharmacies, grocery stores and mass merchandise
stores across the United States. NRDM provides a platform to analyze and interpret the data. There is a fee to access the system.

Health departments may develop agreements with pharmacies to report aggregate sales data for over-the-counter cough/cold/flu/anti-fever medications and prescription cough/cold/flu/anti-fever medications filled. These data can be difficult to interpret without advanced statistical trend analysis.

**Internet search-based surveillance**
Google estimates influenza activity by analyzing internet searches and shares the information through Google Flu Trends. Google searches for influenza and influenza-related terms increase when influenza-like illness increases. Google compared their trend lines with ILI trend lines released by the CDC from 2004 to 2009. During this time period, the peaks in both systems at the national level appeared to match.

Google Flu Trend information is available at the national and state levels. Some city-level data are also available but it is unclear how well these data correlate to ILI activity. As of August 2010, city-level trends are available for 7 cities in Texas: Addison, Austin, Dallas, Fort Worth, Houston, Lubbock and San Antonio. Google Flu Trends can be freely accessed at [http://www.google.org/flutrends/](http://www.google.org/flutrends/).

**Self-report surveillance**
Flu Near You is an initiative of the American Public Health Association to track self-reports of influenza-like illness by the general public. Anyone can sign up to participate. Every Monday, an email is sent to participants asking them to record any symptoms they had during the previous week through a web link or through a smart phone application. In addition to allowing people to report symptoms of influenza, the site allows users to search for locations providing vaccine and see how many people reported illness in their community. Flu Near You can be freely accessed at [https://flunearyou.org](https://flunearyou.org).

**Border Influenza Surveillance Network**
The Border Influenza Surveillance Network (BISN) is a multi-state collaboration facilitated by the CDC US-Mexico Unit to share influenza data from the border regions of California, New Mexico, Texas and Mexico. The network uses data from existing influenza surveillance activities. Texas has 32 counties that qualify as border counties based upon their distance to the US-Mexico border. In Texas, Regions 8, 9/10 and 11 participate in BISN. The regional influenza surveillance coordinator or a regional employee working with the Early Warning Infectious Disease Surveillance (EWIDS) Program shares influenza data with the CDC US-Mexico Unit during influenza season.
Section V: Recruitment and Retention of Influenza Surveillance Reporters

Table of Contents

- Recruitment and Retention of Influenza Surveillance Reporters
  Overview V.2
- Reporters to Consider for Recruitment V.3
  - Healthcare providers V.3
  - Hospitals V.3
  - Laboratories V.4
  - Schools V.5
- Steps for Recruiting V.6
- ILINet Recruitment V.10
  - ILINet recruitment process V.10
- Retention of Influenza Surveillance Reporters V.11
- Sample Tools V.12
  - Example healthcare provider/hospital letter V.12
  - Example of ILINet recruitment handout V.13
  - Example NREVSS recruitment handout V.14
  - Example influenza reports V.15
Recruitment and Retention of Influenza Surveillance Reporters

Overview

Recruiting and retaining reporters is an important aspect of maintaining a comprehensive and cohesive influenza surveillance system. The following section outlines tips for identifying potential influenza reporters, recruiting them and encouraging them to continue reporting.

Before recruiting new reporters, it is a good idea to first identify who currently submits regular influenza reports to you. Where are your current reporters located? What types of entities do they represent (e.g., hospital, large clinic, private physician’s office, school, etc.)? Do you have regular reporters in each of your counties and major population centers? Use the information to help prioritize your search for new reporters.

If you already have good geographic and population coverage in your jurisdiction then you may want to consider how well and how often your reporters are reporting. Do they submit reports every week, most weeks or just some weeks? Use this information to identify which reporters may need encouragement or additional training.

Section IVa provides the number of recommended ILINet providers for each county in Texas with a population of at least 100,000 persons. Health jurisdictions are welcome to increase the number of ILI reporters in their jurisdiction above what is recommended for ILINet. If health jurisdictions want to increase representativeness, consider a minimum goal of one reporter for every major population center in addition to the number of ILINet providers recommended for the county. The additional reporters may be ILINet providers or may report ILI directly to the health department. The DSHS ILINet Coordinator has created a plan for systematic ILINet recruiting in each DSHS Region based on recent population estimates and study data from the University of Texas. These recruitment plans are available upon request from flutexas@dshs.state.tx.us.
Reporters to Consider for Recruitment

Healthcare providers
In the context of influenza surveillance, a healthcare provider (HCP) is defined as a medical professional who delivers healthcare services that may include diagnosis of or treatment for influenza and ILI. Healthcare providers may be physicians, nurses, physician assistants or nurse practitioners. The following practices are the ones most likely to see persons with ILI:

- Primary care
- Family practice
- General practice
- Pediatrics
- Internal medicine
- Acute / Urgent care
- Student health centers

There are several opportunities for healthcare providers to contribute to influenza surveillance in Texas. The following table outlines the activities in which healthcare providers are eligible to participate.

<table>
<thead>
<tr>
<th>Activity</th>
<th>Description of HCP participation</th>
</tr>
</thead>
<tbody>
<tr>
<td>ILINet</td>
<td>HCPs report weekly on the total number of patients seen in their practice and the number of patients by age group seen with ILI. HCPs submit reports online or by fax directly to the CDC. Upon approval from the DSHS ILINet Coordinator, data for multiple sites may be emailed as spreadsheet to <a href="mailto:flutexas@dshs.state.tx.us">flutexas@dshs.state.tx.us</a>.</td>
</tr>
<tr>
<td>ILI Activity</td>
<td>This activity is more flexible as far as the types of data that are reported by the HCP. HCPs usually report rapid influenza test results, number of patients seen with ILI and total number of patients seen. The data are submitted by fax, email or phone directly to the health department.</td>
</tr>
<tr>
<td>Laboratory Surveillance</td>
<td>HCPs may submit nasopharyngeal swabs collected from patients with suspected influenza to the DSHS Laboratory in Austin or a participating LRN laboratory in Texas. Specimen collection supplies, testing and shipping are provided free of charge to the provider. Results are not for diagnostic purposes.</td>
</tr>
</tbody>
</table>

Hospitals
Hospitals are another good source of influenza data. Many hospitals are part of expansive medical systems in a community. The hospital may have access to information on patients seen in affiliated clinics as well as at the hospital. In these instances, one person may be able to submit influenza reports for multiple locations. Here is a list of possible elements from which a hospital could report influenza data:

- Patients seen in emergency room with ILI
- Outpatients with ILI seen at affiliated clinics co-located with hospital and away from the hospital
• Patients admitted to the hospital with ILI
• Tests ordered for influenza and test results

Hospitals can participate in the same activities for influenza surveillance as healthcare providers. The following table outlines the activities in which hospitals are eligible to participate.

<table>
<thead>
<tr>
<th>Activity</th>
<th>Description of hospital participation</th>
</tr>
</thead>
<tbody>
<tr>
<td>ILINet</td>
<td>Hospitals report weekly on the total number of patients seen in their facility and the number of patients by age group seen with ILI. Hospitals submit reports online.</td>
</tr>
<tr>
<td>ILI Activity</td>
<td>This activity is more flexible as far as the types of data that are reported by the hospital. Hospitals usually report rapid influenza test results, number of patients seen with ILI and total number of patients seen. The data are submitted by fax, email or phone directly to the health department.</td>
</tr>
<tr>
<td>Laboratory Surveillance</td>
<td>Hospitals may submit nasopharyngeal swabs collected from patients with suspected influenza to the DSHS Laboratory in Austin or a participating LRN laboratory in Texas. Specimen collection supplies, testing and shipping are provided free of charge to the hospital. Results are not for diagnostic purposes.</td>
</tr>
</tbody>
</table>

**Laboratories**

Laboratories are another potential source for influenza surveillance data. Laboratories may be independent commercial facilities or may be part of a hospital. Public health laboratories in Texas that are part of the Laboratory Response Network (LRN) already participate in influenza surveillance. Data from these laboratories tend to be shared directly with the affiliated health department.

Laboratories are not the best source of ILI data; however, they are a good source of influenza data. The number of influenza tests conducted can be an estimate of ILI. It is an imperfect estimate because laboratories usually do not have information on the symptoms of the patients, and therefore it is unknown if the patient symptoms meet a standard definition of ILI. The strength of laboratories is identifying confirmed influenza. Laboratory data can also be used to calculate the percentage of tests positive for influenza.

The following table outlines the activities in which laboratories are eligible to participate.

<table>
<thead>
<tr>
<th>Activity</th>
<th>Description of laboratory participation</th>
</tr>
</thead>
<tbody>
<tr>
<td>ILI Activity</td>
<td>Laboratories may report the total number of influenza tests conducted and the number that are positive for influenza A, influenza B and/or a subtype of influenza A or lineage of influenza B. The data are submitted by fax, email or phone directly to the health department.</td>
</tr>
</tbody>
</table>
### Laboratory Surveillance

Laboratories may submit nasopharyngeal swabs collected from patients with suspected influenza to the DSHS Laboratory in Austin or a participating LRN laboratory in Texas. Specimen collection supplies, testing and shipping are provided free of charge to the laboratory. Results are not for diagnostic purposes.

### National Respiratory and Enteric Virus Surveillance System (NREVSS)

Laboratories that conduct testing for influenza and other respiratory and enteric viruses may submit weekly reports online to NREVSS. Laboratories report the type of test, the number of tests performed and the number of positive tests for influenza virus, parainfluenza viruses, respiratory and enteric adenoviruses, rhinovirus, human metapneumovirus, respiratory syncytial virus, rotavirus and enterovirus.

### Electronic Laboratory Reporting (ELR)

Laboratories can work with the DSHS NBS Project Office to submit electronic reports of notifiable conditions directly to NBS. However, since influenza is not a reportable condition, it is not routinely uploaded into NBS at this time.

### Schools (primary and secondary)

Illness and absenteeism data from schools can be a good indicator of the impact of influenza in a community. Depending on how the school tracks absenteeism, it may be difficult for a school to report ILI activity. However, many schools are able to report good estimates of ILI.

<table>
<thead>
<tr>
<th>Activity</th>
<th>Description of school participation</th>
</tr>
</thead>
<tbody>
<tr>
<td>ILI Activity</td>
<td>Schools may be able to report the total number of students seen by the school nurse and the number of students seen by the school nurse with ILI. Some schools may also be able to report the total number of students absent and the number of students reported as absent with ILI (reported by parent). The data are submitted by fax, email or phone directly to the health department.</td>
</tr>
<tr>
<td>School Surveillance System (examples: TALHO’s Roll Call, Tarrant County APC system, other school-specific online system)</td>
<td>Various school surveillance systems are in place throughout Texas. Each of these systems allows schools to log in to an online website to report data. The types of data collected may vary from system to system.</td>
</tr>
</tbody>
</table>
Steps for Recruiting

1. Identify potential reporters
   There are several methods for identifying potential reporters in your jurisdiction. One of the best ways is to review which providers currently report notifiable conditions to your health department. These reporters already have an established relationship with public health and may be agreeable to supporting voluntary influenza surveillance as well.

   Phone book and internet searches are also good tools to locate potential reporters in your jurisdiction. For example, internet searches may help you to locate large clinic networks in your area that may be able to assist with influenza surveillance by providing electronic data feeds from multiple providers who see patients with ILI.

   The Texas Medical Board (TMB) website can be used to identify healthcare providers in your jurisdiction. You can search by city and specialty on the website. Alternatively, more extensive data is available for purchase. The TMB website is http://www.tmb.state.tx.us/.

   Insurance company provider finders (example: Blue Cross Blue Shield) can also be used to identify healthcare providers in your jurisdiction. This resource only identifies providers who accept a particular type of insurance; however, the contact information is updated frequently and the user can sort by practice types.

   Two resources for hospitals are the Texas Hospital Association website at http://www.tha.org/TXHospitalsDirectory.asp and the DSHS website at http://www.dshs.state.tx.us/HFP/apps.shtm#directoryhosp .

   To identify laboratories, check with local hospitals and healthcare providers to see which laboratories they typically use. Some hospital laboratories may act as reference laboratories for area clinics and smaller hospitals.

   Searchable information on public schools is available on the Texas Education Agency website at http://www.tea.state.tx.us/. Accredited private school information is available on the Texas Private School Accreditation Commission website at http://www.tepsac.org/search_start.cfm.

2. Approach potential reporters
   Once you have identified the provider or entity you would like to recruit, start by calling his office. Identify yourself as calling from the health department. Ask if you can schedule a time to call and speak with someone about influenza surveillance.

   The best contact at a private physician’s office or clinic is usually the lead physician or lead nurse. For hospitals, the infection preventionist (IP) (formerly referred to as the infection control practitioner) is a good first contact. The IP is typically the primary hospital staff member responsible for reporting notifiable conditions to health departments. The IP is familiar with the hospital setting and may be able to help assess
the types of data that the hospital will be able to provide. Other potential contacts in a hospital are the laboratory director and the emergency department director. The school nurse is a good contact at grade schools. School nurses often already have established relationships with public health. You may also want to approach the school principal or superintendent to obtain administrative support from the school.

When you speak with your contact, review the purpose of influenza surveillance. Explain what amount and type of information is preferred from the reporter, the approximate amount of time the reporting activity is expected to take (if known) and what the health department does with the data. If the contact indicates interest in participating in influenza surveillance, identify who will be responsible for reporting.

Here are sample talking points:

- **Purpose of influenza surveillance**
  - Monitor influenza and ILI activity in our communities

- **Information collected**
  - We would like a weekly report with an aggregate count of patients you see with ILI.
  - We would also like a weekly aggregate count of any influenza testing results including rapid influenza test results and other influenza tests.
  - We do not collect patient identifiers.

- **How information is used**
  - To target recommendations for influenza prevention and control to communities
  - To target vaccination campaigns to communities that are seeing higher levels of influenza activity
  - To determine if circulating influenza viruses are covered by the current seasonal influenza vaccine

- **Benefits to public health**
  - Increased ability to determine when and where influenza activity is occurring

- **Benefits to the reporter**
  - Supporting public health activities that benefit the entire community
  - Establish communication channels between your practice and public health

Faxing or mailing a recruiting letter can be done in addition to or as an alternative to calling a potential reporter. See the sample letters at the end of this section.

3. **Identify the best activity for the reporter’s participation**
   
   During the initial conversation with your contact, you should be able to gauge what level of participation the reporter is willing to support. For healthcare providers and hospitals, it will be important to decide if they are better suited for ILINet or ILI activity reporting.

   Use the decision tree on the following page to help select the best activity for healthcare providers and hospitals.
| i | Is the provider willing to report the total number of patients seen for any reason and the number of patients seen with ILI each week?  
If yes, go to # ii  
If no, go to # iii |
|---|---|
| ii | Is the provider willing to break down the number of patients seen with ILI by age group?  
If yes, go to # iv  
If no, go to # v |
| iii | Thank the provider for his interest and explain that those are the minimum expectations for participating in influenza reporting. Remind the provider to contact you at any time in the future if he has questions about influenza or wants to report unusual increases in influenza activity at his practice. If the provider wants to submit specimens periodically for influenza testing, consider using the provider in laboratory surveillance. |
| iv | Consider recruiting the provider for participation in ILINet or have the provider report directly to you and share the data with the DSHS ILINet Coordinator so it can also be incorporated into ILINet. If the provider reports directly to you, you can ask for information that is not collected in ILINet such as rapid influenza test results. The DSHS ILINet Coordinator can assist with cross-jurisdictional recruitment for large clinic systems with centralized data administration.  
Go to # viii |
| v | Is the provider willing to report the number of rapid influenza tests performed and their results each week?  
If yes, go to # vi  
If no, go to # vii |
| vi | Provide a report template that includes rapid influenza test results  
Go to # viii |
| vii | Provide a report template that does not include rapid influenza test results  
Go to # viii |
| viii | Is the provider interested in submitting nasopharyngeal swabs on a subset of patients with suspected influenza for surveillance testing?  
If yes, go to # ix  
If no, go to # x |
| ix | Consider using this provider in laboratory surveillance if additional submissions are needed from the Health Service Region.  
Go to # x |
x Thank the provider for agreeing to participate and remind him to contact you at any time in the future if he has questions about influenza or wants to report unusual increases in influenza activity at his practice.

4. Provide the reporter with instructions and materials
   Send appropriate reporting forms, a letter of appreciation and information on the reporting process and deadlines. Examples of report forms can be found in Section IVc of this handbook.

5. Initiate and monitor reporting
   After a reporter agrees to participate, it is still necessary to monitor the reporter’s participation. You should follow up with any new reporters after they submit their first reports to see if they have any questions or concerns about the process. Periodically monitor all of your reporters to see if they are submitting reports on a regular basis. If any provider misses more than 1 week, call the provider to follow up and address any reporting barriers.
ILINet Recruitment

Local health departments may recruit providers to report directly to the local health department or to report through ILINet. Identification and initial recruitment of providers is essentially the same process and is described in-depth under Steps for Recruiting. The overall process showing the responsibilities of the local health department and the recruited provider is below.

**ILINet Recruitment Process**

1) The local/regional health department identifies a provider who is interested in participating in ILINet surveillance.
   a. See section on Steps for Recruiting starting on page V.6.

2) The local/regional health department gives the provider information on ILINet and an ILINet application form.
   a. See example handout on ILINet on page V.13.
   b. The ILINet application form is available on the bottom of the page at [www.dshs.state.tx.us/idcu/disease/influenza/surveillance/ilinet/](http://www.dshs.state.tx.us/idcu/disease/influenza/surveillance/ilinet/).

3) The provider submits the completed application to DSHS in Austin by fax (512-776-7616) or by email (flutexas@dshs.state.tx.us).

4) DSHS EAIDB Influenza Surveillance Team coordinates with the CDC to get the provider a provider ID and password to access the ILINet website.

5) The provider ID and password are emailed to the provider. A work folder with instructions for reporting is also mailed to the provider. This takes from 1 to 2 weeks.

6) The provider starts collecting data and reporting each Tuesday.
Retention of Influenza Surveillance Reporters

Retention of consistent reporters is a key facet of a strong influenza surveillance system. Most influenza surveillance is voluntary. Reporters take time out of their busy schedules to share information with public health because they believe the surveillance is worthwhile and they have a desire to support public health. As with any volunteer activity, if participants see value in the work they are doing, they are more likely to continue.

Retention efforts can be divided roughly into three major categories: feedback, recognition and incentives.

Feedback activities simultaneously inform the reporters that their data are being used by public health as well as provide them an indication of how they are performing. Examples of feedback include:

- Calling the reporter when a report is not submitted
- Calling the reporter to verify large increases or decreases in reporting numbers
- Providing midseason and end of season summary reports showing the number of weeks that reports were submitted by the provider

Recognition activities provide a mechanism for the health department to thank the reporter and highlight the importance of reporter participation. Examples of recognition include:

- Sending a formal letter of appreciation for agreeing to participate in influenza surveillance
- Sending a formal letter of appreciation for having submitted reports ___% of weeks during the previous influenza season

Incentives are methods to motivate reporting. Examples of incentives include:

- Providing free shipping and testing of some influenza specimens (through laboratory surveillance programs)
- Providing testing or shipping supplies that will help the providers in their practices

For example, current incentives for ILINet participants include:

- A certificate of appreciation signed by the State Epidemiologist of Texas for providers who report for at least half of the weeks during influenza season
- A subscription to the *Morbidity and Mortality Weekly Report*
- A subscription to *Emerging Infectious Diseases*
- Free specimen collection supplies, testing and shipping for a limited number of influenza surveillance specimens at the DSHS Austin Laboratory

One of the best methods to encourage continued reporting is to demonstrate to reporters how their work is benefitting public health. If reporters believe that the work they are doing is being used in a meaningful manner then they are more likely to continue doing it. One way to accomplish this is to provide the reporters a copy of the Texas Weekly Flu Report in a format they prefer. Reports may be emailed, faxed or mailed to their practice. Providers will appreciate a report highlighting influenza and ILI activity in their local areas in addition to the state report.
Sample Tools

Example influenza surveillance recruitment letter for a healthcare provider or hospital

Dear healthcare provider,

The [insert name of health department] is enhancing the surveillance for influenza morbidity in [insert jurisdiction]. Continually changing influenza viruses cause substantial disease in the United States, resulting in 200,000 hospital admissions and approximately 23,000 deaths every year.

As influenza illness is not a reportable condition in Texas, your participation in influenza surveillance is critical for monitoring the annual impact of influenza. The information obtained from influenza surveillance guides prevention and control activities, vaccine strain selection, patient care decisions and epidemic severity assessment. Influenza surveillance is also an important tool in the early detection of new viral strains that could have pandemic implications. Participating in influenza surveillance activities helps protect public health in our community, Texas and the nation.

Participants in influenza surveillance are asked to report once a week on the total number of patient visits and the number of patient visits for influenza-like illness (ILI). The information can be reported directly to the health department by fax, phone or email. Another option is to report via the internet using the Centers for Disease Control and Prevention’s ILINet surveillance system. Most providers report that it takes them less than 30 minutes a week to compile and report their data; the reported data are made available to health departments for analysis.

The cost to you is less than 30 minutes of your time each week. Influenza reporters receive feedback on the data submitted and summaries of regional, state and national influenza data. Providers may also submit some specimens for influenza testing to the Texas Department of State Health Services Laboratory at no charge.

If you would like more information about participation in influenza surveillance, please contact me at (###) ###-####.

Thank you for your consideration to Help Protect Texas!

Sincerely,

[Insert contact person’s information]
Now You Can Help With…

Influenza Surveillance

...In Only a Few Minutes a Week!

What is an ILINet provider?
An ILINet provider conducts surveillance for influenza-like illness (ILI) in collaboration with the state health department and the Centers for Disease Control and Prevention (CDC). Data reported by ILINet providers, in combination with other influenza surveillance data, provide a national picture of influenza virus and ILI activity in the U.S.

What data do ILINet providers collect? How and to whom are data reported?
ILINet providers report the total number of patient visits each week and the number of patient visits for influenza-like illness by age group (0-4 years, 5-24 years, 25-49 years, 50-64 years and >65 years). These data are transmitted once a week via the Internet or fax to a central data repository at CDC. Most providers report that it takes them less than 30 minutes a week to compile and report their data. In addition, ILINet providers can submit specimens from a subset of patients for influenza testing free of charge.

Who can be an ILINet Provider?
Healthcare providers of any specialty (e.g., family practice, internal medicine, pediatrics, infectious diseases) in any type of practice (e.g., private practice, public health clinic, urgent care center, emergency room, university student health center) are eligible to be ILINet providers. Practice settings that are not eligible are elementary, middle, or high school health centers, and any type of institutional setting such as nursing homes or prisons.

Why volunteer?
Influenza viruses are constantly evolving and cause substantial morbidity and mortality (approximately 23,000 deaths) almost every winter. Data from ILINet providers are critical for monitoring the impact of influenza and, in combination with other influenza surveillance data, can be used to guide prevention and control activities, vaccine strain selection, and patient care. ILINet providers receive feedback on the data submitted, summaries of state and national influenza data, and a free subscription to CDC’s Morbidity and Mortality Weekly Report and Emerging Infectious Diseases journal. The most important consideration is that the data provided are critical for protecting the public’s health.

For more information on influenza surveillance through ILINet, please contact the Texas Department of State Health Services Influenza Surveillance Team at flutexas@dshs.state.tx.us
What is NREVSS?
NREVSS is an online laboratory reporting system created by the Centers for Disease Control and Prevention (CDC) for a variety of respiratory and enteric viruses, including influenza virus, parainfluenza viruses, respiratory and enteric adenoviruses, rhinovirus, human metapneumovirus, respiratory syncytial virus, rotavirus, and enterovirus. Data entered in NREVSS are used to track temporal and geographic patterns of these viruses and make public health decisions.

What kind of information is entered in NREVSS?
Weekly counts of the number of tests performed and the number of positive tests are entered for any or all of the viruses for which NREVSS collects data. The type of test (i.e., antigen detection test, viral culture, electron microscopy, or PCR) is also captured in the system. Reporting laboratories enter their data from the previous week by noon each Tuesday. The data reported weekly are a summary of the previous week’s laboratory data, and the reporting weeks follow the CDC’s MMWR week format.

Who can volunteer?
Volunteer laboratories must
- Perform acceptable testing types for any of the viruses for which NREVSS collects data
- Enter their data into the NREVSS system on a weekly basis, preferably year-round

In Texas, there is a great need for volunteer laboratories in the West Texas/Midland/El Paso area, in the northern “Panhandle” area and in the eastern/northeastern areas of the state. Laboratories from other areas of the state are also encouraged to volunteer.

Why volunteer?
Your laboratory’s participation in NREVSS allows valuable data to be shared with public health partners across the state and the nation. Data entered in NREVSS are reviewed weekly by several epidemiologists throughout Texas and at the national level for use in weekly reports and to monitor virus trends in the state. In Texas, the RSV data also help inform the annual Medicaid coverage of palivizumab injections for high-risk children.

How do I sign up?
Contact the CDC NREVSS program coordinators for access to enter NREVSS data. The coordinators are:
Amber Haynes (vtj2@cdc.gov)
Mila Prill (gik8@cdc.gov)

Thank you for your contribution to influenza viral surveillance in Texas!
**Example Influenza Reports**
Links to additional influenza report examples can be found in Section III of this manual.

This influenza report is emailed out by Health Service Region 4/5N:

**Influenza Surveillance Weekly Summary Report**

**Start of School Year Sees “Quiet” Flu Activity**
The influenza (flu) activity for Health Service Region 4/5 for the “pre-flu season” week ending August 28, 2010 was “sporadic” with minimal flu activity. During week 34, we received 27 reports from healthcare professionals and 27 reports from schools and daycares. Reports were received from 18 of 35 counties in the health service region. Though flu season officially starts in October, Texas continues to collect flu data in order to detect problems as early as possible.

**Reports from Healthcare Professionals**
56% of facilities reported no flu activity, while 88% of healthcare facilities that previously reported activity reported that flu or influenza-like activity has either stayed the same or decreased since the last reporting week. Lab confirmed flu cases were reported in only one county (Angelina) which reported a case of influenza type B. Six counties reported influenza-like activity only. [see “definitions” below]

**Disease Reporting Hotline**
1-866-310-9698

**Spotlight: Daycares**
This year, the influenza surveillance program has included daycares in flu surveillance efforts. Daycares are encouraged to submit weekly reports. To submit the weekly daycare report, click HERE.

**Reports from Schools and Daycares**
Following the end of the first official week of public school, we received 27 school reports compared to an average of 89 reports during the peak of flu season in 2009-2010. Unlike 2009’s “fast start flu season,” flu-related absenteeism reported during the first week of school was minimal with a median rate of 5% compared to better than 15% absenteeism at the start of the 2009 school year. 85% of schools reported no influenza or influenza-like activity. The median population for reporting schools was 410 students.

**Influenza Definitions**
ILI: [Influenza-Like Illness] is illness with fever ≥100° AND cough or sore throat
Confirmed Case: a person with ILI AND laboratory confirmed influenza by rapid test, PCR or viral culture.

**Useful Web Links**
- Statewide Weekly Influenza Report
- Prevention and Control of Influenza with Vaccines
- Healthcare Professionals Online Report Form
- Online Report Form for Schools
- Daycare Online Report Form

To subscribe to the weekly flu surveillance newsletter click here.
Questions or Comments? Email us or call 1-866-310-9698

Recruitment and Retention Last updated 09/13/2013 V.15
This influenza report is emailed out by Health Service Region 2/3:

**Flu Report for HSR 2/3**


The “regular” influenza season ended on Week 20, week ending May 22, 2010. However, HSR 2/3 is still monitoring influenza from a few influenza reporting partners that have agreed or want to continue to report influenza activity throughout the summer months. At least 3 different influenza reporters from HSR 2 and HSR 3 have agreed to report influenza activity to DSHS HSR 2/3 Regional Office in Arlington.

The level of reported flu activity **increased** when compared to last week. The level of reported influenza-like illness and rapid flu tests (influenza A, B, or non-differentiated) **increased** when compared to last week. Influenza activity for week 38 of the 2009-2010 influenza season is **lower** when compared to the same time period last year. Influenza activity will be defined as having influenza-like illness symptoms, rapid test positive results or having positive flu cultures or PCR testing.

- 15 of 49 counties (31%) in the region reported influenza activity for CDC Week 38.
  - 6 of 30 counties (20%) in Region 2 reported influenza activity.
  - 9 of 19 counties (47%) in Region 3 reported influenza activity.
- Flu A was detected via rapid flu test in 3 counties in HSR 2/3.
  - Collin, Nolan and Tarrant Counties
- Flu B was detected via rapid flu test in 1 county in HSR 2/3.
  - Tarrant County
- Flu A was not detected via culture or PCR in HSR 2/3.
- Flu B was not detected via culture or PCR in HSR 2/3.
- ILI only was reported in 12 counties in HSR 2/3.
  - Coleman, Erath, Foard, Hood, Hunt, Jack, Knox, Mitchell, Palo Pinto, Parker, Somervell and Wise Counties
- Non-differentiated flu was not detected via rapid flu test in HSR 2/3.
- There were no reported institutional outbreaks or school closures in HSR 2/3 during Week 38.

**Table 1. DSHS HSR 2/3 Flu Data Summary by Week**

<table>
<thead>
<tr>
<th>CDC Week</th>
<th># of ILI</th>
<th># of Flu A Rapid Positive</th>
<th># of Flu B Rapid Positive</th>
<th># of Flu A Culture or PCR Positive</th>
<th># of Flu B Culture or PCR Positive</th>
</tr>
</thead>
<tbody>
<tr>
<td>40 (Oct. 04-Oct. 10)</td>
<td>7563</td>
<td>5493</td>
<td>18</td>
<td>171</td>
<td>26</td>
</tr>
<tr>
<td>41 (Oct. 11-Oct. 17)</td>
<td>4834</td>
<td>4357</td>
<td>31</td>
<td>115</td>
<td>23</td>
</tr>
<tr>
<td>42 (Oct. 18-Oct. 24)</td>
<td>4490</td>
<td>1499</td>
<td>22</td>
<td>198</td>
<td>21</td>
</tr>
<tr>
<td>43 (Oct. 25-Oct. 31)</td>
<td>2958</td>
<td>1475</td>
<td>12</td>
<td>127</td>
<td>11</td>
</tr>
<tr>
<td>44 (Nov. 01-Nov. 07)</td>
<td>2685</td>
<td>606</td>
<td>20</td>
<td>68</td>
<td>10</td>
</tr>
<tr>
<td>45 (Nov. 08-Nov. 14)</td>
<td>1830</td>
<td>464</td>
<td>13</td>
<td>39</td>
<td>4</td>
</tr>
</tbody>
</table>

Recruitment and Retention Last updated 09/13/2013
<table>
<thead>
<tr>
<th>Week</th>
<th>Cases</th>
<th>Deaths</th>
<th>ILI</th>
<th>Hospitalizations</th>
</tr>
</thead>
<tbody>
<tr>
<td>46 (Nov. 15-Nov. 21)</td>
<td>1366</td>
<td>153</td>
<td>2</td>
<td>93</td>
</tr>
<tr>
<td>47 (Nov. 22-Nov. 28)</td>
<td>1199</td>
<td>86</td>
<td>11</td>
<td>7</td>
</tr>
<tr>
<td>48 (Nov. 29-Dec. 05)</td>
<td>812</td>
<td>130</td>
<td>5</td>
<td>9</td>
</tr>
<tr>
<td>49 (Dec. 06-Dec. 12)</td>
<td>911</td>
<td>107</td>
<td>11</td>
<td>27</td>
</tr>
<tr>
<td>50 (Dec. 13-Dec. 19)</td>
<td>898</td>
<td>97</td>
<td>13</td>
<td>27</td>
</tr>
<tr>
<td>51 (Dec. 20-Dec. 26)</td>
<td>385</td>
<td>45</td>
<td>2</td>
<td>11</td>
</tr>
<tr>
<td>52 (Dec. 27-Jan. 02)</td>
<td>999</td>
<td>36</td>
<td>6</td>
<td>6</td>
</tr>
<tr>
<td>01 (Jan. 03-Jan. 09)</td>
<td>1077</td>
<td>65</td>
<td>9</td>
<td>6</td>
</tr>
<tr>
<td>02 (Jan. 10-Jan. 16)</td>
<td>1011</td>
<td>106</td>
<td>15</td>
<td>15</td>
</tr>
<tr>
<td>03 (Jan. 17-Jan. 23)</td>
<td>1032</td>
<td>83</td>
<td>6</td>
<td>22</td>
</tr>
<tr>
<td>04 (Jan. 24-Jan. 30)</td>
<td>858</td>
<td>57</td>
<td>16</td>
<td>12</td>
</tr>
<tr>
<td>05 (Jan. 31-Feb. 06)</td>
<td>1039</td>
<td>32</td>
<td>11</td>
<td>17</td>
</tr>
<tr>
<td>06 (Feb. 07-Feb. 13)</td>
<td>881</td>
<td>78</td>
<td>10</td>
<td>7</td>
</tr>
<tr>
<td>07 (Feb. 14-Feb. 20)</td>
<td>664</td>
<td>52</td>
<td>4</td>
<td>7</td>
</tr>
<tr>
<td>08 (Feb. 21-Feb. 27)</td>
<td>664</td>
<td>51</td>
<td>8</td>
<td>10</td>
</tr>
<tr>
<td>09 (Feb. 28-Mar. 06)</td>
<td>678</td>
<td>98</td>
<td>4</td>
<td>0</td>
</tr>
<tr>
<td>10 (Mar. 07-Mar. 13)</td>
<td>464</td>
<td>78</td>
<td>2</td>
<td>14</td>
</tr>
<tr>
<td>11 (Mar. 14-Mar. 20)</td>
<td>370</td>
<td>13</td>
<td>3</td>
<td>3</td>
</tr>
<tr>
<td>12 (Mar. 21-Mar. 27)</td>
<td>416</td>
<td>36</td>
<td>4</td>
<td>3</td>
</tr>
<tr>
<td>13 (Mar. 28-Apr. 03)</td>
<td>385</td>
<td>22</td>
<td>2</td>
<td>3</td>
</tr>
<tr>
<td>14 (Apr. 04-Apr. 10)</td>
<td>331</td>
<td>20</td>
<td>1</td>
<td>2</td>
</tr>
<tr>
<td>15 (Apr. 11-Apr. 17)</td>
<td>310</td>
<td>17</td>
<td>2</td>
<td>1</td>
</tr>
<tr>
<td>16 (Apr. 18-Apr. 24)</td>
<td>278</td>
<td>15</td>
<td>3</td>
<td>2</td>
</tr>
<tr>
<td>17 (Apr. 25-May 01)</td>
<td>324</td>
<td>2</td>
<td>0</td>
<td>1</td>
</tr>
<tr>
<td>18 (May 02-May 08)</td>
<td>303</td>
<td>7</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>19 (May 09-May 15)</td>
<td>272</td>
<td>1</td>
<td>0</td>
<td>1</td>
</tr>
<tr>
<td>20 (May 16-May 22)</td>
<td>321</td>
<td>1</td>
<td>0</td>
<td>1</td>
</tr>
<tr>
<td>21 (May 23- May 29)</td>
<td>184</td>
<td>1</td>
<td>1</td>
<td>0</td>
</tr>
<tr>
<td>22 (May 30-June 05)</td>
<td>197</td>
<td>0</td>
<td>1</td>
<td>0</td>
</tr>
<tr>
<td>23 (June 06-June 12)</td>
<td>202</td>
<td>0</td>
<td>1</td>
<td>0</td>
</tr>
<tr>
<td>24 (June 13-June 19)</td>
<td>137</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>25 (June 20-June 26)</td>
<td>116</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>26 (June 27-July 03)</td>
<td>107</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>27 (July 04-July 10)</td>
<td>111</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>28 (July 11-July 17)</td>
<td>117</td>
<td>1</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>29 (July 18-July 24)</td>
<td>105</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>30 (July 25-July 31)</td>
<td>99</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>31 (Aug. 01-Aug. 07)</td>
<td>106</td>
<td>0</td>
<td>1</td>
<td>0</td>
</tr>
<tr>
<td>32 (Aug. 08-Aug. 14)</td>
<td>83</td>
<td>1</td>
<td>1</td>
<td>0</td>
</tr>
<tr>
<td>33 (Aug. 15-Aug. 21)</td>
<td>71</td>
<td>2</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>34 (Aug. 22-Aug. 28)</td>
<td>99</td>
<td>1</td>
<td>0</td>
<td>1</td>
</tr>
<tr>
<td>35 (Aug. 29-Sept. 04)</td>
<td>137</td>
<td>1</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>36 (Sept. 05-Sept. 11)</td>
<td>164</td>
<td>2</td>
<td>0</td>
<td>1</td>
</tr>
<tr>
<td>37 (Sept. 12-Sept. 18)</td>
<td>158</td>
<td>1</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>38 (Sept. 19-Sept. 25)</td>
<td>190</td>
<td>8</td>
<td>2</td>
<td>0</td>
</tr>
<tr>
<td>Grand Total</td>
<td>44991</td>
<td>15400</td>
<td>273</td>
<td>1026</td>
</tr>
</tbody>
</table>

**Recruitment and Retention** Last updated 09/13/2013
State of Texas

The abbreviated Week 38 state report from DSHS is not available at the time of this report. During week 37, week ending Sept. 18, 2010, in Texas:

- Two (0.99%) specimens tested by NREVSS laboratories in Texas were positive for influenza A; one of these was collected from a Texas resident returning from Germany and was identified as 2009 influenza A (H1N1) by PCR testing.
- Percentage of visits for influenza-like illness as reported by ILINet providers in Texas was below the regional baseline.
- Influenza reports were received from all Health Service Regions (HSRs) for week 37. For a map of Health Service Regions please visit the following website: http://www.dshs.state.tx.us/regions/state.shtm.
  - HSR 7 reported an increased level of flu activity compared to week 36.
  - HSRs 2/3, 4/5N, 6/5S, 8, 9/10, and 11 reported the same level of flu activity compared to week 36.
  - HSR 1 did not determine a flu activity level for week 37 compared to week 36.
- Eight hospital laboratories and public health agencies across Texas reported conducting a total of 202 influenza tests (antigen, culture, and PCR) to the National Respiratory and Enteric Virus Surveillance System (NREVSS) sponsored by the Centers for Disease Control and Prevention (CDC).
Forty-seven percent of the influenza tests reported to NREVSS were antigen detection tests; these tests cannot identify the subtype of influenza detected.

The complete detailed weekly report for the state can be found at: http://www.dshs.state.tx.us/idcu/disease/influenza/surveillance/2010/.

United States

CDC is no longer publishing a weekly national flu report for the 2009-2010 Season. The first weekly influenza surveillance report of the 2010-2011 Season (week 40, week ending October 9, 2010) will be published on October 15, 2010.

For past reports, please visit: http://www.cdc.gov/flu/weekly/.

For questions or concerns relating to this report or flu surveillance in Region 2/3, please call or contact Johnathan Ledbetter, Epidemiologist, at 817-264-4512.
Section VI: Laboratory Support

Table of Contents

- Viral Transport Medium VI.2
  - Receiving and storing DSHS VTM VI.3
- Ordering Supplies VI.4
- Testing Performed by DSHS Austin VI.6
  - Summary of DSHS influenza testing methods VI.8
- Specimen Collection VI.9
- How to Submit Specimens VI.11
  - Specimen storage VI.11
  - Specimen shipping VI.11
  - Specimen rejection VI.13
- LRN Overview VI.14
- Frequently Asked Questions VI.15
- G-2V Submission Form Example VI.16
- Packaging Diagrams VI.17
- Sample VTM Order Form VI.19
Viral Transport Medium (VTM)

The majority of the viral transport medium (VTM) shipped to providers throughout the season is prepared in July or August each year by the DSHS Media Preparation Group in the DSHS Austin Laboratory. Usually 2,500 to 3,000 tubes of VTM are prepared each season with an expiration date of September 30 of the following year. Quality control is performed on the VTM by the Viral Isolation Team in August or September, prior to the beginning of the official influenza season. DSHS-prepared VTM may be supplemented with commercially-prepared VTM.

VTM is designed to maintain the stability and viability of viruses while outside of the host organism or laboratory tissue culture. Most VTM contains antibiotics to inhibit the overgrowth of viruses by bacteria that also may be present in clinical respiratory specimens. The DSHS VTM, also called influenza transport medium, is specifically made for use in influenza surveillance.

VTM prepared by DSHS contains tryptose-phosphate broth, gelatin, penicillin and streptomycin sulfate. Quality control for DSHS-prepared VTM is performed using only influenza viruses. In theory, DSHS VTM should be able to successfully transport other viruses besides influenza virus; however, this is not recommended except in an urgent or outbreak situation. When in doubt, check with the specific disease program and laboratory to which you wish to submit the specimen. For commercially-prepared VTM, refer to the package insert for approved uses. Because VTM contains antibiotics, it is not an appropriate medium to use for bacterial testing; this also applies in outbreak situations in which viral and bacterial testing will need to be performed on specimens from each patient.

DSHS-prepared VTM should be stored frozen, preferably at -20˚C or below, until needed. If a freezer is not available, VTM should be stored for no longer than one month in a refrigerator (2–8˚C). The antibiotics contained in the medium will not remain effective when VTM is stored for a long period of time at refrigeration temperatures. If the VTM is stored frozen, it should be allowed to thaw either at room temperature or at refrigeration temperature prior to specimen collection. Avoid incubating, microwaving or heating the VTM to speed the thawing process. For commercially-prepared VTM, refer to the package insert for approved storage conditions and timeframes.

Appropriate types of VTM for influenza surveillance include DSHS-prepared VTM, any commercially prepared VTM approved for general viral transport and universal transport medium (UTM). Inappropriate transport types for influenza surveillance specimens include dry swabs, swabs in saline and transport medium used for gonorrhea and Chlamydia testing.

Beginning in the 2012-2013 influenza season, media provided to influenza surveillance submitters may be commercially prepared. This media should be stored according to the manufacturer’s instructions. Specimen collection and shipping instructions will remain the same as those listed for the DSHS prepared VTM.
Receiving and Storing DSHS VTM

1. DSHS ships sterile viral transport medium (VTM) tubes to the surveillance sites overnight with frozen cold packs in a Sterile Media Shipper ("X Box"). Please return the Sterile Media Shippers and enclosed freezer bricks to the DSHS Laboratory according to the instructions on the box.

2. When received at the sites, the VTM tubes should be stored frozen (-20 ºC or below). It is preferable to store the VTM in the upright position. The caps on the VTM may loosen and result in leakage if stored horizontally.

3. If a freezer is not available at the site, then the VTM tubes should be refrigerated (2–8 ºC) and used within one month. Avoid storing the tubes for a long period of time in a refrigerator; instead, shipments of media can be mailed as needed during the season.

4. Discard any expired medium.

5. The plastic conical tubes with blue screw caps and the cold boxes (if ordered) provided by DSHS should be used to ship influenza surveillance specimens back to DSHS. Do not use the DSHS-provided containers for other specimens, or to ship specimens to other laboratories.
Ordering Supplies

Influenza surveillance related supplies should be ordered prior to the beginning of the official influenza season (referred to as an “initial” order) and throughout the season as needed (referred to as “replenishment” orders). Influenza surveillance supplies are maintained, packaged and shipped to submitters by the Container Preparation Group in the DSHS Austin Laboratory.

Typical influenza surveillance supplies that can be ordered from DSHS include the following:
- Nasopharyngeal (NP) swabs
- Viral transport medium (VTM)
- Plastic conical tubes with blue screw caps—labeled with a biohazard sticker—that serve as secondary containment for specimens
- Specimen shipping boxes (aka “cold boxes”) of various sizes
- Cold packs, two per cold box supplied
- Current DSHS Influenza Laboratory Surveillance Protocol
- FedEx waybills (for DSHS Austin submitters who already have shipping boxes onsite)

<table>
<thead>
<tr>
<th>Supply type</th>
<th>Automatically included in “initial” preseason orders</th>
<th>Automatically included in all VTM replenishment orders</th>
<th>Included upon request</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nasopharyngeal (NP) swabs</td>
<td>Yes</td>
<td>Yes</td>
<td>N/A</td>
</tr>
<tr>
<td>Viral transport medium (VTM)</td>
<td>Yes</td>
<td>Yes</td>
<td>N/A</td>
</tr>
<tr>
<td>Specimen shipping boxes* (various sizes)</td>
<td>No</td>
<td>No</td>
<td>Yes</td>
</tr>
<tr>
<td>Cold packs</td>
<td>No</td>
<td>No</td>
<td>Yes</td>
</tr>
<tr>
<td>Plastic conical tubes with blue screw caps</td>
<td>Yes</td>
<td>Yes</td>
<td>N/A</td>
</tr>
<tr>
<td>(secondary containment)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Current DSHS influenza surveillance protocol</td>
<td>Yes</td>
<td>No</td>
<td>Yes</td>
</tr>
<tr>
<td>FedEx waybills**</td>
<td>No, unless shipping boxes ordered</td>
<td>No</td>
<td>Yes</td>
</tr>
</tbody>
</table>

*Please instruct submitters to reuse remaining shipping boxes from previous seasons if they still have them onsite.

**FedEx waybills are provided to DSHS Austin submitters when they order shipping boxes or upon request. LRNs are expected to cover shipping costs for their submitters.

Orders for VTM and supplies must include the following information:
- Name of ordering agency
- Shipping address of ordering agency
- Name of a contact person who will receive the order at the ordering agency
- Phone number and email address for the contact person at the ordering agency
• Number of VTM tubes requested
• Number of cold boxes requested
• If the bulk order will cover several agencies, the number of agencies to which the order will be distributed
• Whether the site is a high, medium or low volume submitter:
  o low = fewer than 8 specimens per shipment
  o medium = 9–25 specimens per shipment
  o high = more than 25 specimens per shipment

See page VI.18 for an example of the VTM and supplies order form.

Preseason or “initial” orders should be placed with the DSHS Emerging and Acute Infectious Disease Branch (EAIDB) Influenza Surveillance Coordinator prior to the beginning of influenza season, if possible. Regional health departments (RHDs) should collect orders from their RHD submitters as well as orders from their local health departments and forward those to flutexas@dshs.state.tx.us. Initial orders are typically made in August.

Replenishment orders for influenza surveillance submitters, initial orders for new sites recruited during the season, and special orders for respiratory outbreaks should also be forwarded to the DSHS EAIDB Influenza Surveillance Coordinator throughout the season at flutexas@dshs.state.tx.us. DSHS Austin reserves the right to make changes to VTM and supply orders as needed. Please note that orders sent directly to the DSHS Laboratory’s Container Preparation Group may be rerouted to the DSHS EAIDB Influenza Surveillance Coordinator for approval before being filled. Please double-check the shipping address for the submitter before placing the VTM or supply order. For all VTM and supply orders, the agency/site ordering the supplies needs to have a person onsite during normal business hours to receive the order. This person should be instructed to store the VTM in the refrigerator or freezer immediately upon arrival.

VTM orders shipped by the Container Preparation Section of the DSHS Laboratory are always shipped via overnight mail; other supplies (e.g., shipping boxes) may be shipped by overnight mail or another shipping method. VTM and supplies are shipped according to the following policy: VTM orders received by the Container Preparation Section on Monday through Wednesday are shipped out the same week they are received; orders received after Wednesday are shipped out the following week. Orders will not be shipped on Fridays except in an emergency. In an emergency situation, the receiving site will need to provide the name and phone number of the person who will be present at the shipping address to receive the shipment on Saturday. Please contact DSHS EAIDB and the DSHS Container Preparation Section in the case of an emergency order (see contact information in the appendix).
Testing Performed by DSHS Austin

The DSHS Austin Laboratory performs a real time RT-PCR (reverse transcription polymerase chain reaction) test on all influenza surveillance specimens using PCR kits supplied annually by CDC. Viral isolation, multiplex PCR respiratory virus panel testing and pyrosequencing are other tests available upon request when supplies are available at the DSHS Austin Laboratory.

Acceptable specimens for routine influenza surveillance include nasopharyngeal (NP) swabs (generally considered the best specimen for routine influenza surveillance), nasal swabs, nasal aspirates, nasal washes, and throat swabs. Lower respiratory specimens may be submitted as needed and include bronchoalveolar lavages, bronchial washes, and tracheal aspirates. This is due to the requirements of the RT-PCR test kits supplied by CDC, which are the main screening tests used for influenza surveillance in Texas public health laboratories. Submission of influenza surveillance specimen types other than those listed above may result in the specimen being rejected as “unsatisfactory for testing.”

Specimens tested for influenza virus via RT-PCR at Texas public health laboratories are identified by type (i.e., A or B) and subtype [i.e., 2009 A (H1N1), seasonal A (H1N1) or A (H3N2)], if applicable. Specimens found to be positive for unsubtypeable influenza A are forwarded to CDC for identification and confirmation. The DSHS Austin Laboratory can also perform PCR testing for influenza A (H5N1) and (H7N9) upon request. If you wish to request testing for non-seasonal influenza A viruses, please contact the DSHS EAIDB Influenza Surveillance Team at 512-776-7676.

Specimens tested for influenza by viral culture are identified by type (A or B) through immunofluorescence testing. Viral isolation (i.e., culture) using a rhesus monkey kidney cell line is performed on 5–10 randomly selected positive influenza surveillance specimens every two weeks during the season, or according to the current CDC sampling protocol. Some influenza negative specimens may also be cultured as time and supplies allow.

Beginning in the 2010-2011 influenza season, the DSHS Austin Laboratory began testing a subset of influenza positive specimens via pyrosequencing for mutations that confer antiviral resistance. Currently the only testing capability is for oseltamivir resistance of H1N1 subtypes and results will only be released to public health.

The DSHS Laboratory also has the capability to run a multiplex PCR respiratory virus panel assay (i.e., Luminex). Luminex testing of influenza surveillance specimens depends upon availability of time, supplies and reagents. Beginning in the 2013-2014 season, nasopharyngeal specimens collected during outbreak investigations will be tested on the respiratory virus panel. If testing for multiple respiratory viruses is desired in an outbreak situation and the specimens collected are not NP specimens, comprehensive cell culture (i.e., viral isolation, clinical) testing should be requested on the G-2V Specimen Submission Form.

In general, RT-PCR testing results should be available within 1–4 business days from the date the specimen is received at the laboratory. Viral isolation results are available from 3–15 days after the specimen is received; specimens showing no growth are held for at least 10 days to
ensure optimal time for virus recovery. Viral isolation results are not reported to submitters unless that test was specifically requested by the submitter. Pyrosequencing results are available 1–2 weeks after the specimen is received; these results are not reported to the submitter. Multiplex PCR assay (i.e., Luminex) testing results are available from 2–4 business days after the specimen is received; however, because the test is not yet fully validated, individual patient results are not released to providers. Situations and factors that may cause a turnaround time to fall outside of these ranges include having to rerun a test for various reasons, negative test results via culture, extremely high numbers of influenza specimens received at the laboratory, staffing shortages or other unforeseen laboratory or public health emergencies.

The DSHS Laboratory sends a representative sample of influenza viruses to the CDC throughout the influenza season. This sample includes a variety of specimens from different geographic areas in Texas, different types and subtypes of influenza detected by Texas public health laboratories, cases of apparent vaccine failure, isolates possibly resistant to antiviral agents and other isolates from unusual cases. The CDC influenza laboratory performs additional tests on these influenza isolates such as antigenic characterization and antiviral resistance. Antigenic characterization identifies the specific influenza strain; data from this test are used to monitor circulating viruses and inform the decision of which viruses are recommended for inclusion in the vaccine for the upcoming year. CDC typically characterizes from 50–100 influenza isolates sent from DSHS each season.

Antiviral resistance testing determines whether or not an influenza isolate is resistant to the neuraminidase inhibitors—oseltamivir and zanamivir—or the adamantanes (rimantadine and amantadine). Influenza A viruses are tested for resistance to both classes of antiviral agents, and the majority of currently circulating influenza A viruses are typically resistant to the adamantanes. Because influenza B viruses lack an M2 protein, adamantanes are ineffective against them; therefore, influenza B viruses are only tested for resistance to the neuraminidase inhibitors.

Both antigenic characterization and antiviral resistance results can be found in the Texas Weekly Flu Report. The typical turnaround time for results from CDC’s antigenic characterization testing or antiviral resistance testing is 1–3 months; however, resistant viruses are reported to the state health departments immediately for investigation. Antigenic characterization and antiviral resistance testing results are not reported to submitters.
## Summary of DSHS Influenza Testing Methods

<table>
<thead>
<tr>
<th>Testing Method</th>
<th>Also known as</th>
<th>Tests for</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Real-time Reverse Transcription</td>
<td>rRT-PCR or PCR</td>
<td>Influenza A and B; influenza A subtypes 2009 H1, seasonal H1, H3 (H5 and H7 upon request)</td>
<td>Primary surveillance test at DSHS and LRN laboratories</td>
</tr>
<tr>
<td>Polymerase Chain Reaction</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Viral isolation</td>
<td>Culture</td>
<td>Parainfluenza viruses, influenza viruses, respiratory syncytial virus, herpes viruses, adenovirus and enterovirus</td>
<td>Performed on a percentage of influenza positive and influenza negative specimens (latter, time permitting); results not reported to submitters unless test specifically requested by submitter</td>
</tr>
</tbody>
</table>
Specimen Collection

Nasopharyngeal (NP) specimens are the preferred specimen type for influenza surveillance. NP specimens are the only acceptable specimens for multiplex PCR assay (e.g. Luminex) testing. Limited influenza testing can be performed on other respiratory specimen types but prior approval is required. Non-nasal / non-NP swab specimens should only be submitted if no other specimens are available and there is a strong public health need for the results (such as confirming influenza in a pediatric death investigation).

For seasonal influenza surveillance, collect specimens from patients who present with clinical symptoms resembling acute influenza infection or an influenza-like illness (one swab per patient). Please do not include patients with allergy symptoms, strep throat, or any other confirmed diagnosis that explains the symptoms. Typical symptoms of influenza infection generally include fever (typically > 100 °F), malaise, myalgia (muscle aches), cough, rhinorrhea (runny nose), sore throat, chills and headache. Select patients who present with recent onset (i.e., patients whose symptom onset was within 3–4 days of presenting to the clinic).

Texas public health laboratories are also interested in receiving the following priority specimens and specimens of interest for influenza surveillance:

- Patients with an extremely severe or unusual illness presentation
- Patients not responding to antiviral treatment
- Patients with a history of animal contact (avian/swine)
- Patients with a history of international travel
- Early and late season specimens
- Outbreak specimens
- Specimens from influenza-associated pediatric deaths
- Unsubtypeable influenza A specimens detected in a laboratory that can perform subtyping

Thaw frozen VTM (at either refrigeration or room temperature) completely before specimen collection. Use sterile, polyester-tipped, plastic shaft nasopharyngeal swabs and viral transport media (VTM) for specimen collection. Dacron or rayon-tipped swabs with a plastic shaft or any other commercially available sterile collection system intended for virus isolation also may be used. Cotton-tipped or calcium alginate swabs are not acceptable because they can inhibit the PCR test. After specimen collection, insert the fiber tip of the swab into the VTM (be sure to fully submerge the fiber tip inside the VTM) in the specimen tube and break off the shaft so that the swab fits completely within the tube. Please tighten the cap securely.

Nasopharyngeal specimen collection

Basic instructions for collecting NP specimens are available in the appendix of this handbook. A video demonstrating proper technique for nasopharyngeal collection for pertussis testing can be found on the CDC website at http://www.cdc.gov/pertussis/clinical/diagnostic-testing/specimen-collection.html#swab-testing. Though the video demonstrates specimen collection for pertussis, the basic technique for collecting a specimen for influenza testing is the same. Two swabs are recommended for pertussis testing but only one swab is needed for influenza testing.
Additional videos are also available on the COPAN website at http://www.copanusa.com/index.php/education/videos/. DSHS recommends that providers wear appropriate personal protective equipment including gloves, a mask and eye protection when collecting nasopharyngeal specimens.
How to Submit Influenza Specimens

Specimen Storage
At a minimum, all influenza surveillance specimens must be kept cold (2–8˚C) from the time of collection until testing. Specimens may also be stored frozen (-70˚C) after collection. Avoid multiple freeze/thaw cycles as this may inhibit recovery of virus in culture. Specimens should be stored in an upright position with caps tightened. Ship specimens to a Texas public health laboratory as soon as possible after collection. Timely transport to the laboratory will increase the likelihood of recovering the influenza virus from specimens.

Specimen Shipping
Specimens maintained at refrigerated temperatures (2–8˚C) before and during shipping must be received at the laboratory no more than 72 hours after the specimen collection time. Please include a sufficient number of cold packs to keep the specimen at the appropriate temperature until it is received at a Texas public health laboratory. For the DSHS Austin lab, if no collection time is specified on the G-2V Specimen Submission Form, the assumption will be made that the specimen was collected at 12:01am on the date of collection specified on the G-2V form. Specimens maintained in a frozen (-70˚C) state before and during shipping and shipped on dry ice are not subject to these time requirements. Please include a sufficient amount of dry ice to keep frozen specimens frozen until they are received at a Texas public health laboratory.

Each specimen should be submitted to the laboratory using the DSHS G-2V Specimen Submission Form or the appropriate specimen submission form for the local LRN laboratory. For the DSHS Austin lab, each submitter must have a submitter identification number on file with the DSHS Austin Laboratory and must submit specimens using copies of the personalized, master G-2V form. The submitter identification number and contact information are pre-filled on each submitter’s personalized G-2V form. For help obtaining a submitter ID or a personalized G-2V form for the DSHS Austin Laboratory, please contact Laboratory Reporting at 512-776-7578. For more information, see http://www.dshs.state.tx.us/lab/MRS_forms.shtm.

Please complete the following sections of the DSHS G-2V Specimen Submission Form for each influenza surveillance specimen sent to the DSHS Laboratory:

- Section 1, Submitter Information:
  - Submitter/TPI Number
  - NPI Number
  - Submitter name, address and contact information

- Section 2, Patient Information:
  - Patient name, date of birth and address
  - Date and time of specimen collection
  - ICD diagnosis code

- Section 3, Specimen Source or Type (please check appropriate box)
Texas Influenza Surveillance Handbook  Section VI

- Section 4, Virology
  - Check the box labeled “Influenza surveillance {Influenza real-time RT-PCR}”
  - Please indicate if the patient received the current season’s influenza vaccine and the date it was received
  - Please indicate if the patient has recent travel (especially international) or animal contact (i.e., avian or swine)

- Section 5, Ordering Physician Information
  - Ordering Physician’s Name and NPI Number

- Section 6, Payor Source
  - Check with your Regional Influenza Surveillance Coordinator for instructions on completing payor source. See the appendix for contact information.

  Note: Submitters who do not complete the form correctly and are billed will not be reimbursed.

See the example G-2V form on page VI.16. The patient and specimen identifiers must match between the specimen tube and the G-2V form.

Specimens must be packed in triple containment. When using influenza surveillance shipping supplies provided by DSHS, the VTM tube is the primary container, the plastic conical tube with blue screw cap (labeled with a biohazard sticker) in which the VTM tube is placed is the secondary container, and the Styrofoam cold box is the tertiary container. Non-DSHS shipping supplies must meet IATA and other shipping regulations. Place enough paper towels or other absorbent material in the secondary container to absorb the entire contents of the VTM tube if leakage or breakage should occur. Be sure to tighten caps on the primary and secondary containers. Then place the Styrofoam box in a corrugated cardboard box (provided), and tape it for shipping. Do not seal the Styrofoam lid. (The cardboard shipping boxes provided by DSHS have a Styrofoam liner inside. Please keep these two units together; do not separate the Styrofoam box from the outer cardboard box.) Place a completed G-2V laboratory form for each specimen in the shipment on top of the Styrofoam box inside the cardboard box. If dry ice is used, do not tape the Styrofoam box; this allows venting of the carbon dioxide as the dry ice melts.

Influenza surveillance specimens fall under Category B shipping regulations; a specimen submitter must be familiar with the regulations for Category B in order to ship specimens in this category. For Category B shipments, the shipping box must be labeled with the following:
- UN 3373/Category B Biological Substances label
- Directional arrows label
- Submitter’s address and contact person’s information
- Shipping address and contact person’s information
- Dry ice label (if applicable)

Do not place a biohazard sticker on the outer mailing container. Category B shipments are accepted by FedEx and Lone Star Overnight. If it can be avoided, try not to use more than 5 pounds of dry ice in a shipping container because of limits for some of the shipping companies.
It is the responsibility of the shipper to make sure that all packaging and labeling meet the current criteria.

Specimens should be shipped as soon as possible after collection and should arrive at the laboratory within 72 hours of collection (unless they are maintained frozen throughout shipping). It is recommended to collect specimens Monday through Wednesday and to ship Monday through Thursday. Please do not ship specimens to the DSHS or LRN laboratories on Friday unless it is an emergency and you have received approval from the appropriate laboratory, the DSHS Emerging and Acute Infectious Disease Branch (see the appendix for contact information) and the local health department (if applicable). Specimens should always be shipped using overnight mail.

The shipping address is:

Texas Department of State Health Services
Walter Douglass (512) 776-7569
Laboratory - MC 1947
1100 West 49th Street
Austin, TX 78756-3194

**Specimen Rejection**

Please be aware of the most common reasons for specimen rejection:

- Unfrozen specimens received at the laboratory more than 72 hours after specimen collection
- Submission of specimen types other than those listed on page VI.6
- Specimens arriving at ambient temperature
- Specimens collected with calcium alginate or wooden shaft swabs
- Specimens submitted in expired medium
- Broken or leaking specimen tubes
- Absence of patient identifiers on the specimen and/or the laboratory submission form
- Mismatch of patient identifiers between the specimen and the laboratory submission form
- No date of collection on submission form
- No specimen included with the submission form
Overview of the Texas Laboratory Response Network (LRN)

The Laboratory Response Network (LRN) was established in 1999 by the Department of Health and Human Services Centers for Disease Control and Prevention (CDC), in response to Presidential Decision Directive 39.

This network is comprised of state and local public health, federal, military and international laboratories. The main function of the LRN is to ensure that these laboratories have the capacity to respond to biological and chemical threats as well as other public health emergencies.

The LRN laboratories are categorized as either national, reference or sentinel laboratories based on their respective testing capabilities. National laboratories, such as the CDC, perform definitive testing of specimens that cannot be tested or confirmed by a reference laboratory due to its Biosafety Level rating. Reference laboratories, which include state public health, veterinary and international laboratories, provide confirmatory testing for many select agents. The sentinel laboratory category contains the largest number of LRN laboratories and is composed of hospital, clinical and commercial diagnostic laboratories that perform routine diagnostic and rule-out testing in addition to referring specimens to reference laboratories.

In Texas there are ten LRN laboratories, one in each of the following cities: Corpus Christi, Dallas, El Paso, Fort Worth, Harlingen, Houston, Lubbock, San Antonio, Tyler and Wichita Falls. The DSHS Laboratory in Austin also functions as an LRN. The primary function of these laboratories is to respond to biological threats, emerging infectious disease and other public health emergencies; additionally, since 2008 the LRNs (except Wichita Falls) have performed influenza surveillance testing for select providers in their local areas.

The LRN laboratories perform a real time RT-PCR test to identify influenza types (A or B) and subtypes [2009 H1N1, seasonal A (H1N1), A (H3N2)], if applicable. The LRN laboratories also have the capability to test for influenza A (H5N1) by RT-PCR. The typical turnaround time for influenza surveillance RT-PCR testing is 2–5 business days. Viral isolation and other testing for influenza is not available through the LRNs.

The LRN laboratories have different testing capacities and most assist in the recruiting of their influenza surveillance submitters. Please contact the local LRN laboratory for more information about its testing capacity, role in influenza surveillance and LRN-specific laboratory specimen submission form. Contact information for the LRNs is located in the appendix.
Frequently Asked Questions

General
Q2: Are supplies, shipping and testing provided free of charge for influenza surveillance specimens?
A2: Yes. Supplies (e.g., VTM and swabs) are available at no cost to influenza surveillance specimen submitters identified by the regional and local health departments; shipping (via FedEx) for influenza surveillance specimens is also free from designated submitters to the DSHS Laboratory in Austin. Influenza surveillance testing is provided free of charge as long as the approved submitter fills out the billing information correctly on the G-2V Specimen Submission Form.

Viral Transport Medium (VTM)
Q1: If I have expired VTM on hand that has not been used, what should I do with it?
A1: Discard it in a regular trash container. Please do not send the expired VTM back to DSHS Austin.

Q2: If I don’t have any VTM, can I submit an influenza specimen in saline?
A2: No. Influenza surveillance specimens must be submitted in medium suitable for viral transport, like FTM, VTM or UTM.

Rapid Influenza Tests
Q1: The patient had a negative rapid influenza test result. Should I still submit a specimen from this person for influenza surveillance testing?
A1: Rapid influenza tests are less reliable than viral culture and PCR testing. If the rapid influenza test is negative but the physician strongly suspects influenza based on the clinical presentation, then we highly recommend submitting a nasopharyngeal specimen for confirmatory laboratory testing.

Swabs
Q1: Can I use a throat swab as a NP swab?
A1: NP swabs are typically smaller and more flexible than throat swabs and are more comfortable for patients.

Q2: Why can’t I use a calcium alginate swab or a swab with a wooden shaft?
A2: The testing protocol for the rRT-PCR test performed in the DSHS Laboratory prohibits use of these types of swabs because they can inhibit the test.

Shipping
Q1: It is Friday and I want to submit an influenza specimen on a patient. Can I ship it today?
A1: It is better to freeze the specimen and ship it frozen on dry ice on Monday. Some shipping companies do not deliver on Saturday, and there are no laboratory staff members on duty during the weekend to ensure that the specimen is stored properly over the weekend. If there is an urgent need for testing, contact the influenza surveillance team to coordinate shipping.
Instructions for Completing the G-2V Specimen Submission Form* for Influenza Laboratory Surveillance

*Note: Instructions in this document refer to the DSHS G-2V Specimen Submission Form (Sep 2013).

Complete Section 5, “Ordering Physician Information,” by providing the physician’s name and NPI number.

Ensure Section 1, “Submitter Information,” has the correct submitter name, address, phone, and contact information. This section should be pre-populated on your master form**.

Complete Section 2, “Patient Information,” with date and time of specimen collection, patient name, address, date of birth, and any other pertinent information (e.g., diagnosis or symptoms).

Complete Section 3, “Specimen Source or Type,” by checking the appropriate box or boxes.

Complete Section 4, “Virology,” by selecting the box marked “Influenza surveillance (Influenza real-time RT-PCR)”. Indicate patient’s flu vaccination status for the current season and date of vaccination, if known. If applicable, indicate patient travel history and/or animal contact.

Complete Section 6, “Payor Source,” contact your Regional Influenza Surveillance Coordinator for payor source information.

When submitting priority specimens, indicate reason for submission in blank space at the bottom of Section 4 (e.g., “pediatric flu death”, “severe illness”, “travel to China”, etc.).
Packaging Diagram 1

Packaging and Labeling of Biological Substances, Category B

Do not put any patient information on outer or secondary containers or lids

Biohazard Label should already be on outside of secondary container

DO NOT put biohazard label on outer container
Packaging Diagram 2

Viral Transport Medium (VTM) glass specimen vial (Primary Container)

Patient NP swab

Plastic conical tube with screw cap (Secondary Container)

Fill secondary container with absorbent material

If specimens will arrive at the lab within 72 hours of collection, refrigerate at 2–8°C and ship **overnight** on cold packs.

If specimens will arrive at the lab more than 72 hours after time of collection, freeze at -70°C and ship **overnight** on dry ice.

G-2V forms go on top of closed Styrofoam box inside the cardboard box

Federal Express waybill

Shipping labels should be on outer cardboard box

Cardboard Box

UN3373

Biological Substance Category B

IISP G-2V Forms

Place a sufficient number of ice packs on top of the plastic conical tubes

Styrofoam Lid

Freezer or Cold Packs, or Dry Ice

Styrofoam Box

Place FedEx waybill on outside of cardboard box
### VTM Order Form Example

<table>
<thead>
<tr>
<th>Facility/Culture Surveillance Site Name</th>
<th>Shipping Address</th>
<th>City</th>
<th>Zip</th>
<th>Name of person placing order</th>
<th>Phone number of person placing order</th>
<th>E-mail of person placing order</th>
<th>Name of person receiving VTM</th>
<th>Phone number of person receiving VTM</th>
<th>E-mail of person receiving VTM</th>
<th>Number of VTM tubes requested</th>
<th>Large or small volume site?</th>
<th>Number of specimen shipping boxes requested</th>
</tr>
</thead>
<tbody>
<tr>
<td>Health Clinic A</td>
<td>111 Jane Street</td>
<td>Austin</td>
<td>78758</td>
<td>Mary Smith</td>
<td>512.289.1111</td>
<td><a href="mailto:mary.smith@healthclinic.com">mary.smith@healthclinic.com</a></td>
<td>Jake Doe</td>
<td>512.678.9999</td>
<td><a href="mailto:jake.doe@healthstate.tx.us">jake.doe@healthstate.tx.us</a></td>
<td>20</td>
<td>small</td>
<td>2</td>
</tr>
</tbody>
</table>

**Laboratory Support** Last updated 09/13/2013
# Section VII: Influenza Outbreaks

## Table of Contents

- Outbreaks Overview
  - VII.2
- Why Conduct an Outbreak Investigation?
  - VII.2
- Which Outbreaks Should Be Investigated?
  - VII.3
- What is an Outbreak?
  - VII.4
- Outline of an Outbreak Response
  - VII.6
- Basic Information to Collect
  - VII.8
- Case Definitions
  - VII.10
- Line Lists
  - VII.12
- Epi Curves
  - VII.16
  - Instructions for creating a basic epi curve using Microsoft Excel 2003
    - VII.17
  - Other outbreak graphs
    - VII.19
- Case Confirmation
  - VII.20
- Basic Control Measures for Influenza
  - VII.21
  - General recommendations for the public
    - VII.21
  - General recommendations for long term care facilities
    - VII.21
  - General recommendations for schools
    - VII.22
  - Use of antivirals for prophylaxis
    - VII.23
  - Environmental cleaning information
    - VII.23
  - Notes on using these recommendations for non-influenza outbreaks
    - VII.24
- Resources and Training
  - VII.25
- References
  - VII.27
Outbreaks Overview

Clusters of respiratory illnesses are challenging to investigate because infectious respiratory diseases are sometimes difficult to distinguish from non-infectious causes of respiratory symptoms. Local testing capacity is also limited for many respiratory pathogens. Another challenge is just deciding if it is an outbreak or not. It is important to find out if the reported number of cases is greater than the expected number of cases at that location for that time of year. An investigator must also find out if the cases are related (by contact, relationship, physical location or pathogen) to each other. Some outbreaks require more investigative work than others depending on how many people are or could be impacted, the health status of the potentially exposed population, how widespread the outbreak is or how quickly the outbreak is spreading and the severity of the illness. At a minimum, all reported outbreaks should be documented and basic control measures should be provided or reviewed. See page VII.3 for indicators of when more intensive investigations should be performed.

Every epidemiologist develops his or her own style of investigating outbreaks. Experience is crucial to honing good investigative intuition. This section is meant to help new outbreak investigators get started as well as to serve as a basic reference for more experienced investigators.

Why Conduct an Outbreak Investigation? (1)

1. To determine the likely sources of exposure and mechanisms of transmission in order to eliminate them and prevent new exposures

2. To determine risk factors for illness in order to mitigate those risks in the specific setting/location

3. To identify the cause of the outbreak to help guide treatment and care for the remaining cases that have not fully recovered

4. To document what occurred before and during the outbreak to decrease the time it takes to control or to prevent future outbreaks
Which Outbreaks Should Be Investigated? (2)

According to the Centers for Disease Control and Prevention (CDC) website, when deciding how to respond to a respiratory disease outbreak, public health agencies must take into consideration many factors such as the availability of resources and competing agency priorities. While each agency needs to determine the level of public health response appropriate for each outbreak, several characteristics of respiratory outbreaks typically warrant further investigation of the outbreak and an urgent response. The characteristics below should not be viewed as a comprehensive or definitive list, but should serve as a general guide to determine which outbreaks merit further investigation.

- Outbreaks of unknown etiology
- Outbreaks associated with severe disease outcomes, such as death or hospitalization
- Outbreaks for which identification of the causative agent or potential dual infections is needed, determined *a priori*
- Outbreaks which may be useful to answer epidemiologic, laboratory or infection control questions
- Outbreaks of possible vaccine-preventable diseases
- Outbreaks associated with institutional settings or with a likely (controllable) environmental source
- Clusters of respiratory infection potentially caused by a bioterrorism agent
- Outbreaks among a vulnerable population
- Outbreaks which have generated excessive public anxiety
- Outbreaks which are either very large or rapidly progressing

The list above, which is taken directly from the CDC website, can be used for any infectious respiratory disease outbreak. In addition to the above list, DSHS has defined what respiratory clusters and outbreaks health departments should investigate and those outbreaks for which summary reports are requested. See page VII.4 for operational definitions on outbreaks requiring summary reports.
What is an Outbreak?

An outbreak is a localized increase in a disease, symptom or syndrome that clearly exceeds the expected level. For rare diseases (e.g., measles, anthrax), a single case may be considered an outbreak. Several public health, medical, and regulatory agencies and organizations provide definitions of what constitutes an outbreak.

The Centers for Medicaid and Medicare Services (CMS) defines an outbreak in healthcare facilities as “the occurrence of more cases of a particular infection than is normally expected, the occurrence of an unusual organism, or the occurrence of unusual antibiotic resistance patterns.” CMS further elaborates on what constitutes an outbreak by describing the following scenarios as outbreak indicators (3):

- one case of an infection that is highly communicable
- trends that are 10 percent higher than the historical rate of infection for the facility that may reflect an outbreak or seasonal variation and therefore warrant further investigation
- occurrence of three or more cases of the same infection over a specified length of time on the same unit or other defined area

The American Medical Directors Association expands on the three or more cases indicator by specifying that three or more cases must occur within the same 24 hour period (4).

CDC also has definitions for respiratory clusters and outbreaks. A respiratory cluster is defined as three or more cases of acute febrile respiratory illness (AFRI) occurring within 48 to 72 hours in residents who are in close proximity to each other (e.g., in the same area of the facility). A respiratory outbreak is defined as a sudden increase of AFRI cases over the normal background rate (5).

For long term care facilities, CDC suggests that an outbreak might be occurring if there is a single confirmed case of influenza along with at least one other case of respiratory infection (5,6).

The Infectious Diseases Society of America recommends facilities implement facility wide influenza outbreak control measures when two or more people have ILI and one person tests positive for influenza (7).

All medical or long term care facilities should be aware of definitions used by their regulatory agencies and adhere to those standards for notifying their regulators. Schools should also be aware of reporting requirements as established by the Texas Education Association. Any suspected outbreak reported to a regulatory agency should also be reported to the local health department. Any facility or entity with a concern about increases of specific infectious disease occurrences should contact their local or regional health department.
Health departments in Texas can use the following operational definitions for deciding which cluster or outbreak investigations/reports should have a completed outbreak summary report form faxed to DSHS:

In hospital or clinic settings:
- a sudden increase of cases over the normal background rate
- three or more healthcare-associated infections of AFRI or ILI among patients or healthcare workers on the same unit within 72 hours
- one or more healthcare-associated infections of confirmed influenza

In long term care settings:
- a sudden increase of cases over the normal background rate
- three or more cases of AFRI or ILI among residents or healthcare workers who are in close proximity with each other (e.g., same area of the facility) within 72 hours
- Two or more cases of AFRI or ILI among residents when there is at least one confirmed influenza case in the facility.

In school or child care settings:
- a sudden increase of cases or absenteeism over the normal background rate
- five or more cases of AFRI or ILI in one week among students or staff in an epidemiologically linked group (e.g., single class, sports team or after school group)

In other settings:
- a sudden increase of cases over the normal background rate
- five or more cases of AFRI or ILI within one week in people in the same area of the building or work group.

Selected terms in the operational outbreak definitions:
- Healthcare-associated infection (HAI) of influenza: Onset of new respiratory symptoms and positive influenza test was > 3 days after admission to hospital
- Acute febrile respiratory illness (AFRI): An illness characterized with onset in the past 4 days of fever and at least one of the following: cough, sore throat, rhinorrhea or nasal congestion
- Influenza-like illness (ILI): An illness characterized with a fever greater than or equal to 100°F plus a cough and/or a sore throat in the absence of a known cause other than influenza
Outline of an Outbreak Response

No two outbreak investigations are the same. The course of the outbreak investigation depends on multiple factors including the pathogen, the setting of the outbreak, the number of people involved, the demographics of the people involved, the geographic spread and the severity of the illness. Interest in the outbreak by the facilities involved, the health departments involved, the media and community leaders also influences outbreak investigations. Outbreak investigators must be flexible and able to expand or limit the investigation as needed based on the information that is learned over the course of the investigation. The following outline describes some of the key processes and decisions that occur in outbreak investigations.

1. Receive Initial Report
   - Collect basic information on the situation being reported. See page VII.8.
   - Provide basic respiratory control measures and/or review control measures the entity has already implemented. See page VII.21.

2. Assess Situation
   - Determine if the situation requires additional follow-up.
     - Affirmative answers to the following questions indicate additional follow-up is warranted:
       - Is the outbreak ongoing?
       - Will health department involvement help stop the outbreak?
       - Will health department involvement help the facility to prevent future outbreaks?
       - See pages VII.3 and 4 for additional outbreak characteristics meriting further investigation.
     - Consult with fellow epidemiologists and supervisor if uncertain.
   - Determine who will fill the lead investigator role.

3. Conduct Outbreak Investigation
   - Notify appropriate partners of the outbreak investigation initiation.
     - Include background on the outbreak and expectations for assistance that may be requested.
       - Alert internal chain of command and public affairs.
       - Alert appropriate DSHS regional office(s).
   - Develop and maintain case definitions, a line list and an epidemic curve (epi curve). See pages VII.10 - VII.19.
   - Confirm the existence of an outbreak through historical review of similar cases, case investigation and laboratory testing. See page VII.20.
   - Review and/or recommend diagnostic testing; assist with coordination of specimen collection or submission as necessary. See page VII.20.
     - Arrange for 5 to 10 specimens to be tested for influenza even if rapid influenza testing has already been done.
   - Identify risk factors using appropriate epidemiologic tools and investigation/study designs:
     - Review case medical records
4. Expand Investigation (as needed)
   • Consider utilizing an incident command system (ICS) structure to ensure that the roles of individuals and assisting agencies are clearly defined.
   • Surge internally as needed
     o Identify staff who can assist with data entry, interviewing and other tasks as necessary.
   • Surge externally as needed
     o Activate MOUs/MOAs with other health departments.
     o Utilize volunteers and/or student groups.
     o Request assistance from DSHS regional office
       ▪ DSHS epidemiologists can act as subject matter experts for consultation with investigation plans and operations.
       ▪ DSHS epidemiologists can also provide surge capacity for investigation operations.
       ▪ DSHS can provide logistical support for laboratory testing, control measure recommendations and acquisition and distribution of chemoprophylaxis and vaccines.
       ▪ DSHS regional epidemiologists can request assistance from DSHS EAIDB epidemiologists.
     o CDC Epi Aid teams are valuable resources for conducting in-depth studies associated with the investigation. CDC Epi Aid teams can only be requested by the state epidemiologist. Contact DSHS EAIDB to start the CDC Epi Aid request process.
   • Note for cross-jurisdictional investigations:
     o DSHS regional epidemiologist should facilitate the coordination of investigations involving multiple counties within a single region.
     o DSHS EAIDB epidemiologists should facilitate the coordination of investigations crossing multiple regions or states.

5. Communicate Findings and Document Investigation
   • Share findings and final recommendations in writing with the facility.
   • Provide a final update to internal and external partners.
   • Draft a written report summarizing the investigation.
     o Consider sharing the experience with the public health community through presentations at conferences, publishing in public health newsletters, publishing in peer reviewed journals and/or Epi-X reports.
   • Conduct an after action report on the investigation and use the results to improve future investigation responses.
   • Submit the outbreak summary report to DSHS. A respiratory outbreak report form is available on the DSHS website.
Basic Information to Collect

When a call is received regarding a potential outbreak, it is important to collect as much information as possible. The information collected during the initial report will help describe the situation and determine what resources are needed to respond. The following list has basic information that should be collected for any outbreak.

On the reporter
- Name of caller
- Caller’s title/position
- Caller’s phone number

On the setting/facility
- Type of cluster/outbreak setting (e.g., private party/celebration/event, nursing home, jail)
- If applicable, date of event
- Name of setting
- Address of setting
- Setting/facility contact person
- Phone number of setting/facility contact person
- Total number of people in the setting
- If applicable, total number of staff

On potential cases
- Number of people ill
- If applicable, number of staff ill
- Description of symptoms seen
- Number of people hospitalized
- Number of people deceased
- Date of first onset of illness
- Date of most recent onset of illness
- What medical evaluation has been done?
- What diagnostic testing has been done? Results?

On control measures
- What control measures have already been implemented?
- Have efforts been made to separate people who are ill from those who are not?

Additional information to consider requesting
- For private events/parties/celebrations
  - Name and contact information of attendees
- For facilities
  - Line list of cases to include names, onset dates, symptoms, room number(s) and any other information you feel may help determine risk
  - Map of the facility
  - Calendar of events
### Example data from two different outbreak settings:

<table>
<thead>
<tr>
<th>Question</th>
<th>Wedding Scenario</th>
<th>Nursing Home Scenario</th>
</tr>
</thead>
<tbody>
<tr>
<td>Name of caller:</td>
<td>Mrs. Smith</td>
<td>Mrs. Jackson</td>
</tr>
<tr>
<td>Caller’s title/position:</td>
<td>Mother of the Bride</td>
<td>Guardian of a resident</td>
</tr>
<tr>
<td>Caller’s phone number:</td>
<td>512-458-1234</td>
<td>512-458-5678</td>
</tr>
<tr>
<td>Type of cluster/outbreak setting (private party/celebration/event, nursing home, jail, etc.):</td>
<td>Private celebration - wedding</td>
<td>Nursing home</td>
</tr>
<tr>
<td>If applicable, date of event:</td>
<td>01/01/10</td>
<td>n/a</td>
</tr>
<tr>
<td>Name of setting:</td>
<td>Mrs. Smith’s House</td>
<td>Long Life Nursing Home</td>
</tr>
<tr>
<td>Address of setting:</td>
<td>123 Somestreet, Austin, TX</td>
<td>123 Anotherstreet, Austin, TX</td>
</tr>
<tr>
<td>Setting/facility contact person:</td>
<td>Bride is Mrs. Taylor</td>
<td>Mr. Davids – Director</td>
</tr>
<tr>
<td>Phone number of setting/facility contact person:</td>
<td>Same as caller</td>
<td>512-458-1289</td>
</tr>
<tr>
<td>Total number of people in the setting:</td>
<td>100</td>
<td>100</td>
</tr>
<tr>
<td>If applicable, total number of staff:</td>
<td>n/a</td>
<td>20</td>
</tr>
<tr>
<td>Number of people ill:</td>
<td>Maybe 30</td>
<td>30</td>
</tr>
<tr>
<td>If applicable, number of staff ill:</td>
<td>n/a</td>
<td>1</td>
</tr>
<tr>
<td>Description of symptoms seen:</td>
<td>Sore throat, fever</td>
<td>Sore throat, fever, some pneumonia</td>
</tr>
<tr>
<td>Number of people hospitalized:</td>
<td>0</td>
<td>3</td>
</tr>
<tr>
<td>Number of people deceased:</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Date of first onset of illness:</td>
<td>01/02/10</td>
<td>02/13/10</td>
</tr>
<tr>
<td>Date of most recent onset of illness:</td>
<td>01/05/10</td>
<td>02/25/10</td>
</tr>
<tr>
<td>What medical evaluation has been done?</td>
<td>Unknown</td>
<td>3 were hospitalized, waiting for diagnosis</td>
</tr>
<tr>
<td>What testing has been done? Results?</td>
<td>n/a</td>
<td>Bacterial cultures on 3 hospitalized are pending. 5 people were rapid influenza test negative</td>
</tr>
<tr>
<td>What control measures have already been implemented?</td>
<td>n/a</td>
<td>Hand hygiene training. Made hand sanitizer available to most residents</td>
</tr>
<tr>
<td>Have efforts been made to separate people who are ill from those who are not?</td>
<td>n/a</td>
<td>Yes</td>
</tr>
<tr>
<td>Comments</td>
<td>Guests started calling mother of the bride saying they were ill and wanted to know if others are ill too. Willing to provide guest list to us. No food served.</td>
<td>Caller said everyone ill at nursing home. Spoke with director and got more info. They will send us a line list.</td>
</tr>
</tbody>
</table>
Case Definitions

In order to accurately count how many cases of an illness have occurred, it is necessary to clearly define what constitutes a case. In public health, there are two main uses for case definitions: 1) surveillance of notifiable conditions for reporting purposes and 2) outbreak investigations.

Case definitions are different from a doctor’s diagnosis. A diagnosis is a process of determining what is affecting an individual’s health status and guides what treatment options will be employed. There is room for some subjective consideration by the individual physician for determining the most likely cause of illness. Case definitions for public health surveillance specify what criteria must be met in order to count a person as a case. Surveillance case definitions are not meant to be diagnostic. Case definitions tend to have strict criteria to ensure that there is less variation in what is counted as a case.

Case definitions have four parts:
- Clinical criteria – symptoms and/or laboratory results
- Person – who can be a case
- Place – the outbreak location, where the person was exposed or where the person resides
- Time – when onset or exposure occurred

Surveillance case definitions for reporting individual cases of a notifiable condition describe clinically compatible symptoms and what laboratory testing is required. The person and place portions are understood as residents of the appropriate health jurisdiction. The time portion is implied to be the current reporting year. Case definitions for notifiable conditions are standardized within each state. Case definitions for notifiable conditions in Texas can be found in the Epi Case Criteria Guide located at http://www.dshs.state.tx.us/idcu/ under the disease reporting link. The case definitions used in Texas are based upon but not always identical to the case definitions used by the CDC.

Case definitions for outbreaks are determined by the lead outbreak investigator. If the outbreak crosses multiple health jurisdictions, then all of the involved health jurisdictions should agree upon a case definition. Outbreak case definitions need to be very clear and should explicitly state the person, place and time parts of the case definition. The clinical criteria portion of the case definition may be identical, more restrictive or less restrictive than the clinical criteria in a case definition for a notifiable condition. A clear outbreak definition helps to distinguish between cases associated with the outbreak and coincidental cases that may occur sporadically in the same county/city/community but are unrelated to the outbreak.

What works well for clinical criteria may vary depending on the setting. For example, using 100°F as an indicator of fever in a nursing home resident may not be a good indicator of fever resulting from an infectious disease process. Frail, elderly individuals often have lower baseline temperatures than healthy, younger individuals. Thus, frail nursing home residents infected with influenza may have a fever (higher than normal temperature) that does not exceed 100 °F. (8) Patients of any age with severe neurologic or neurodevelopmental conditions may also only have “subtle deviations from their baseline medical status and be unable to communicate symptoms effectively” (9). It may be more reliable to define fever in a nursing home outbreak (or any
setting with frail, elderly or immunocompromised individuals) as a temperature two or more degrees above the patient/resident’s baseline temperature.

Example surveillance case definition (from the Epi Case Criteria Guide):
Legionellosis: Legionellosis is associated with two clinically and epidemiologically distinct illnesses: Legionnaires disease, which is characterized by fever, myalgia, cough, clinical or radiological pneumonia, and Pontiac fever, a milder illness without pneumonia.

Confirmed: A clinically compatible case that meets at least one of the confirmatory laboratory criteria

Confirmatory laboratory criteria:
- Isolation of any *Legionella* organism from respiratory secretions, lung tissue, pleural fluid, or other normally sterile fluid, or
- Detection of *Legionella pneumophila* serogroup 1 antigen in urine using validated reagents, or
- Demonstration of seroconversion by a fourfold or greater rise in specific serum antibody titer between paired acute and convalescent phase serum specimens to *Legionella pneumophila*

Example outbreak case definitions:
Case definition in outbreak 1: A resident or employee of nursing home X with onset of diarrhea and nausea (or vomiting) since June 23, 2011.

Case definition in outbreak 2: Confirmed - An employee or inmate at correctional facility Y with onset of fever over 100ºF and cough lasting 3 or more days since November 2009 AND either a chest x-ray positive for pneumonia or a positive PCR test for *C. pneumoniae* infection. Probable - An employee or inmate at correctional facility Y with onset of fever over 100º F and cough lasting 3 or more days since November 2009.
Line Lists

Data from outbreak investigations are usually kept in one or more of three formats: hardcopy, database and line list. Hard copies of medical records, interview forms and investigation notes should be kept in accordance with the health department’s record retention policy. Databases are often used to enter and store the extensive data collected from record reviews and interviews. Epi Info is an example of a database that is frequently used in public health to enter, store and analyze outbreak investigation data. A line list is a line by line listing of key information on each case in an outbreak investigation. Line lists can be created using almost any word processor or spreadsheet such as Microsoft Excel.

Basic line lists allow for quick review of key case characteristics. Each line on the list represents one person or case. Some line lists may also include close contacts or controls. The following information is typically captured on a line list:

- Demographics
- Symptoms
- Date of onset
- Hospitalization status
- Outcome (recovered/died)
- Lab test results
- Immunization history
- Travel history
- Epidemiologic links

The exact information collected in a line list depends on the specific illness or setting. For example, symptoms can be expanded or removed to capture the symptoms of interest in the investigation. In a respiratory outbreak investigation, the investigator should capture immunization status for influenza and pneumococcal disease. In a norovirus outbreak investigation, vaccination status for influenza is not relevant and would not be captured in the line list.

Here is an example of a simple line list with case definitions:

<table>
<thead>
<tr>
<th>Case status*</th>
<th>Case initials</th>
<th>Age</th>
<th>Home zip code</th>
<th>Date of onset</th>
<th>Fever</th>
<th>Headache</th>
<th>Cough</th>
<th>Sore throat</th>
<th>Flu test result</th>
<th>Previously vaccinated</th>
<th>Attended gathering</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>C</td>
<td>CM</td>
<td>39</td>
<td>78665</td>
<td>07/01/11</td>
<td>Y</td>
<td>N</td>
<td>Y</td>
<td>Y</td>
<td>PCR +</td>
<td>N</td>
<td>Y</td>
<td></td>
</tr>
<tr>
<td>P</td>
<td>LB</td>
<td>35</td>
<td>78755</td>
<td>07/01/11</td>
<td>Y</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>Rapid test +</td>
<td>Y</td>
<td>Y</td>
<td>Vaccinated on 06/28/11</td>
</tr>
<tr>
<td>C</td>
<td>IB</td>
<td>29</td>
<td>78664</td>
<td>06/29/11</td>
<td>Y</td>
<td>Y</td>
<td>N</td>
<td>Y</td>
<td>Rapid test +</td>
<td>N</td>
<td>Y</td>
<td>Ill at gathering</td>
</tr>
<tr>
<td>P</td>
<td>MF</td>
<td>37</td>
<td>78756</td>
<td>07/02/11</td>
<td>Y</td>
<td>Y</td>
<td>Y</td>
<td>N</td>
<td>Not done</td>
<td>N</td>
<td>N</td>
<td>Friend of IB</td>
</tr>
</tbody>
</table>

*All cases must have had onset after 06/28/11 and either attended the gathering or are close contacts of someone who attended the gathering.
C: confirmed case meets ILI definition AND has a positive influenza test (includes rapid test)
P: probable case meets ILI definition but does not have a positive influenza test OR does not meet ILI definition but has a positive rapid test
Template line list for public health department use with an influenza outbreak:

<table>
<thead>
<tr>
<th>Case status</th>
<th>Case ID</th>
<th>First name</th>
<th>Last name</th>
<th>Age</th>
<th>Sex</th>
<th>Race</th>
<th>Ethnicity</th>
<th>City of residence</th>
<th>Affiliation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Confirmed</td>
<td>123</td>
<td>Example</td>
<td>Example</td>
<td>71</td>
<td>M</td>
<td>W</td>
<td>H</td>
<td>Austin</td>
<td>Resident</td>
</tr>
<tr>
<td>Probable</td>
<td>456</td>
<td>Example</td>
<td>Example</td>
<td>45</td>
<td>F</td>
<td>B</td>
<td>NH</td>
<td>Hutto</td>
<td>Staff</td>
</tr>
<tr>
<td>Not a Case</td>
<td>789</td>
<td>Example</td>
<td>Example</td>
<td>62</td>
<td>M</td>
<td>A</td>
<td>NH</td>
<td>Austin</td>
<td>Resident</td>
</tr>
</tbody>
</table>

### Medical Information

<table>
<thead>
<tr>
<th>Date of onset of flu symptoms</th>
<th>Cough</th>
<th>Sore throat</th>
<th>Fever</th>
<th>SOB</th>
<th>Date symptoms resolved</th>
<th>Underlying conditions</th>
<th>Hospitalized</th>
<th>Died</th>
</tr>
</thead>
<tbody>
<tr>
<td>2/4/2011</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>2/7/2011</td>
<td>Heart Disease</td>
<td>Yes</td>
<td>No</td>
</tr>
<tr>
<td>2/6/2011</td>
<td>No</td>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
<td>2/9/2011</td>
<td>Asthma</td>
<td>No</td>
<td>No</td>
</tr>
<tr>
<td>2/1/2011</td>
<td>Yes</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>2/2/2011</td>
<td>None</td>
<td>No</td>
<td>No</td>
</tr>
</tbody>
</table>

### Flu Test

<table>
<thead>
<tr>
<th>Flu test</th>
<th>Flu test result</th>
<th>Flu test collection date</th>
<th>Date antivirals given</th>
<th>Date antivirals ended</th>
<th>Name of antiviral given</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rapid Test</td>
<td>Flu A</td>
<td>2/6/2011</td>
<td>n/a</td>
<td>n/a</td>
<td>n/a</td>
</tr>
<tr>
<td>Not Done</td>
<td>Negative</td>
<td>2/1/2011</td>
<td>n/a</td>
<td>n/a</td>
<td>n/a</td>
</tr>
</tbody>
</table>

### Vaccination

<table>
<thead>
<tr>
<th>Vaccinated for flu this season</th>
<th>Date of most recent flu vaccination</th>
<th>Date of pneumococcal vaccination</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>No</td>
<td>Unknown</td>
<td>10/15/2011</td>
<td>index case</td>
</tr>
<tr>
<td>Unknown</td>
<td>Unknown</td>
<td>Unknown</td>
<td></td>
</tr>
<tr>
<td>Yes</td>
<td>10/15/2010</td>
<td>n/a</td>
<td>1 day of cough, no other symptoms, tested negative</td>
</tr>
</tbody>
</table>
In addition to helping public health departments describe outbreaks, line lists can also be used by infection preventionists to monitor outcomes of cases and contacts of cases within a facility. The line lists used by infection preventionists will likely include more information than needed by the health department. It may also be necessary for the infection preventionist to maintain separate lists on patients or residents and on staff.

Facility influenza line list template for residents or patients:

<table>
<thead>
<tr>
<th>General Patient Information</th>
</tr>
</thead>
<tbody>
<tr>
<td>Case status</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Symptoms</th>
</tr>
</thead>
<tbody>
<tr>
<td>Date of onset of flu symptoms</td>
</tr>
<tr>
<td>2/4/2011</td>
</tr>
<tr>
<td>n/a</td>
</tr>
<tr>
<td>n/a</td>
</tr>
</tbody>
</table>

| Flu Test | Flu Treatment/Prophylaxis |
|-----------------------------|
| Flu test | Flu test result | Flu test collection date | Date antivirals given | Date antivirals ended | Name of antiviral given |
| PCR | Negative | 2/6/2011 | n/a | n/a | n/a |
| Not Done | n/a | 2/6/2011 | 2/5/2011 | 2/7/2011 | Relenza |

| Vaccination | Infection Control | Other |
|-----------------------------|
| Vaccinated for flu this season | Date of most recent flu vaccination | Date of pneumococcal vaccination | Date droplet precautions initiated | Other patient specific control measures | Notes |
| No | Unknown | 10/15/2011 | 2/4/2011 | Visitation restricted | 1st case |
| Unknown | Unknown | Unknown | n/a | Hand hygiene sign on door | Fever associated with septicemia infection |
| Yes | 2/5/2011 | 2/5/2011 | n/a | Hand hygiene sign on door | Spent several hours visiting patient 123 |
Facility influenza line list template for staff:

<table>
<thead>
<tr>
<th>Status</th>
<th>First name</th>
<th>Last name</th>
<th>Date of birth</th>
<th>Station number</th>
<th>Shift</th>
<th>Worked in room with flu case</th>
</tr>
</thead>
<tbody>
<tr>
<td>Contact - Minimal</td>
<td>Example</td>
<td>Example</td>
<td>10/10/1975</td>
<td>1</td>
<td>A</td>
<td>No</td>
</tr>
<tr>
<td>Contact - Minimal</td>
<td>Example</td>
<td>Example</td>
<td>01/01/1965</td>
<td>2</td>
<td>A</td>
<td>Yes</td>
</tr>
<tr>
<td>Contact - High</td>
<td>Example</td>
<td>Example</td>
<td>05/05/1970</td>
<td>1</td>
<td>B</td>
<td>Yes</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Date of onset of flu symptoms</th>
<th>Cough</th>
<th>Sore throat</th>
<th>Fever</th>
<th>SOB</th>
<th>Date last worked before onset of flu symptoms</th>
<th>Date symptoms resolved</th>
</tr>
</thead>
<tbody>
<tr>
<td>n/a</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>n/a</td>
<td>n/a</td>
</tr>
<tr>
<td>n/a</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>n/a</td>
<td>n/a</td>
</tr>
<tr>
<td>n/a</td>
<td>Yes</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>n/a</td>
<td>n/a</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Flu test</th>
<th>Flu test result</th>
<th>Flu test collection date</th>
<th>Date antivirals given</th>
<th>Date antivirals ended</th>
<th>Name of antiviral given</th>
</tr>
</thead>
<tbody>
<tr>
<td>Not done</td>
<td>n/a</td>
<td>n/a</td>
<td>2/5/2011</td>
<td>2/7/2011</td>
<td>Tamiflu</td>
</tr>
<tr>
<td>Not done</td>
<td>n/a</td>
<td>n/a</td>
<td>n/a</td>
<td>n/a</td>
<td>n/a</td>
</tr>
<tr>
<td>PCR</td>
<td>Negative</td>
<td>2/6/2011</td>
<td>n/a</td>
<td>n/a</td>
<td>n/a</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Vaccinated for flu this season</th>
<th>Date of most recent flu vaccination</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>No</td>
<td>n/a</td>
<td>Contraindication for flu vaccine</td>
</tr>
<tr>
<td>Yes</td>
<td>10/14/2010</td>
<td>Called in sick for 2 days for non-respiratory illness</td>
</tr>
<tr>
<td>Yes</td>
<td>10/19/2010</td>
<td>Cough associated with allergen</td>
</tr>
</tbody>
</table>
Epi Curves

An epidemic curve or epi curve is a graphical representation of the number of cases occurring over time. Epi curves are typically histograms. The y-axis is the number of cases and the x-axis is a specific time interval that depicts when onset occurred. The time interval of onset may be in minutes, hours, days or even weeks depending on the pathogen. Day representing date of onset is the most commonly used time interval. Epi curves facilitate visualization of the start, magnitude, duration and end of the outbreak. Epi curves can also help determine whether the exposure was a one-time exposure or is ongoing. Epi curves can be hand-drawn or created in a program like Microsoft Excel.

Hand-Drawn Epi Curve Template:

Example Epi Curve
Instructions for creating a basic epi curve using Microsoft Excel 2003

1. Start with a line list in an Excel workbook
   - Each row should represent one case
   - There needs to be a column for date of onset

   Note: If you created the line list in another program (Access, Epi Info, etc.), you can usually export it to Excel or a CSV file which Excel can read

2. Create a pivot chart
   - Click on any cell with data in it.
   - From the menu at the top of the screen go to ‘Data’ then select ‘Pivot table and pivot chart report’
   - The pivot wizard will open
     - Under ‘what kind of report do you want to create’, select ‘Pivot chart report’
     - Select ‘next’
     - Select ‘finish’
   - Two new sheets will be added to your workbook.
   - The sheet labeled as a ‘chart’ is your new pivot chart.
   - Drag the variable name for the column with date of onset to the area that says ‘Drop category fields here’ (found on the bottom of the page).
   - The x-axis should now display all of the dates of onset.
   - Drag the variable name for the column with the person’s name (or any other variable that is a text only field and is entered for all cases) to the area that says ‘drop data items here’ (found in the center of the page).

3. Turn the chart into an epi curve
   - The pivot chart should have defaulted to a column chart. If it did not, then you will need to right-click on the white area around the chart and select ‘chart type’. Select ‘column’ as the chart type.
   - An epi curve is actually a histogram, not a column chart. A histogram should not have any spaces between the columns. To remove the spaces, right-click on any of the columns. Select ‘format data series’. Click on the tab labeled ‘options’. Change the gap width to 0.

4. Improve the appearance of the epi curve
   - Remove the legend: In the white area around the chart, right-click and select ‘chart options’. Click on the tab for ‘legend’. Uncheck the box that says ‘show legend’.
   - Change the title: The title defaults to total. Double-click on the word ‘total’. The word ‘total’ will be highlighted. Type in your new title for the epi curve.
   - You now have a basic epi curve that you can print out or copy and paste into a Word document.
5. What to do when the date range in the x-axis does not include every date in the time frame
Before you start creating the epi curve, check to see what onset dates you have. Look at the range from the first onset date to the last onset date. Are there any dates between the first onset and the last onset where no one had an onset? If yes, then you will need to add an extra row to your line list for each missing date. The only data that should be entered on the row is the date of onset. Do not enter any other information. Now when you create the epi curve, the x-axis will have a label for every date in your date range and it will show 0 cases for the dates you inserted.

This same technique can be used to add dates before or after the dates you have cases. Adding the extra days before or after also makes your epi curve more attractive and demonstrates a baseline of cases before or after the outbreak.

This is what your epi curve should look like:

![Example EpiCurve]

6. Need to stratify the data?
Pick the variable that you want to stratify your data by. For example, you may want to show if the cases were male/female, residents/staff, or primary/secondary cases.
On the pivot chart, drag the variable name that you want to stratify by to the area that says ‘Drop series fields here’ (found above the legend).
Other outbreak graphs
Once you have mastered creating epi curves, you can explore other graphical methods of visually displaying your data. The graph below was created by Kelly Johnson, an epidemiologist with Harris County Public Health and Environmental Services. It shows both date of onset and incubation period for each case.
Case Confirmation

One of the essential steps in an outbreak investigation is to confirm the existence of an outbreak. Do all of the initially reported “cases” actually have the same illness? The first thing to do is to review the symptoms of the initial “cases” to see if they have similar patterns of illness suggesting a common cause. Once the key symptoms have been identified, a case definition can be created to guide what will be considered a case. See page VII.10 for information on creating a case definition. The clinical picture of the cases can also be used to help narrow down what etiologic agent may be causing the outbreak. The CDC has a spreadsheet showing basic risk factors for and clinical characteristics of many common respiratory pathogens. The spreadsheet can be found at http://emergency.cdc.gov/urdo/differential.asp.

Laboratory testing can be performed to identify the actual pathogen. In an outbreak in a facility, the facility can use its usual laboratory for the majority of testing and should do so for any clinical testing. The DSHS laboratory can provide support by helping with the preliminary identification of the pathogen and, for some pathogens, performing advanced testing such as serotyping, antimicrobial resistance testing or pulsed-field gel electrophoresis (PFGE). It is important to notify the DSHS Emerging and Acute Infectious Disease Branch (EAIDB) when collecting specimens for an outbreak investigation. The EAIDB works with the DSHS laboratory to approve specimen testing in outbreaks.

In most outbreaks, every case does not need to be tested by the DSHS laboratory. Ideally between 5 and 10 specimens should be collected when the outbreak is first detected to identify what pathogen is responsible. If the outbreak is ongoing, consult with EAIDB to determine if and how many specimens should be collected from future cases for testing by DSHS.

In order to decide from which cases to collect specimens, look for patients with the most recent dates of onset (preferably within the last two days) who are unrelated and (when possible) who have not started antimicrobial (antibiotic/antiviral) treatment yet. Please do not delay treatment for cases while waiting for testing supplies or test results.

All specimens submitted to the DSHS laboratory must follow the guidelines from the DSHS laboratory Manual of Reference Services found at http://www.dshs.state.tx.us/lab/default.shtm.

Each specimen must be accompanied by the appropriate laboratory submission form: G-2A for viral testing and G-2B for bacterial or fungal testing. The specimen must be clearly labeled with the patient’s first name, last name and date of birth. The information on the specimen needs to match the information on the laboratory submission form.

Nasopharyngeal (NP) swabs are the preferred specimen source for identifying viral respiratory pathogens. Instructions for collecting an NP swab can be found in the appendix of this handbook. For guidance on acceptable specimens for identifying bacterial pathogens, review the DSHS laboratory guidance at http://www.dshs.state.tx.us/lab/bac_guidelines.shtm#guidelines.
Basic Control Measures for Influenza

General recommendations for the public (10)

- Get vaccinated for influenza every year. Influenza vaccination is recommended for everyone over six months of age.
- Wash hands frequently with soap and water, especially after coughing or sneezing.
- Use alcohol-based hand sanitizers when facilities are not available for hand washing.
- Cover coughs and sneezes with a disposable tissue or your arm/sleeve.
- Avoid touching your eyes, nose or mouth.
- Avoid close contact with people who are sick.
- When you are sick, limit contact with others and stay home until you are fever-free for 24 hours without the use of fever-reducing medications.
- Seek medical care immediately if you develop any of the following: difficult or painful breathing, shortness of breath at rest, wheezing, coughing up bloody sputum, pain or pressure in the chest or abdomen, sudden dizziness, extreme drowsiness or difficulty waking, confusion or disorientation, severe earache, severe or persistent vomiting, fever lasting three to four days without improvement, or improvement followed by sudden high fever and return of symptoms.

General recommendations for long term care facilities (5, 6)

- Provide annual influenza vaccination to all residents who do not have a medical contraindication and do not refuse vaccination. Don’t forget to vaccinate new residents who may have arrived after the vaccinations were given to other residents.
- Actively promote annual influenza vaccination of all healthcare personnel, volunteers and other staff.
- When a person is suspected or confirmed to have influenza, implement standard and droplet precautions for seven days after onset or until symptom-free for 24 hours, whichever is longer. Standard and droplet precautions should be continued even if the patient was/is on antiviral therapy.
- Administer influenza antiviral medications for treatment when influenza is detected.
- Implement prevention strategies and educational campaigns, such as respiratory hygiene/cough etiquette programs. Post signs for staff, residents and visitors.
  - Examples at www.cdc.gov/flu/professionals/infectioncontrol/resphygiene.htm
- Conduct surveillance and influenza testing even outside of influenza season to identify cases.
- Discourage ill staff and volunteers from coming to work until they are fever-free for at least 24 hours without the use of fever-reducing medications.
- Discourage ill family and friends from visiting.
- Ensure that healthcare personnel who are not directly employed by the facility are also aware of the policies.
- When influenza is confirmed in at least one person and at least two people develop symptoms of influenza within a 72-hour period in the facility, consider the following:
Conduct active surveillance on a daily basis including influenza testing to detect new cases. Active surveillance should continue for at least one week after the last confirmed influenza case occurred.

Offer influenza vaccination to any unvaccinated staff and patients/residents who do not have medical contraindications.

All non-ill residents should be given chemoprophylaxis regardless of vaccination status. Chemoprophylaxis should be continued for a minimum of two weeks and should continue 7 to 10 days after the last influenza case is detected. Use clinical judgment to determine if chemoprophylaxis should be continued longer if extended viral shedding is suspected (as may occur with young children or in severely immunocompromised patients).

Staff should be monitored for symptoms of illness and treated with antivirals at the first sign of illness. Staff are not recommended for chemoprophylaxis unless they are unvaccinated, they were recently (i.e., within the past two weeks) vaccinated with TIV or the influenza strain detected in the facility does not match the vaccine.

Isolate or cohort ill residents/patients.

Restrict staff movement between wards/buildings/wings especially between ill and non-ill residents/patients.

Screen for and restrict ill visitors and personnel from entering the facility.

Assign staff returning to work after illness to work with currently ill patients/residents. This protects well staff from ill patients/residents and ensures that previously ill staff do not infect well patients/residents if they return to work while still infectious.


Detailed guidance for all healthcare settings can also be found on the CDC website at http://www.cdc.gov/flu/professionals/infectioncontrol/healthcaresettings.htm and http://www.cdc.gov/HAI/settings/settings.htm.

General recommendations for schools (11)

- Encourage annual influenza vaccination for all students and those staff who do not have medical contraindications.
- Suggest early treatment of students and staff at higher risk for influenza complications.
- Facilitate use of respiratory etiquette and hand hygiene by students and staff.
- Ensure that sick students and adults do not come to the facility. According to the Texas Administrative Code Title 25 Part 1 Chapter 97 rule §97.7, any student with a fever is required to be excluded until the fever subsides without the use of fever-suppressing medications.
- Discourage attendance at school events by sick people.
- Identify symptomatic individuals as soon as possible and separate them from asymptomatic individuals.
- Perform routine environmental cleaning.
During influenza outbreaks or if illness is unusually severe, consider the following:
  o Increase social distancing within the school environment.
  o Advise that students with sick household members stay home.
  o Ensure that symptomatic individuals do not return to school until 24 hours after fever has resolved without the use of fever-reducing medications.
  o Consider selective school dismissal for high risk individuals.
  o Consider school dismissals. The superintendent of independent school districts has the authority to close schools. This decision should be made only after consultation with the local health authority and the local health department.

Use of antivirals for prophylaxis (5, 6, 12)
Antiviral chemoprophylaxis should be used for controlling influenza outbreaks in nursing homes and other long term care facilities that house large numbers of patients at higher risk for influenza complications. Antiviral chemoprophylaxis can also be considered for controlling influenza outbreaks in closed or semi-closed settings (e.g., correctional facilities or other settings in which persons live in close proximity).

Antiviral chemoprophylaxis is not recommended for use in controlling influenza outbreaks in groups of healthy children or adults based on potential exposures in the community, workplace, school or other settings. Instead, early recognition of illness and prompt treatment is recommended.

When antiviral chemoprophylaxis is given, it should be given to all non-ill patients/residents regardless of vaccination status. Chemoprophylaxis should be continued for a minimum of two weeks and should continue 7 to 10 days after the last influenza case is detected. Updated antiviral recommendations are available on the CDC website at http://www.cdc.gov/flu/professionals/antivirals/index.htm.

Environmental cleaning information (11, 13-15)
According to the CDC, influenza viruses can generally survive on inanimate objects from two to eight hours. Influenza viruses are fragile, so standard cleaning and disinfection are sufficient when done properly.
  • Perform routine cleaning of hard surfaces that are frequently touched by using water and soap (or detergent). Common household cleaners that kill germs can also be used. Always follow the label directions on cleaning products. Hard surfaces that are frequently touched may include doorknobs, bedside tables, bathroom sinks, toilets, counters, phones, toys and computer keyboards or mice.
  • Wash bed sheets and towels with normal laundry soap and tumble dry on a hot dryer setting. Hold all dirty laundry away from your face and body. Wash your hands right after touching dirty laundry. It is okay to wash a sick person’s bedding or clothes with other people’s laundry.
  • Wash the sick person’s eating utensils and dishes with normal dish soap or place them in the dishwasher. It is okay to wash the sick person’s eating utensils and dishes with other people’s dishes.
• Avoid touching used tissues and other waste when emptying waste baskets. Wash your hands immediately after emptying waste baskets or touching used tissues.

**Notes on using these recommendations for non-influenza outbreaks**

Influenza is a respiratory illness spread primarily through droplets. The basic control measures described in this section are applicable to most infectious respiratory diseases because the measures target pathogens spread via droplets. Respiratory hygiene, hand hygiene and droplet infection control measures are critical for preventing infectious respiratory disease outbreaks.

For details on prophylaxis, vaccination and other control measures specific to a non-influenza respiratory pathogen refer to the Control of Communicable Diseases Manual, the Red Book and the CDC website.
Resources and Training

Books


Websites

DSHS websites

- www.dshs.state.tx.us
- www.texasflu.org
- www.dshs.state.tx.us/idcu/investigation/
- www.dshs.state.tx.us/idcu/disease/influenza/

CDC websites

- www.cdc.gov
- www.flu.gov/
- www.cdc.gov/flu/other_flu.htm
- http://emergency.cdc.gov/urdo/
- www.cdc.gov/mmwr/preview/mmwrhtml/rr5908a1.htm

Other health department websites

- www.health.state.ny.us/diseases/communicable/control/respiratory_disease_checklist.htm
Trainings

North Carolina Center for Public Health Preparedness has a variety of free online trainings including basic epidemiology, outbreak investigations and ICS for public health at http://nccphp.sph.unc.edu/training/index.php.

North Carolina Center for Public Health Preparedness also has a series called Focus on Field Epidemiology. Focus on Field Epidemiology is set up for use as a self-study course and has materials that instructors can use for training. http://cphp.sph.unc.edu/focus/

The Centers for Disease Control and Prevention has a variety of epidemiology training tools at http://www.cdc.gov/AppliedEpiCompetencies/. These trainings include a self-study course called Principles of Epidemiology in Public Health Practice, (www.cdc.gov/training/products/ss1000/ss1000-ol.pdf) and case studies (www.cdc.gov/epicasestudies/ and www.cdc.gov/eis/casestudies/casestudy-list.htm).

The Centers for Disease Control and Prevention also has an e-learning center with resources for several public health trainings at www.cdc.gov/learning/.

FEMA has free online trainings for ICS. http://training.fema.gov/
References


5. Infection Control Measures for Preventing and Controlling Influenza Transmission in Long-Term Care Facilities [Internet]. Centers for Disease Control and Prevention (CDC), Department of Health and Human Services; 1 Aug 2009 [10 Sept 2010]. Available from http://www.cdc.gov/flu/professionals/infectioncontrol/


9. Severe Influenza Among Children and Young Adults with Neurologic and Neurodevelopmental Conditions – Ohio 2011. MMWR 6 January 2012; 60(51); 1729-1733. Available from: http://www.cdc.gov/mmwr/preview/mmwrhtml/mm6051a1.htm?s_cid=mm6051a1_w


### Section VIII: Glossary and Acronyms

<table>
<thead>
<tr>
<th>Term</th>
<th>Definition</th>
</tr>
</thead>
<tbody>
<tr>
<td>Acute febrile respiratory illness</td>
<td>An illness characterized with onset in the past 4 days of fever and at least one of the following: cough, sore throat, rhinorrhea or nasal congestion</td>
</tr>
<tr>
<td>Acute respiratory illness</td>
<td>An illness characterized with onset in the past 4 days of at least two of the following: fever, cough, sore throat, rhinorrhea or nasal congestion</td>
</tr>
<tr>
<td>CLIA-waived</td>
<td>Refers to a test that is exempt or waived from all regulatory procedures; most of these tests are very simple to carry out and use standardized equipment, which reduces the chances of inaccuracy</td>
</tr>
<tr>
<td>Cluster</td>
<td>A grouping of a disease, symptom or syndrome in time or geographic area that appears to be greater than expected</td>
</tr>
<tr>
<td>Epidemic</td>
<td>An increase in a disease, symptom or syndrome in a community or region that clearly exceeds the expected level</td>
</tr>
<tr>
<td>Healthcare-associated infection</td>
<td>Healthcare-associated infections (HAIs) are infections that patients acquire during the course of receiving healthcare treatment for other conditions</td>
</tr>
<tr>
<td>Health department</td>
<td>A division of government that is responsible for oversight or care of matters relating to public health</td>
</tr>
<tr>
<td>Health jurisdiction</td>
<td>The geographic area or population that a health department serves</td>
</tr>
<tr>
<td>ILI provider</td>
<td>A healthcare provider who reports influenza and ILI directly to a local/regional health department; also see ILINet provider</td>
</tr>
<tr>
<td>ILI reporter</td>
<td>Anyone who reports influenza or ILI; also see ILI provider</td>
</tr>
<tr>
<td>ILINet provider</td>
<td>A healthcare provider who reports ILI through ILINet</td>
</tr>
<tr>
<td>Influenza-like illness</td>
<td>An illness characterized with a fever greater than or equal to 100°F plus a cough and/or a sore throat in the absence of a known cause other than influenza</td>
</tr>
<tr>
<td>Term</td>
<td>Definition</td>
</tr>
<tr>
<td>-----------------------------</td>
<td>------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>Long term care</td>
<td>Defined by CMS as “a variety of services that help people with health or personal needs and activities of daily living over a period of time. Long term care can be provided at home, in the community, or in various types of facilities, including nursing homes and assisted living facilities.”</td>
</tr>
<tr>
<td>MMWR week</td>
<td>Defined by the CDC for data collection and reporting purposes; the reporting week begins on Sunday and ends on the following Saturday. Interchangeable with reporting week</td>
</tr>
<tr>
<td>Nosocomial infection</td>
<td>Defined by the Centers for Medicaid as an infection that generally occurs after 72 hours from the time of admission to a healthcare facility; Also called a healthcare-associated or facility- acquired infection.</td>
</tr>
<tr>
<td>Novel Influenza</td>
<td>A human case of infection with an influenza A virus subtype or strain that is different from currently circulating human influenza H1 and H3 viruses. May be referred to as variant influenza.</td>
</tr>
<tr>
<td>Outbreak</td>
<td>A localized increase in a disease, symptom or syndrome that clearly exceeds the expected level</td>
</tr>
<tr>
<td>Pandemic</td>
<td>A worldwide outbreak or an outbreak that crosses international borders and affects an extremely large number of people</td>
</tr>
<tr>
<td>Reporting week</td>
<td>Defined for data collection and reporting purposes; the reporting week begins on Sunday and ends on the following Saturday. Interchangeable with MMWR week</td>
</tr>
<tr>
<td>Sensitivity</td>
<td>Probability of correctly diagnosing a case: the number of true positives that test positive over all true positives.</td>
</tr>
<tr>
<td>Serum, acute</td>
<td>Serum collected when a person is acutely ill; should be collected no later than 3-5 days after illness onset</td>
</tr>
<tr>
<td>Serum, convalescent</td>
<td>Serum collected from a person who is recovering from a particular infection; usually collected 2-4 weeks after onset</td>
</tr>
<tr>
<td>Specificity</td>
<td>Probability of correctly diagnosing a non-case: The number of true negatives who test negative over all true negatives</td>
</tr>
<tr>
<td>Surveillance</td>
<td>Systematic ongoing collection, collation, analysis and interpretation of health related data and the timely dissemination of information to people who can use the information for action</td>
</tr>
<tr>
<td>Term</td>
<td>Definition</td>
</tr>
<tr>
<td>---------------------------</td>
<td>---------------------------------------------------------------------------</td>
</tr>
<tr>
<td>Syndrome</td>
<td>A set of clinically recognizable symptoms that tend to occur with specific diseases or types of diseases</td>
</tr>
<tr>
<td>Syndromic surveillance</td>
<td>Surveillance of specific syndromes usually done through an automated, electronic system</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Acronym or Abbreviation</th>
<th>Meaning</th>
</tr>
</thead>
<tbody>
<tr>
<td>AAP</td>
<td>American Academy of Pediatrics</td>
</tr>
<tr>
<td>AAR</td>
<td>After action report</td>
</tr>
<tr>
<td>ACIP</td>
<td>Advisory Committee on Immunizations Practices</td>
</tr>
<tr>
<td>AFRI</td>
<td>Acute febrile respiratory illness</td>
</tr>
<tr>
<td>ALF</td>
<td>Assisted living facility</td>
</tr>
<tr>
<td>APC</td>
<td>Advanced Practice Center</td>
</tr>
<tr>
<td>APIC</td>
<td>Association for Professionals in Infection Control and Epidemiology</td>
</tr>
<tr>
<td>ARI</td>
<td>Acute respiratory illness</td>
</tr>
<tr>
<td>ASAP</td>
<td>As soon as possible</td>
</tr>
<tr>
<td>AVR</td>
<td>Antiviral resistant</td>
</tr>
<tr>
<td>BAL</td>
<td>Bronchoalveolar lavage</td>
</tr>
<tr>
<td>BIDS</td>
<td>Border Infectious Disease Surveillance</td>
</tr>
<tr>
<td>BISN</td>
<td>Border Influenza Surveillance Network</td>
</tr>
<tr>
<td>BMI</td>
<td>Body mass index</td>
</tr>
<tr>
<td>BRFSS</td>
<td>Behavioral Risk Factor Surveillance System</td>
</tr>
<tr>
<td>BSL</td>
<td>Biosafety Level</td>
</tr>
<tr>
<td>BT</td>
<td>Bioterrorism</td>
</tr>
<tr>
<td>CASPER</td>
<td>Community Assessment for Public Health Emergency Response</td>
</tr>
<tr>
<td>ccIIIV</td>
<td>Cell culture-based inactivated influenza vaccine</td>
</tr>
<tr>
<td>CDC</td>
<td>Centers for Disease Control and Prevention</td>
</tr>
<tr>
<td>CIDRAP</td>
<td>Center for Infectious Disease Research and Policy (University of Minnesota)</td>
</tr>
<tr>
<td>CLIA</td>
<td>Clinical Laboratory Improvement Amendments</td>
</tr>
<tr>
<td>CMS</td>
<td>Centers for Medicaid and Medicare Services</td>
</tr>
<tr>
<td>CO</td>
<td>(DSHS) central office</td>
</tr>
<tr>
<td>COB</td>
<td>Close of business</td>
</tr>
<tr>
<td>CSTE</td>
<td>Council of State and Territorial Epidemiologists</td>
</tr>
<tr>
<td>CSV</td>
<td>Comma-separated values</td>
</tr>
<tr>
<td>DFA</td>
<td>Direct fluorescent antibody test</td>
</tr>
<tr>
<td>DISTRIBUTE</td>
<td>Distributed Surveillance Taskforce for Real-time Influenza Burden Tracking and Evaluation – no longer an active system</td>
</tr>
<tr>
<td>DOB</td>
<td>Date of birth</td>
</tr>
<tr>
<td>DOD</td>
<td>Date of death</td>
</tr>
<tr>
<td>DSHS</td>
<td>(Texas) Department of State Health Services</td>
</tr>
<tr>
<td>EAIDB</td>
<td>(DSHS) Emerging and Acute Infectious Disease Branch</td>
</tr>
<tr>
<td>ED</td>
<td>Emergency department</td>
</tr>
<tr>
<td>EIA</td>
<td>Enzyme immunoassay (interchangeable with ELISA)</td>
</tr>
<tr>
<td>Acronym or Abbreviation</td>
<td>Meaning</td>
</tr>
<tr>
<td>-------------------------</td>
<td>---------</td>
</tr>
<tr>
<td>EIP</td>
<td>Emerging Infections Program</td>
</tr>
<tr>
<td>ELC</td>
<td>Epidemiology &amp; Laboratory Capacity</td>
</tr>
<tr>
<td>ELISA</td>
<td>Enzyme-linked immunosorbent assay (interchangeable with EIA)</td>
</tr>
<tr>
<td>EMS</td>
<td>Emergency medical services</td>
</tr>
<tr>
<td>ER</td>
<td>Emergency room</td>
</tr>
<tr>
<td>ERT (DSHS)</td>
<td>Epidemiology Response Team</td>
</tr>
<tr>
<td>ESSENCE</td>
<td>Electronic Surveillance System for the Early Notification of Community-based Epidemics</td>
</tr>
<tr>
<td>EWIDS</td>
<td>Early Warning Infectious Disease Surveillance</td>
</tr>
<tr>
<td>FDA</td>
<td>Food and Drug Administration</td>
</tr>
<tr>
<td>FEMA</td>
<td>Federal Emergency Management Agency</td>
</tr>
<tr>
<td>FTM</td>
<td>Flu transport medium</td>
</tr>
<tr>
<td>GISN (WHO)</td>
<td>Global Influenza Surveillance Network</td>
</tr>
<tr>
<td>HAI</td>
<td>Healthcare-associated infection</td>
</tr>
<tr>
<td>HCP</td>
<td>Healthcare provider/professional</td>
</tr>
<tr>
<td>HD</td>
<td>Health department</td>
</tr>
<tr>
<td>HHS</td>
<td>Health and Human Services</td>
</tr>
<tr>
<td>HI</td>
<td>Hemagglutination inhibition</td>
</tr>
<tr>
<td>HICPAC</td>
<td>Healthcare Infection Control Practices Advisory Committee</td>
</tr>
<tr>
<td>HIV</td>
<td>Human immunodeficiency virus</td>
</tr>
<tr>
<td>HPAI</td>
<td>highly pathogenic avian influenza</td>
</tr>
<tr>
<td>HSR (DSHS)</td>
<td>Health Service Region</td>
</tr>
<tr>
<td>IATA</td>
<td>International Air Transport Association</td>
</tr>
<tr>
<td>IC</td>
<td>Infection control</td>
</tr>
<tr>
<td>ICD</td>
<td>International Classification of Diseases</td>
</tr>
<tr>
<td>ICP</td>
<td>Infection control practitioner</td>
</tr>
<tr>
<td>ICS</td>
<td>Incident command system</td>
</tr>
<tr>
<td>ICU</td>
<td>Intensive care unit</td>
</tr>
<tr>
<td>ID</td>
<td>Identification</td>
</tr>
<tr>
<td>IDCU (DSHS)</td>
<td>Infectious Disease Control Unit</td>
</tr>
<tr>
<td>IDEAS</td>
<td>Infectious Disease Epidemiology and Surveillance</td>
</tr>
<tr>
<td>IFA</td>
<td>Indirect fluorescent antibody test</td>
</tr>
<tr>
<td>IHC</td>
<td>Immunohistochemical</td>
</tr>
<tr>
<td>IIISP</td>
<td>Influenza Incidence Surveillance Project</td>
</tr>
<tr>
<td>IIV</td>
<td>Inactivated influenza vaccine</td>
</tr>
<tr>
<td>IIV3</td>
<td>Trivalent inactivated influenza vaccine</td>
</tr>
<tr>
<td>IIV4</td>
<td>Quadrivalent inactivated influenza vaccine</td>
</tr>
<tr>
<td>ILI</td>
<td>Influenza-like illness</td>
</tr>
<tr>
<td>ILINet</td>
<td>U.S. Outpatient Influenza-like Illness Surveillance Network</td>
</tr>
<tr>
<td>IP</td>
<td>Infection preventionist</td>
</tr>
<tr>
<td>IRID (DSHS)</td>
<td>Infectious Respiratory and Invasive Disease (Team)</td>
</tr>
<tr>
<td>ITM</td>
<td>Influenza transport medium</td>
</tr>
<tr>
<td>LAIV</td>
<td>Live, attenuated influenza vaccine</td>
</tr>
<tr>
<td>LHD</td>
<td>Local health department</td>
</tr>
<tr>
<td>Acronym or Abbreviation</td>
<td>Meaning</td>
</tr>
<tr>
<td>-------------------------</td>
<td>---------</td>
</tr>
<tr>
<td>LIMS</td>
<td>Laboratory information management system</td>
</tr>
<tr>
<td>LRN</td>
<td>Laboratory Response Network</td>
</tr>
<tr>
<td>LTC</td>
<td>Long term care (facility)</td>
</tr>
<tr>
<td>MAARI</td>
<td>Medically attended acute respiratory illness</td>
</tr>
<tr>
<td>MC</td>
<td>Mail code</td>
</tr>
<tr>
<td>MMWR</td>
<td>Morbidity and Mortality Weekly Report</td>
</tr>
<tr>
<td>MOA</td>
<td>Memorandum of agreement</td>
</tr>
<tr>
<td>MOU</td>
<td>Memorandum of understanding</td>
</tr>
<tr>
<td>N/A</td>
<td>Not applicable</td>
</tr>
<tr>
<td>NBS</td>
<td>NEDSS Base System</td>
</tr>
<tr>
<td>NEDSS</td>
<td>National Electronic Disease Surveillance System</td>
</tr>
<tr>
<td>NP</td>
<td>Nasopharyngeal</td>
</tr>
<tr>
<td>NPI</td>
<td>National provider identifier</td>
</tr>
<tr>
<td>NPV</td>
<td>Negative predictive value</td>
</tr>
<tr>
<td>NRDM</td>
<td>National Retail Data Monitor (system)</td>
</tr>
<tr>
<td>NREVSS</td>
<td>National Respiratory and Enteric Virus Surveillance System</td>
</tr>
<tr>
<td>NVSN</td>
<td>New Vaccine Surveillance Network</td>
</tr>
<tr>
<td>OP</td>
<td>Oropharyngeal</td>
</tr>
<tr>
<td>OTC</td>
<td>Over-the-counter</td>
</tr>
<tr>
<td>PAHO</td>
<td>Pan American Health Organization</td>
</tr>
<tr>
<td>PFGE</td>
<td>Pulsed-field gel electrophoresis</td>
</tr>
<tr>
<td>PCR</td>
<td>Polymerase chain reaction</td>
</tr>
<tr>
<td>PEP</td>
<td>Post exposure prophylaxis</td>
</tr>
<tr>
<td>PHEP</td>
<td>Public Health Emergency Preparedness</td>
</tr>
<tr>
<td>PHLIMS</td>
<td>Public health laboratory information management system</td>
</tr>
<tr>
<td>PHP</td>
<td>Public Health Preparedness</td>
</tr>
<tr>
<td>PPE</td>
<td>Personal protective equipment</td>
</tr>
<tr>
<td>PPV</td>
<td>Positive predictive value</td>
</tr>
<tr>
<td>ProMed</td>
<td>Program for Monitoring Emerging Diseases</td>
</tr>
<tr>
<td>PUI</td>
<td>Patient under investigation</td>
</tr>
<tr>
<td>RHD</td>
<td>Regional health department</td>
</tr>
<tr>
<td>RIV</td>
<td>Recombinant hemagglutinin influenza vaccine</td>
</tr>
<tr>
<td>RNA</td>
<td>Ribonucleic acid</td>
</tr>
<tr>
<td>RODS</td>
<td>Real-Time Outbreak and Disease Surveillance</td>
</tr>
<tr>
<td>rRT-PCR</td>
<td>Real-time reverse transcription polymerase chain reaction</td>
</tr>
<tr>
<td>SARI</td>
<td>Severe acute respiratory illness</td>
</tr>
<tr>
<td>SHD</td>
<td>State health department</td>
</tr>
<tr>
<td>SOB</td>
<td>Shortness of breath</td>
</tr>
<tr>
<td>SSN</td>
<td>Social security number</td>
</tr>
<tr>
<td>TALHO</td>
<td>Texas Association of Local Health Officials</td>
</tr>
<tr>
<td>TEA</td>
<td>Texas Education Agency</td>
</tr>
<tr>
<td>THA</td>
<td>Texas Hospital Association</td>
</tr>
<tr>
<td>TIV</td>
<td>Trivalent inactivated vaccine (used prior to 2013-14 season)</td>
</tr>
<tr>
<td>TPI</td>
<td>Texas provider identifier</td>
</tr>
<tr>
<td>Acronym or Abbreviation</td>
<td>Meaning</td>
</tr>
<tr>
<td>------------------------</td>
<td>--------------------------------------------</td>
</tr>
<tr>
<td>UN</td>
<td>United Nations</td>
</tr>
<tr>
<td>USMU</td>
<td>(CDC) US-Mexico Unit</td>
</tr>
<tr>
<td>UTM</td>
<td>Universal transport medium</td>
</tr>
<tr>
<td>VTM</td>
<td>Viral transport medium</td>
</tr>
<tr>
<td>WHO</td>
<td>World Health Organization</td>
</tr>
</tbody>
</table>
Appendix

Table of Contents

- DSHS Contact Information
  - DSHS Central Office Influenza Surveillance Team
  - DSHS Laboratory
  - DSHS Regional Influenza Surveillance Coordinators
- LRN Contact Information
- Where to Find Influenza Data
- Recommended Influenza Resources
- Nasopharyngeal Swab Collection for Influenza
- Investigation and Report Forms
# DSHS Contact Information

**DSHS Central Office Influenza Surveillance Team**
Influenza reports, VTM orders and influenza surveillance questions should be sent to flutexas@dshs.state.tx.us. All members of the team have access to and monitor this email box.

<table>
<thead>
<tr>
<th>Name</th>
<th>Position</th>
<th>Email</th>
<th>Phone</th>
</tr>
</thead>
<tbody>
<tr>
<td>Carol Davis</td>
<td>Epidemiologist / Respiratory Team Lead</td>
<td><a href="mailto:carol.davis@dshs.state.tx.us">carol.davis@dshs.state.tx.us</a></td>
<td>512-776-6223</td>
</tr>
<tr>
<td>Lesley Brannan</td>
<td>Epidemiologist / Influenza Surveillance Coordinator</td>
<td><a href="mailto:lesley.brannan@dshs.state.tx.us">lesley.brannan@dshs.state.tx.us</a></td>
<td>512-776-6354</td>
</tr>
<tr>
<td>Robert “Bob” Russin</td>
<td>ILINet Coordinator</td>
<td><a href="mailto:robert.russin@dshs.state.tx.us">robert.russin@dshs.state.tx.us</a></td>
<td>512-776-6242</td>
</tr>
</tbody>
</table>

**DSHS Laboratory**

<table>
<thead>
<tr>
<th>Name</th>
<th>Position</th>
<th>Email</th>
<th>Phone</th>
</tr>
</thead>
<tbody>
<tr>
<td>Crystal Van Cleave</td>
<td>Microbiologist / Viral Isolation Team Lead</td>
<td><a href="mailto:crystal.vancleave@dshs.state.tx.us">crystal.vancleave@dshs.state.tx.us</a></td>
<td>512-776-7594</td>
</tr>
<tr>
<td>Martha Thompson</td>
<td>Medical Virology Group Manager</td>
<td><a href="mailto:martha.thompson@dshs.state.tx.us">martha.thompson@dshs.state.tx.us</a></td>
<td>512-776-7515</td>
</tr>
<tr>
<td>Richard Zapata</td>
<td>Container Preparation Group Team Lead</td>
<td><a href="mailto:richard.zapata@dshs.state.tx.us">richard.zapata@dshs.state.tx.us</a></td>
<td>512-776-2976</td>
</tr>
<tr>
<td>Priscilla Trevino</td>
<td>Container Preparation Group Manager</td>
<td><a href="mailto:priscilla.trevino@dshs.state.tx.us">priscilla.trevino@dshs.state.tx.us</a></td>
<td>512-776-2936</td>
</tr>
<tr>
<td>Walter Douglass</td>
<td>Manager – Microbiological Check-In Group</td>
<td><a href="mailto:walter.douglass@dshs.state.tx.us">walter.douglass@dshs.state.tx.us</a></td>
<td>512-776-7569</td>
</tr>
<tr>
<td>Vanessa Telles</td>
<td>Special Projects Coordinator (LRNs), Emergency Preparedness Branch</td>
<td><a href="mailto:vanessa.telles@dshs.state.tx.us">vanessa.telles@dshs.state.tx.us</a></td>
<td>512-776-3475</td>
</tr>
</tbody>
</table>
**DSHS Regional Influenza Surveillance Coordinators**

<table>
<thead>
<tr>
<th>Name</th>
<th>Region</th>
<th>Email</th>
<th>Phone</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cindy Hernandez</td>
<td>Region 1 Influenza</td>
<td><a href="mailto:cynthiaa.hernandez@dshs.state.tx.us">cynthiaa.hernandez@dshs.state.tx.us</a></td>
<td>806-783-6448</td>
</tr>
<tr>
<td>Scott Mize</td>
<td>Region 2/3 Influenza</td>
<td><a href="mailto:scott.mize@dshs.state.tx.us">scott.mize@dshs.state.tx.us</a></td>
<td>817-264-4706</td>
</tr>
<tr>
<td>Horace McCorvey</td>
<td>Region 4/5N Influenza</td>
<td><a href="mailto:horace.mccorvey@dshs.state.tx.us">horace.mccorvey@dshs.state.tx.us</a></td>
<td>903-533-5210</td>
</tr>
<tr>
<td>Huai Lin</td>
<td>Region 6/5S Influenza</td>
<td><a href="mailto:huai.lin@dshs.state.tx.us">huai.lin@dshs.state.tx.us</a></td>
<td>713-767-3232</td>
</tr>
<tr>
<td>Sandi Henley</td>
<td>Region 7 Influenza</td>
<td><a href="mailto:sandi.henley@dshs.state.tx.us">sandi.henley@dshs.state.tx.us</a></td>
<td>254-771-6729</td>
</tr>
<tr>
<td>Connie Alaniz</td>
<td>Region 8 Influenza</td>
<td><a href="mailto:connie.alaniz@dshs.state.tx.us">connie.alaniz@dshs.state.tx.us</a></td>
<td>210-949-2066</td>
</tr>
<tr>
<td>Avi Raju</td>
<td>Region 9/10 Influenza</td>
<td><a href="mailto:avi.raju@dshs.state.tx.us">avi.raju@dshs.state.tx.us</a></td>
<td>432-571-4155</td>
</tr>
<tr>
<td>Vivienne Heines</td>
<td>Region 11 Influenza</td>
<td><a href="mailto:vivienne.heines@dshs.state.tx.us">vivienne.heines@dshs.state.tx.us</a></td>
<td>361-888-7837 Ext 235</td>
</tr>
</tbody>
</table>

![Map of Texas showing regional public health coverage](image-url)
# LRN Contact Information

<table>
<thead>
<tr>
<th>LRN Location</th>
<th>Name</th>
<th>Position</th>
<th>Office Phone</th>
</tr>
</thead>
<tbody>
<tr>
<td>Corpus Christi</td>
<td>Ashley Cox</td>
<td>BT Coordinator</td>
<td>361-826-7214</td>
</tr>
<tr>
<td>Dallas</td>
<td>Joey Stringer</td>
<td>BT Coordinator</td>
<td>972-692-1323</td>
</tr>
<tr>
<td>El Paso</td>
<td>Minerva Cutter</td>
<td>BT Coordinator</td>
<td>915-543-3255</td>
</tr>
<tr>
<td>South Texas/</td>
<td>Kristina Zamora</td>
<td>BT Coordinator</td>
<td>956-364-8369</td>
</tr>
<tr>
<td>Harlingen</td>
<td></td>
<td>Supervisor, Molecular</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Diagnostics Section</td>
<td></td>
</tr>
<tr>
<td>Houston</td>
<td>Meilan Bielby</td>
<td></td>
<td>832-393-3956</td>
</tr>
<tr>
<td>Lubbock</td>
<td>Anna Gibson</td>
<td>BT Coordinator</td>
<td>806-885-0232</td>
</tr>
<tr>
<td>San Antonio</td>
<td>Patricia Blevins</td>
<td>BT Coordinator</td>
<td>210-207-5883</td>
</tr>
<tr>
<td>Tarrant County</td>
<td>Rebecca McMath</td>
<td>BT Coordinator</td>
<td>817-321-4755</td>
</tr>
<tr>
<td>Tyler</td>
<td>Janine Yost</td>
<td>BT Coordinator</td>
<td>903-877-5056</td>
</tr>
</tbody>
</table>
Where to Find Influenza Data

World Health Organization

Centers for Disease Control and Prevention
- Weekly surveillance reports: http://www.cdc.gov/flu/weekly/fluactivitysurv.htm

Texas Department of State Health Services
- Infectious Disease Control Unit influenza surveillance page: http://www.dshs.state.tx.us/idcu/disease/influenza/surveillance/
- Texasflu.org surveillance page [including 2009 influenza A (H1N1) data]: http://www.dshs.state.tx.us/txflu/TX-surveillance.shtm

Department of Defense
- Naval Health Research Center Operational Infectious Diseases Department: http://www.med.navy.mil/sites/nhrc/geis/Pages/default.aspx

Google
- Google Flu Trends: http://www.google.org/flutrends/
Recommended Influenza Resources

World Health Organization
- WHO on Twitter: WHO @WHO

U.S. Department of Health and Human Services
- Flu and Pandemic Flu website: http://www.flu.gov/

Centers for Disease Control and Prevention
- Seasonal Influenza website: http://www.cdc.gov/flu/

Texas Department of State Health Services
- Main influenza page: http://www.texasflu.org
- Infectious Disease Control Unit flu page: http://www.dshs.state.tx.us/idcu/disease/influenza/
- Immunization Branch website: http://www.dshs.state.tx.us/immunize/

Center for Infectious Disease Research and Policy (CIDRAP)
- http://www.cidrap.umn.edu/

International Society for Infectious Diseases – ProMed mail
- http://www.promedmail.org/
Nasopharyngeal Swab Collection for Influenza

MATERIALS FOR NASOPHARYNGEAL SWAB COLLECTION:

- Nasopharyngeal swab: Dacron or rayon tipped with a flexible plastic shaft
  - Note: cotton-tipped or calcium alginate swabs are not acceptable
- Thawed viral transport medium (check expiration date and discard if expired)
- Gloves (suggested gloves are powder-free)
- Mask for covering nose and mouth of health worker (e.g., surgical mask)
- Facial tissues (for patient use)
- Eye protection/goggles for health worker (to protect from coughs, sneezes or splashes)

NASOPHARYNGEAL SWAB COLLECTION PROCEDURE:

- Wash or sanitize your hands and put on a mask with face shield or with goggles.
- Ask the patient to look slightly upward and steady the patient’s head with one hand under his or her chin if necessary.
- Gently insert dry swab through one nostril horizontally (straight back not upwards), along the floor of the nasal passage into the nasopharynx. The distance from the nose to the ear gives an estimate of the distance the swab should be inserted. If resistance is encountered during insertion, remove the swab and attempt insertion into the opposite nostril.
- Rotate swab 2 to 3 times and leave in place for up to 10 seconds.
- Remove the swab slowly. Offer the patient a tissue in case he or she is going to sneeze or cough.
- Immediately place swab into the viral transport medium. Break off or cut the shaft of the swab so that it fits completely into the tube.
- Label the VTM vial with the patient’s first name, last name and date of birth.
- Completely fill out the DSHS G-2A Laboratory Specimen Submission Form.
- Store the vial at 2-8°C until ready to ship. Specimens need to be shipped cold with enough ice packs to maintain the temperature. **Cold specimens must be received by the DSHS laboratory within 72 hours of collection.** Specimens may also be stored frozen and shipped on dry ice. Frozen specimens may be received by the DSHS lab > 72 hours after collection if they are shipped on dry ice and arrive frozen.

A video demonstrating proper technique for nasopharyngeal collection is available at http://www.cdc.gov/pertussis/clinical/diagnostic-testing/specimen-collection.html#swab-testing. The video references collecting two swabs for pertussis testing. Only one swab is needed for influenza / influenza-like illness surveillance testing.
### Investigation and Report Forms

Investigation and report forms are available on the DSHS website at: [http://www.dshs.state.tx.us/idcu/investigation/](http://www.dshs.state.tx.us/idcu/investigation/)

The following investigation and/or report forms are available for influenza:

<table>
<thead>
<tr>
<th>Form</th>
<th>Description</th>
<th>Required</th>
</tr>
</thead>
<tbody>
<tr>
<td>Influenza-associated pediatric death investigation form</td>
<td>This form is to investigate and report cases of influenza-associated mortality in children under 18 years of age.</td>
<td>Yes</td>
</tr>
<tr>
<td>General influenza investigation form</td>
<td>This form is to investigate cases of influenza such as during an outbreak or during periods of unusual flu activity. It is also used for investigating novel influenza.</td>
<td>Only for novel influenza or when requested</td>
</tr>
<tr>
<td>Influenza investigation form supplemental pages</td>
<td>This form captures information that is not always needed in an influenza investigation but has been requested in the past by the CDC for special situations including novel influenza, out of season influenza, pregnant/postpartum influenza, etc.</td>
<td>Only for novel influenza or when requested</td>
</tr>
<tr>
<td>Contract tracking form</td>
<td>This form is designed to help keep track of contacts in a respiratory or invasive disease investigation.</td>
<td>Only for novel influenza or when requested</td>
</tr>
<tr>
<td>Respiratory disease outbreak summary form</td>
<td>This form is to report respiratory disease outbreaks. The form captures information that is routinely requested during outbreaks and includes information to help meet performance measures associated with the Public Health Emergency Preparedness (PHEP) funds.</td>
<td>Yes</td>
</tr>
</tbody>
</table>